REGULATION OF YAP BY GLUCOCORTICOIDS by Ruggeri, Naomi




UNIVERSITÀ DEGLI STUDI DI TRIESTE 
 
 
XXVII CICLO DEL DOTTORATO DI RICERCA IN 
BIOMEDICINA MOLECOLARE 	  	  
REGULATION	  OF	  YAP	  BY	  GLUCOCORTICOIDS	  	  Settore	  scientifico-­‐disciplinare:	  BIO/13	  	  	  	  DOTTORANDA:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  COORDINATORE:	  
NAOMI	  RUGGERI	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  PROF.	  GUIDALBERTO	  MANFIOLETTI	  
	  
	  
	  SUPERVISORE	  DELLA	  TESI:	  
PROF.	  GIANNINO	  DEL	  SAL	  	  	  CO-­‐SUPERVISORE	  DELLA	  TESI:	  
DOTT.	  GIOVANNI	  SORRENTINO	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ANNO	  ACCADEMICO	  2013/2014	  
	   2	  
	  
	  	  	  	  	  	  
	   3	  
	  
ABSTRACT	  ....................................................................................................................................	  4	  
INTRODUCTION	  .................................................................................................................	  5	  
1.1	  THE	  HIPPO	  PATHWAY	  ..............................................................................................	  5	  
1.2	  THE	  HIPPO	  PATHWAY	  IN	  DROSOPHILA	  .............................................................	  5	  
1.3	  THE	  HIPPO	  PATHWAY	  IN	  MAMMALS	  ...................................................................	  6	  
1.4	  MECHANISMS	  OF	  REGULATION	  OF	  THE	  HIPPO	  PATHWAY	  ..........................	  9	  
2.1	  YAP	  AND	  TAZ	  PROTEIN	  STRUCTURE	  .................................................................	  12	  
2.2	  YAP	  FUNCTION	  IN	  ORGANS	  AND	  TISSUES	  ........................................................	  14	  
2.3	  THE	  HIPPO	  PATHWAY	  IN	  HUMAN	  CANCERS	  ...................................................	  17	  
2.4	  THE	  HIPPO	  SIGNALLING	  AND	  STEM	  CELL	  PROPERTIES	  ..............................	  19	  
3.1	  GLUCOCORTICOIDS	  SIGNALLING	  .........................................................................	  22	  
3.2	  GLUCOCORTICOID	  RECEPTOR	  ACTIVITY	  .........................................................	  23	  
3.3	  GLUCOCORTICOIDS	  SIGNALLING	  IN	  ORGANS	  ..................................................	  26	  
3.4	  GLUCOCORTICOIDS	  SIGNALLING	  IN	  CANCER	  ..................................................	  28	  
4.1	  BREAST	  CANCER	  .......................................................................................................	  30	  
AIM	  OF	  THE	  THESIS	  ........................................................................................................	  33	  
RESULTS	  .............................................................................................................................	  34	  
Identification	  of	  drugs	  regulating	  YAP	  protein	  levels	  in	  cancer	  cells	  ....................	  34	  
Breast	  Cancer	  cells	  are	  fully	  responsive	  to	  glucocorticoids	  stimulation	  ..............	  35	  
Glucocorticoids	  receptor	  directly	  increase	  YAP	  levels	  and	  activity	  .......................	  36	  
Glucocorticoid	  receptor	  directly	  regulates	  YAP	  mRNA	  transcription	  ...................	  37	  
Glucocorticoids	  regulate	  YAP	  nuclear	  localization	  by	  promoting	  its	  de-­‐
phosphorylation	  and	  nuclear	  accumulation	  ..................................................................	  38	  
Glucocorticoids	  promote	  YAP	  nuclear	  accumulation	  by	  controlling	  actin	  
cytoskeleton	  dynamics	  ...........................................................................................................	  40	  
Glucocorticoids	  are	  serum	  factors	  that	  counteract	  the	  GPCRs-­‐mediated	  negative	  
regulation	  of	  YAP	  .....................................................................................................................	  42	  
Glucocorticoids	  sustain	  breast	  cancer	  stem	  cells	  by	  activating	  YAP	  ......................	  43	  
DISCUSSION	  .......................................................................................................................	  46	  
EXPERIMENTAL	  PROCEDURES	  ............................................................................................	  49	  
FIGURES	  ..............................................................................................................................	  57	  
REFERENCES	  .....................................................................................................................	  65	  
ACKNOWLEDGEMENTS	  ..........................................................................................................	  73	  
APPENDIX	  ...................................................................................................................................	  74	  	  	  	  	  	  	  
	   4	  
ABSTRACT	  	  	  	  
	  
The	  Hippo	  signalling	  pathway	  is	  tumour	  suppressor	  cascade	  with	  a	  central	  role	  in	  the	  
regulation	   of	   fundamental	   cellular	   biological	   processes,	   such	   as	   cell	   proliferation,	  
apoptosis,	  organ	  size	  control	  and	  stem	  cell	  functions.	  The	  Hippo	  pathway	  transduces	  
external	   signals	   that	   come	   to	   the	   cell	   into	   the	   nucleus,	   where	   it	   can	   control	   the	  
expression	   of	   specific	   target	   genes,	   mainly	   involved	   in	   cell	   proliferation	   and	  
differentiation.	   The	   Hippo	   pathway	   is	   an	   inhibitory	   pathway	   that	   control	   by	  
phosphorylation	  and	  inhibition	  Yes-­‐associated	  protein	  (YAP)	  coactivator,	  one	  of	  the	  
two	  nuclear	  effectors	  of	  this	  signalling,	  involved	  in	  the	  regulation	  of	  proliferation	  and	  
organ	  size.	  	  
As	   consequence,	   deregulation	   of	   Hippo	   tumor	   suppressor	   pathway	   or	  
hyperactivation	   of	   its	   downstream	   effectors	   is	   often	   associated	   with	   formation,	  
development	  and	  tumour	  dissemination.	  	  
Consistently,	  YAP	  is	  often	  over-­‐expressed	  in	  a	  broad	  range	  of	  different	  tumours	  and	  
it	   has	   aberrant	   activity	   in	   breast	   cancer	   as	   well	   as	   in	   several	   other	   human	  
carcinomas.	  Up-­‐regulation	  of	  YAP	  activity	  increases	  stem	  cell	  self-­‐renewal	  in	  normal	  
and	  cancer	  stem	  cells.	  	  
In	   this	  work	  we	  describe	  the	   identification	  of	  a	  new	  hormonal-­‐dependent	   layer	   for	  
YAP	   regulation	   in	   breast	   cancer	   by	   the	   glucocorticoids	   and	   we	   analyze	   the	  
mechanisms	   through	   which	   this	   regulation	   occurs.	   We	   found	   that	   Glucocorticoid	  
Receptor	  (GR)	  binds	  directly	  the	  YAP	  promoter	  and	  induces	  the	  transcription	  of	  YAP	  
mRNA	  after	  GC	   stimulation	   in	   cancer	   cells.	  Moreover,	  GC	   lead	   to	  efficient	  YAP	  de-­‐
phosphorylation	   and	   transcriptional	   activation,	   in	   a	   transcription-­‐independent	  
manner,	  by	  inducing	  actin	  cytoskeleton	  reorganization.	  
Importantly,	   inhibition	   of	   the	   GR	   by	  means	   of	   RU486	   (GR	   competitive	   antagonist)	  
strongly	  blunted	  the	  expansion	  of	  the	  cancer	  stem	  cell	  pool	  in	  breast	  cancer	  cells	  by	  
blunting	  the	  GR/YAP	  axis.	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INTRODUCTION	  
1.1	  THE	  HIPPO	  PATHWAY	  	  	  
	  
The	  Hippo	  signalling	  cascade	   is	  a	  highly	  evolutionally	  conserved	  tumour-­‐suppressor	  
pathway	  regulating	  tissue	  growth	  and	  cell	  fate	  (Harvey	  et	  al.,	  2013).	  It	  is	  important	  in	  
the	   regulation	   of	   organ	   size	   by	   governing	   cell	   proliferation,	   stem	   cell	   properties,	  
tissue	  regeneration	  and	  apoptosis	  (Hong	  et	  al.,	  2012).	  Following	  the	  first	  description	  
in	  Drosophila	  melanogaster	  as	  an	  intrinsic	  mechanism	  that	  restricts	  organ	  size	  during	  
development	  and	  that	  maintains	  tissue	  homeostasis	  throughout	  postnatal	  life,	  Hippo	  
pathway	   has	   been	   found	   commonly	   deregulated	   in	   different	   type	   of	   cancers	  
suggesting	   that	   altering	   Hippo	   signalling	   correlates	   with	   tumour	   initiation,	  
progression	  and	  expansion	  (Cordenonsi	  et	  al.,	  2011).	  
The	  Hippo	  pathway	  integrates	  various	  upstream	  inputs	  from	  the	  plasma	  membrane	  
into	   the	   nucleus,	   where	   it	   controls	   the	   transcription	   of	   several	   target	   genes	   that	  
regulates	   cellular	   processes	   such	   as	   cell	   proliferation,	   differentiation	   and	   survival	  
(Johnson	  and	  Halder,	  2014).	  
1.2	  THE	  HIPPO	  PATHWAY	  IN	  DROSOPHILA	  
	  
In	   Drosophila,	   the	   first	   genes	   of	   the	   pathway	   isolated	   using	   the	   mosaic-­‐based	  
screens,	  were	   the	   tumour	   suppressor	   genes	  warts	   (wts),	  hippo	   (hpo)	   and	   salvador	  
(sav).	   Loss	   of	   wts	   leads	   to	   robust	   cell-­‐autonomous	   overgrowth	   in	   a	   variety	   of	  
epithelial	   structures	  such	  as	  eyes,	  wings	  and	   legs	   (Pan,	  2007).	   In	  2002	  Tapon	  et	  al.	  
demonstrated	   that	   loss	   of	   wts	   or	   sav	   leads	   to	   increased	   cell	   proliferation	   and	  
reduction	  in	  apoptosis	  showing	  the	  first	  evidence	  that	  these	  proteins	  regulate	  both	  
processes.	   They	   additionally	   observed	   that	   loss	   of	   wts	   or	   sav	   is	   associated	   with	  
increased	  levels	  of	  the	  cell	  cycle	  regulator	  Cyclin	  E	  (CycE)	  and	  the	  cell	  death	  inhibitor	  
Diap1.	  
One	   year	   later	   the	   Hpo	   gene	   was	   identified,	   showing	   a	   similar	   loss-­‐of-­‐function	  
overgrowth	  phenotype	  to	  that	  reported	  for	  sav	  or	  wts	  (Figure	  1).	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Figure	  1	   The	  Hpo	   signaling	  pathway	   controls	   organ	   size	   in	  Drosophila.	   Images	   from	  Huang	  et	  al.	   (2005).	  A–C	  
show	  images	  of	  wild	  type	  (A)	  and	  flies	  in	  which	  hpo	  (B)	  or	  yki	  (C)	  function	  is	  specifically	  inactivated	  in	  the	  head.	  
While	  inactivation	  of	  hpo	  leads	  to	  massive	  over-­‐	  growth	  of	  the	  eye	  and	  head	  cuticles,	  inactivation	  of	  yki	  leads	  to	  
the	  opposite	  phenotype.	  D	  and	  E	  show	  increased	  cell	  proliferation	  (D)	  and	  decreased	  cell	  death	  (E)	  in	  hpo	  mutant	  
clones	  in	  the	  pupal	  eye.	  (D)	  While	  wild-­‐type	  cells	  (green)	  had	  ceased	  cell	  proliferation	  (red),	  hpo	  mutant	  clones	  
(black)	   continued	   to	   divide.	   (E)	   Conversely,	   normally	   occurring	   cell	   death	   can	   be	   detected	   in	   wild-­‐type	   cells	  
(green)	  but	  not	   in	  hpo	  mutant	   cells	   (black).	  F	   shows	  a	  wild-­‐type	  wing	   imaginal	   disc	   (left)	   and	   a	  wing	  disc	   that	  
overexpressed	  the	  yki	  gene	  (right).	  Yki	  overexpression	  leads	  to	  a	  dramatic	  increase	  in	  wing	  size	  (up	  to	  eight	  times	  
the	  area	  of	  the	  wild-­‐type	  wings)	  (Pan,	  2007).	  
	  
In	  2005	  Huang	  et	  al.	  identified	  the	  transcriptional	  coactivator	  Yorkie	  (Yki)	  as	  a	  critical	  
substrate	  and	  downstream	  effector	  of	  Wts;	   this	   study	  demonstrates	   that	  Yki	   is	   the	  
effector	   of	   the	   overgrowth	   phenotype	   observed	   in	   Hippo	   mutants.	   Yki	   is	  
phosphorylated	  and	  inactivated	  by	  Wts.	  Overexpression	  of	  Yki	  recapitulates	  the	  loss-­‐
of-­‐function	  wts	  phenotypes	   (increased	  diap1	   transcription	   and	   tissue	   overgrowth).	  
Conversely,	   loss	   of	   yki	   leads	   to	   tissue	   atrophy	   and	   diminished	  diap1	   transcription,	  
and	  genetic	  epistasis	  analysis	  placed	  yki	  downstream	  to	  hpo,	  sav,	  or	  wts.	  
1.3	  THE	  HIPPO	  PATHWAY	  IN	  MAMMALS	  	  	  
Component	  of	  hippo	  signaling	  pathway	  are	  highly	  conserved	  during	  evolution	  (Pan,	  
2007)	  (Figure	  2).	  In	  mammals	  the	  hippo	  core	  kinase	  is	  composed	  by	  the	  kinases	  Mst1	  
and	  Mst2	  (mammalian	  STE	  20-­‐like	  protein	  kinase	  1	  and	  2)(Harvey	  et	  al.,	  2003),	  Lats1	  
and	  Lats2	  (the	  large	  tumour	  suppressor	  1	  and	  2)	  (Hao	  et	  al.,	  2008;	  Oka	  et	  al.,	  2008;	  
Zhang	  et	  al.,	  2008),	  Sav1	  (the	  scaffolding	  protein	  Salvador	  homolog	  1	  which	  interacts	  
with	   Mst1/2)	   and	   the	   adaptor	   proteins	   MOB	   kinase	   activator	   1A	   (Mob1A)	   and	  
Hpo kinase cascade and target gene transcription was
accomplished by Huang et al. (2005), who identified the
transcriptional coactivator Yorkie (Yki) as a critical sub-
strate and downstream effector of Wts (Fig. 3A). Unlike
the tumor suppressors of the Hpo pathway, which were
isolated in phenotypic screens using genetic mosaics,
Yki was identified in a yeast two-hybrid screen for Wts-
binding proteins (Huang et al. 2005). Biochemical and
genetic characterization of Yki demonstrates that Yki
fulfills all the criteria expected of a Wts effector in
growth regulation. Yki is phosphorylated and inactivated
by Wts. Overexpression of Yki recapitulates loss-of-func-
tion wts phenotypes, such as increased diap1 transcrip-
tion and tissue overgrowth (Fig. 2). Conversely, loss of
yki leads to tissue atrophy (Fig. 2) and diminished diap1
transcription, and genetic epistasis analysis placed yki
downstream from hpo, sav, or wts. Moreover, like the
tumor suppressors of the Hpo pathway, loss or gain of
function of yki does not affect cell fate determination
despite its effect on imaginal disc growth. Huang et al.
(2005) went on to show that YAP (yes-associated pro-
tein), the mammalian homolog of Yki, possesses similar
activity to its Drosophila counterpart, sugg sting that
YAP likely functions as an oncogene instead of an apo-
ptosis-promoting protein as previously reported (Basu et
al. 2003). Taken together, these results identified Yki as
a critical nuclear effector of the Hpo pathway (Fig. 3A;
Huang et al. 2005).
The isolation of Yki is an important development in
elucidating the Hpo signaling pathway. By linking the
Hpo kinase cascade with a transcriptional regulator, it
provides the most critical evidence supporting th origi-
nal model by Wu et al. (2003), which posits that the Hpo
kinase cascade regulates target genes through a tran-
scriptional, instead of a post-transcriptional, mecha-
nism. The fact that overexpression of Yki can recapitu-
late the wts loss-of-function overgrowth phenotype fur-
ther demonstrates that Yki represents the most critical,
if not the only, output of the Hpo kinase cascade in
growth regulation. As a direct effector of the Hpo kinase
cascade, Yki phosphorylation or Yki transcriptional ac-
tivity provides a convenient assay to monitor Hpo sig-
naling activity. Such assays are especially useful when
testing novel upstream regulators of the Hpo pathway.
Lastly, as the first physiological substrate identified for
any NDR family kinase, molecular studies of Yki phos-
phorylation by Wts could provide general insights into
substrate specificity for this family of protein kinases,
which remains poo ly underst od at present.
Transcriptional targets of the Hpo signaling pathway
While the initial studies have identified cycE and diap1
as transcriptional targets of the Hpo pathway, they are
unlikely to be the only targ ts. Of note, the unctional
relevance of diap1 and cycE expression that occurs upon
loss of Hpo s gnaling has never been rigo ously ex mined
using genetic epistasis tests. Furthermore, cycE overex-
pression combined with inhibition of apoptosis do s not
result in the tissue overgrowth (Neufeld et al. 1998) that
characteristic of inactivation of hpo or activation f
yki, suggesting that there should exist additional tran-
scriptional targets of the Hpo pathway that contribute to
its growth-regulatory function. A strong candidate is the
microRNA molecule bantam, a positive regulator of
imaginal disc growth that, like the known components
of the Hpo pathway, possesses the dual activity of regu-
latin cell proliferation as well as cell death (Brennecke
et al. 2003). Two recent studies, by Thompson and Co-
hen (2006) and Nolo et al. (2006), hav provided multiple
lines of evidence implicating bantam as an additional
target of the Hpo athway. First, bantam expression is
Figure 2. The Hpo signaling pathway
controls organ size in Drosophila. Images
reprinted from Wu et al. (2003), with per-
mission from Elsevier, and Huang et al.
(2005), with permission from Elsevier.
A–C show images of wild type (A) and flies
in which hpo (B) or yki (C) function is spe-
cifically inactivated in the head. While in-
activation of hpo leads to massive over-
growth of the eye and head cuticles, inac-
tivation of yki leads to the opposite
phenotype. D and E show increased cell
proliferation (D) and decreased cell death
(E) in hpo mutant clones in the pupal eye.
(D) While wild-type cells (green) had
ceased cell proliferation (red), hpo mu-
tant clones (black) continued to divide.
(E) Conversely, normally occurring cell
death can be detected in wild-type cells
(green) but not in hpomutant cells (black).
F shows a wild-type wing imaginal disc
(left) and a wing disc that overexpressed the
yki gene (right). Yki overexpression leads
to a dramatic increase in wing size (up to
eight times the area of the wild-type wings).
Pan
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Mob1B	  (which	  interacts	  with	  Lats1	  and	  Lats2,	  respectively).	  	  
	  
	  
Figure	  2.	  Models	  of	  the	  Hippo	  pathway	  in	  Drosophila	  and	  mammals.	  From	  Zhao	  et	  al.,	  2010.	  
	  
When	  the	  Hippo	  pathway	  is	  active,	  MST	  kinases	  can	  bind	  to	  and	  phosphorylate	  Sav1,	  
and	   this	   interaction	   enhances	   the	   kinase	   activity	   of	  Mst1/2.	   Together	  Mst1/2	   and	  
Sav1	   phosphorylate	   and	   activate	   the	   two	   kinases	   Lats1	   and	   Lats2	   (Lats1/2)	   and	  
Mob1;	   the	   latter,	  when	  phosphorylated,	   acts	   as	   a	   scaffolding	  protein	   and	  binds	   to	  
Lats1/2,	  with	   an	   increase	   of	   their	   kinase	   activity.	   Last1/2	   are	   regulated	   by	   a	   great	  
number	   of	   proteins	   and	   among	   them,	   the	   most	   intensively	   studied	   is	   NF2	  
(Neurofibromin	   2	   or	   Merlin),	   which	   promotes	   Lats1/2	   activation	   inducing	   their	  
plasma	   membrane	   localization	   (Zhang	   et	   al.,	   2010).	   When	   activated,	   Lats1/2	   and	  
Mob1	  cofactor,	  in	  turn,	  phosphorylate	  and	  inactivate	  their	  downstream	  targets:	  the	  
transcriptional	  co-­‐activator	  Yes-­‐associated	  protein	   (YAP)	  and	  the	  transcriptional	  co-­‐
activator	  with	  PDZ-­‐binding	  motif	  (TAZ)	  (Hong	  and	  Guan,	  2012)	  (Figure	  3).	  
	  
These pioneering studies converge on one special fea-
ture of the Hippo pathway: It not only functions to inhibit
cell proliferation, but also to promote apoptosis (Edgar
2006). This functio is achieved t least i part by tran-
scriptional activation of cycE, diap1 (for review, see Edgar
2006), and bantammicroRNA (Nolo et al. 2006; Thompson
and Cohen 2006). Therefore, like many other signaling
pathways, the Hippo pathway regulates a transcription
program. The missing transcriptional link was identified
to be Yki (YAP homolog) transcription coactivator using
Wts as bait in yeast two-hybrid (Huang et al. 2005). Yki
regulates transcription of the Hippo pathway target genes,
and its overexpression phenocopies the loss of Hippo
pathway components. A biochemical study showed that
Wts directly phosphorylates Yki and leads to Yki cyto-
plasmic retention and inactivation (Dong et al. 2007).
The Yki transcription coactivator possesses no DNA-
binding activity. Therefore, a key question was the iden-
tification of target transcription factors that mediate Yki
activity. Clues from mammalian YAP-interacting TEAD
family transcription factors and reported Yki yeast two-
hybrid data led to the identification of Scalloped (Sd),
a critical regulator of proliferation and survival of wing
imaginal disc cells and the Drosophila TEAD homolog,
as a direct Yki target transcription factor mediating
Yki-induced gene expression and overgrowth phenotype
(Goulev et al. 2008; Wu et al. 2008; L Zhang et al. 2008;
Zhao et al. 2008b). Therefore, Sd is the first DNA-binding
factor identified to mediate the Hippo pathway effects in
Drosophila.
A search for mutations with similar phenotypes to
Hippo pathway defects yielded the discoveries of Mer and
Ex, two FERM domain-containing cytoskeleton-related
proteins that act upstream of the Hippo pathway core
components (Fig. 2; Hamaratoglu et al. 2006). While the
double mutant of mer and ex mimics mutation of other
Hippo pathway components, the mer or ex single muta-
tion had only a weak effect on inducing extra interom-
matidial cells, a common phenotype in Hippo pathway
mutants. It was shown later that Mer and Ex may have
different contributions to the phenotypes observed,
where mer mutant clones showed defects in apoptosis
and ex mutant clones showed impaired cell cycle exit
(Pellock et al. 2007). However, the biochemical mecha-
nisms of Hippo pathway regulation byMer and Ex remain
unclear, possibly including an indirect effect on receptor
Figure 2. Models of the Hippo pathway in
Drosophila and mammals. In Drosophila, Fat
protocadherin may initiate the Hippo pathway
signal in response to Ds binding, and is mod-
ulated by binding of Lft and phosphorylation
by Dco (Feng and Irvine 2009; Mao et al. 2009;
Sopko et al. 2009). Fat may inhibit a noncon-
ventional myosin Dachs, which represses Wts
protein levels (Cho et al. 2006). Fat may also
activate Ex with an unknown mechanism
(Bennett and Harvey 2006; Silva et al. 2006;
Willecke et al. 2006; Tyler and Baker 2007).
Mer and Ex also activate the Hippo pathway
(Hamaratoglu et al. 2006). They may form a
complex with Hpo and Sav (Yu et al. 2010).
Kibra interacts with both Mer and Ex, and
may also be in the complex (Yu et al. 2010).
Hpo kinase interacts with and phosphory-
lates a scaffold protein, Sav (Wu et al. 2003). To-
gether, they phosphorylate and activate Wts
kinase and its associated protein, Mats (Lai
et al. 2005).Wts phosphorylates a transcription
coactivator, Yki, on three sites (Oh and Irvine
2009). Phosphorylation of Yki S168 induces
14–3–3 binding and cytoplasmic retention
(Dong et al. 2007). Yki may also be retained in the cytoplasm by physical interaction with Ex, Wts, and Hpo (Badouel et al. 2009; H
Oh et al. 2009). When Yki is relieved from inhibition and gets into the nucleus, it binds and activates a transcription factor, Sd, to induce
cycE, diap1, and ex expression (Goulev et al. 2008; Wu et al. 2008; L Zhang et al. 2008). Yki induces bantammicroRNA through Hth and
Tsh (Peng et al. 2009). In mammals, functional significance of Fat and Ex homologs are not clear. However, Mer may still activate the
Hippo pathway (Yokoyama et al. 2008). RASSF, a subgroup of Ras effector proteins, may also activate Mst1/2 (Hpo homolog) (Oh et al.
2006). Relationships between Hpo, Sav, Wts, and Mats are basically conserved in mammalian Mst1/2, Sav1 (Sav homolog), Lats1/2 (Wts
homolog), and M b (Mats homolog). Lats1/2 phosphorylates YAP on fiv conserved HXRXXS motifs (four on TAZ) (Zhao et al. 2007).
Dependent on cell context, there may exist another YAP kinase in response to Mst1/2 and another Lats1/2 kinase (Zhou et al. 2009). S127
(S89 in TAZ) phosphorylation-dependent 14–3–3 bi ding and cytoplasmic retention are conserved in YAP/TAZ (Zhao et al. 2007; Lei et al.
2008). YAP is also inhibited by S381 phosphorylation, which primes CK1d/e phosphorylation of S384, and S387 finally leads to SCFb-TRCP-
mediated ubiquitination and degradation (Zhao et al. 2010). Sd homologs, TEADs, are major YAP target transcription factors. They
mediate expression of CTGF, Gli2, and many other target genes (Zhao et al. 2008b). AREG is induced by YAP through an unidentified
transcription factor (J Zhang et al. 2009). YAP and TAZ also bind Smad1 and Smad2/3 to activate expression of TGF-b and BMP target
genes, respectively, to maintain stem cell pluripotency (Varelas et al. 2008; Alarcon et al. 2009).
Zhao et al.
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Figure	   3	   The	   core	   of	   the	   Hippo	   signalling	   pathway	   and	   its	  mode	   of	   action.	   Schematics	   of	   the	   core	   pathway	  
components	   and	   how	   they	   interact	   are	   depicted.	   (a)	  When	   the	   Hippo	   pathway	   is	   on,	   mammalian	   STE20-­‐like	  
protein	  kinase	  1	   (MST1)	  or	  MST2	  phosphorylate	  Salvador	  homolog	  1	   (SAV1),	   and	   together	   they	  phosphorylate	  
and	  activate	  MOB	  kinase	  activator	  1A	  (MOB1A),	  MOB1B,	  large	  tumour	  suppressor	  homolog	  1	  (LATS1)	  kinase	  and	  
LATS2	  kinase,	  which	  then	  phosphorylate	  Yes-­‐associated	  protein	  (YAP)	  and	  transcriptional	  co-­‐activator	  with	  PDZ-­‐
binding	  motif	   (TAZ).	  Phosphorylated	  YAP	  and	  TAZ	  are	   sequestered	   in	   the	  cytoplasm	  by	   the	  14-­‐3-­‐3	  protein	  and	  
shunted	   for	   proteasomal	   degradation.	   As	   a	   result,	   the	   TEA	   domain-­‐containing	   sequence-­‐specific	   transcription	  
factors	  (TEADs)	  associate	  with	  the	  transcription	  cofactor	  vestigial-­‐like	  protein	  4	  (VGL4)	  and	  suppress	  target	  gene	  
expression.	  (b)	  When	  the	  Hippo	  pathway	  is	  off,	  the	  kinases	  MST1,	  MST2,	  LATS1	  and	  LATS2	  are	  inactive,	  so	  YAP	  
and	  TAZ	  are	  not	  phosphorylated	  and	   instead	  accumulate	   in	   the	  nucleus	  where	   they	  displace	  VGL4	  and	   form	  a	  
complex	  with	   TEADs,	  which	  promotes	   the	   expression	  of	   target	   genes.	   From	   Johnson,	  R.	  &	  Halder,	  G.	   The	   two	  
faces	   of	  Hippo:	   targeting	   the	  Hippo	   pathway	   for	   regenerative	  medicine	   and	   cancer	   treatment.	  Nat.	   Rev.	   Drug	  
Discov.	  13,	  63–79	  (2014).	  
	  
LATS1/2-­‐mediated	   phosphorylation	   occurs	   on	   multiple	   residues	   (S61,	   S109,	   S127,	  
S164,	   S381	   in	   human	   YAP,	   and	   S66,	   S89,	   S117,	   S311	   in	   human	   TAZ)	   inhibiting	  
YAP/TAZ	  activity	  trough	  different	  mechanisms.	  Phosphorylated	  YAP	  on	  S127	  or	  TAZ	  
on	  S89	  are	  retained	  in	  the	  cytoplasm	  by	  interaction	  with	  14-­‐3-­‐3-­‐proteins	  (Zhao	  et	  al.,	  
2010).	  Moreover,	  phosphorylation	  of	  YAP	  on	  S381	  or	  TAZ	  on	  S311	  serves	  as	  priming	  
event	   for	  successive	  phosphorylation	  by	  Casein	  Kinase	   (CK)	  1	  δ/ε	  and	  creation	  of	  a	  
phosphodegron	   motif,	   that	   tags	   the	   proteins	   to	   E3	   ubiquitin	   ligase	   SCFβ-­‐TrCP	   (β-­‐
transduction	   repeat-­‐containing	   E3	   ubiquitin	   protein	   ligase)	   recognition	   and	  






























attachment regulate the localizati n and activity of YAP 
and TAZ, through a process that requires F-actin and 
that is also present in D. melanogaster97–101. In addition, 
G protein-coupled receptors (GPCRs) that relay signals 
from soluble extracellular cues such as lysophospha-
tidic acid and sphingosine-1-phosphate regulate YAP 
and TAZ activity through RHO GTPases, which are 
likely to affect YAP and/or TAZ via modulation of the 
actin cytoskeleton102–104. Thus, pathways that regulate the 
structure of the actin cytoskeleton — for example, by 
activating RHO signalling — affect the Hippo pathway. 
However, although it is generally appreciated that F-actin 
intersects the pathway downstream of the MST kinases, 
the exact mechanism by which this occurs is not known 
and it may involve LATS-de endent and -i dependent 
regulation of YAP and TAZ97–101,105.
A f urth branch of the inputs to the Hippo pathway 
emanates from the adherens junction. Engagement of 
E-cadherin at adherens junctions suppresses the nuclear 
localization and activity of YAP by regul ting MST 
activity106. In addition, the E-cadherin-associated pro-
tein α-catenin regulates YAP directly by sequestering 
YAP–14-3-3 protein (also known as YWHAQ) com-
plexes in the cytoplasm107,108. Furthermore, members 
of the junction-associated Ajuba protein family directly 
inhibit LATS kinase activity109. In D. melanogaster, 
the related Zyxin protein also regulates Warts levels110. 
Whether these adherens junction-associated regulators 
of the Hippo pathway act independently of each other 
or whether they function coordinately to regulate Hippo 
signalling is not yet known. In addition, crosstalk among 
the different regulatory branches is very likely to exist. 
For example, CRB and adherens junctions regulate the 
structure of the actin cytoskeleton, and polarity roteins 
and junction proteins regulate each other111–114.
I  addition to these four major branches of the 
upstream regulators of Hippo signalling, there are 
several other proteins that modulate the activity of 
Figure 1 | The core of the Hippo signalling pathway and its mode of action. Schematics of the core pathway 







which then phosphorylate Yes-associated protein (YAP) and transcripti nal co-activator with PDZ-binding motif (TAZ). 
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subsequent	   ubiquitin-­‐mediated	   proteasomal	   degradation	   (Liu	   et	   al.,	   2010;	   Zhao	   et	  
al.,	  2010).	  On	  the	  other	  hand,	  when	  the	  Hippo	  pathway	   is	  not	  active,	  YAP	  and	  TAZ	  
are	  de-­‐phosphorylated	  and	  accumulate	  in	  the	  nucleus	  where	  they	  drive	  target	  genes	  
expression.	  However,	  since	  they	  lack	  any	  DNA-­‐binding	  domain,	  YAP	  and	  TAZ	  control	  
transcription	  by	   interacting	  with	  a	  range	  of	  DNA-­‐binding	  transcription	  factors,	  such	  
as	  the	  TEAD/TEF	  family	  transcription	  factors	  (TEAD1/2/3/4)	  and	  activate	  their	  target	  
genes	   such	   as	   the	   connective	   tissue	   growth	   factor	   (CTGF)	   and	   the	   Cysteine-­‐rich	  
angiogenic	  inducer	  61	  (CYR61).	  	  
When	  TEADs	  proteins	   don’t	   interact	  with	   YAP	   and	   TAZ,	   they	   form	   complexes	  with	  
the	   Transcription	   cofactor	   vestigial-­‐like	   protein	   4	   (VGL4),	   which	   represses	   target	  
gene	  expression	  (Guo	  et	  al.,	  2013;	  Koontz	  et	  al.,	  2013).	  
Other	  transcription	  factors	  interacting	  with	  YAP	  and	  TAZ	  are	  the	  p53-­‐family	  member	  
p73,	   the	   Runt	   family	   members	   Runx1	   and	   Runx2,	   Pax3,	   Pax8,	   the	   thyroid	  
transcription	  factor-­‐1	  (TTF1),	  TBX5,	  the	  peroxisome	  proliferator-­‐activated	  receptor	  γ	  
(PPARγ),	  and	  SMAD1/2/3/4	  (Piccolo	  et	  al.,	  2014).	  	  
1.4	  MECHANISMS	  OF	  REGULATION	  OF	  THE	  HIPPO	  PATHWAY	  	  
In	  the	  last	  years	  the	  number	  of	  signals	  and	  mechanisms	  able	  to	  regulate	  the	  Hippo	  
pathway	   is	   rising	   progressively.	   MSTs	   are	   regulated	   by	   a	   number	   of	   proteins	  
including:	  TAO	  (thousand	  and	  one	  aminoacid	  protein)	  and	  MARK1	  (MAP/microtubule	  
affinity	   regulating	   kinase	   1)	   which	   directly	   phosphorylates	   and	   activates	   MSTs	  
(Johnson	   and	   Halder,	   2014).	   KIBRA	   (kidney	   and	   brain	   protein)	   and	   Expanded	   are	  
instead	  adaptor	  proteins	  for	  MSTs	  activity	  (Genevet	  et	  al.,	  2010).	  LATSs	  kinases	  are	  
regulated	   by	   NF2,	   the	   tumour	   suppressor	   protein	   Merlin,	   which	   promotes	   LATSs	  
activation	   by	   inducing	   their	   plasma	   membrane	   localization	   (Hamaratoglu	   et	   al.,	  
2006).	  
YAP	   and	   TAZ	   are	   regulated	   by	   different	   signalling:	   extracellular	   factors,	   cell–cell	  
adhesions,	   cell	   polarity	   and	  mechano-­‐transduction.	   The	   Crumbs	   homolog	   complex	  
(CRB)	   localizes	   to	   apical	   junction	   and	   regulates	   cell	   polarity	   (Johnson	   and	   Halder,	  
2014).	   Together	   with	   AMOT	   (angiomotin	   adaptor	   proteins)	   CRB	   inhibits	   YAP	   by	  
promoting	   its	   cytoplasmic	   retention.	   Another	   regulator	   of	   cell	   polarity	   is	   Scribble,	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which	  is	  required	  for	  the	  recruitment	  of	  MST	  and/or	  LATS	  to	  TAZ	  (Cordenonsi	  et	  al.,	  
2011).	  
E-­‐cadherin	  localization	  at	  adherens	  junctions	  suppresses	  the	  nuclear	  localization	  and	  
activity	  of	  YAP	  by	  regulating	  MST	  kinase	  activity	  (Bhat	  et	  al.,	  2011).	  Moreover,	  the	  E-­‐
cadherin-­‐associated	  protein	  α-­‐catenin	  regulates	  YAP	  by	  sequestering	  the	  YAP-­‐14-­‐3-­‐3	  
protein	  complex	  in	  the	  cytoplasm	  (Schlegelmilch	  et	  al.,	  2011).	  	  
YAP	   and	   TAZ	   are	   also	   directly	   regulated	   by	   the	   extracellular	   matrix	   (ECM)	   and	  
stiffness:	  cells	  that	  are	  grown	  on	  stiff	  ECM	  show	  high	  YAP/TAZ	  nuclear	   localization,	  
whereas	   cells	   cultured	   on	   low	   stiffness	   display	   inactivated	   YAP	   and	   TAZ	   in	   the	  
cytoplasm.	   This	   layer	   of	   regulation	   requires	   RHO	   GTPase	   proteins	   activity	   and	  
tension	  of	   the	  actomyosin	   cytoskeleton.	  Although	   it	   is	  unclear	  how	  actin	   regulates	  
YAP	   and	   TAZ,	   the	   small	   GTPase	   RHO-­‐A	   protein	   is	   the	   prime	   regulator	   of	   this	   actin	  
dependency	  (Dupont	  et	  al.,	  2011;	  Sorrentino	  et	  al.,	  2014).	  	  
The	   Hippo	   pathway	   is	   also	   regulated	   by	   GPCRs	   (G-­‐protein	   coupled	   receptors)	  
proteins;	   they	   transduce	   extracellular	   signals	   to	   the	   interior	   of	   the	   cell	   by	   using	  
heterotrimeric	   G	   proteins	   that	   consist	   of	   α-­‐,	   β-­‐	   and	   γ-­‐subunits.	   Among	   the	   Gα	  
proteins,	  Gα11,	  Gα12,	  Gα13,	  Gαi,	  Gαo	  and	  Gαq	  can	  activate	  YAP	  and	  TAZ,	  whereas	  
Gαs-­‐coupled	  signals	  repress	  them.	  This	  regulation	  is	  mediated	  by	  LATS	  kinases	  (Yu	  et	  
al.,	   2012).	   In	   addition	   to	  GPCRs,	   the	   cytokine	   receptor	   leukaemia	   inhibitory	   factor	  
receptor	  (LIFR)	  is	  able	  to	  regulate	  YAP;	  in	  fact	  it	  has	  been	  shown	  that	  loss	  of	  LIFR	  in	  
non-­‐metastatic	   breast	   cancer	   cells	   induces	   migration,	   invasion	   and	   metastatic	  
colonization	   through	   activation	   of	   YAP	   while	   restoring	   LIFR	   expression	   in	   highly	  
malignant	  tumour	  cells	  suppresses	  metastasis	  by	  activating	  the	  Hippo	  kinase	  cascade	  
that	   leads	   to	  phosphorylation,	   cytoplasmic	   retention	  and	   functional	   inactivation	  of	  
YAP	  (Chen	  et	  al.,	  2012)	  (Figure	  4).	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Figure	   4.	   The	  Hippo	   pathway	   network.	  Mammalian	  Hippo	  pathway	   components	   that	  promote	   the	  activity	  of	  
Yes-­‐associated	  protein	   (YAP)	  and	  transcriptional	  co-­‐activator	  with	  PDZ-­‐binding	  motif	   (TAZ)	  are	  shown	   in	  green,	  
whereas	   those	   that	   inhibit	   YAP	   and	   TAZ	   activity	   are	   shown	   in	   red.	   AMOT,	   angiomotin;	   β-­‐TRCP,	   β-­‐transducin	  
repeat-­‐containing	   E3	   ubiquitin	   protein	   ligase;	   CSNK1,	   casein	   kinase	   1;	   CRB,	   Crumbs	   homolog;	   DLG,	   discs	   large	  
homolog;	  FRMD6,	  FERM	  domain-­‐containing	  protein	  6;	  GPCR,	  G	  protein-­‐coupled	  receptor;	  HIPK,	  homeodomain-­‐
interacting	   protein	   kinase;	   KIBRA,	   kidney	   and	   brain	   protein;	   LATS,	   large	   tumour	   suppressor	   homolog;	   MARK,	  
MAP/microtubule	   affinity-­‐regulating	   kinase;	   MASK,	   multiple	   ankyrin	   repeats	   single	   KH	   domain-­‐containing	  
protein;	  MOB1A,	  MOB	   kinase	   activator	   1A;	  MST,	  mammalian	   STE20-­‐like	   protein	   kinase;	   NF2,	   neurofibromin	   2	  
(also	  known	  as	  Merlin);	  PP2A,	  protein	  phosphatase	  2A;	  PTPN14,	  protein	  tyrosine	  phosphatase,	  non-­‐receptor	  type	  
14;	   RASSF,	   RAS	   association	   domain-­‐containing	   family	   protein;	   SAV1,	   Salvador	   homolog	   1;	   SCRIB,	   Scribble	  
homolog;	   SIK,	   salt-­‐inducible	   kinase;	   TAO,	   thousand	   and	   one	   amino	   acid	   protein	   kinase;	   TEAD,	   TEA	   domain-­‐
containing	   sequence-­‐specific	   transcription	   factor;	   VGL4,	   vestigial-­‐like	   protein	   4;	   WBP2,	   WW	   domain-­‐binding	  
protein	  2;	  ZO,	  zona	  occludens	  protein;	  ZYX,	  Zyxin	  protein.	  From	  Johnson	  et	  al.,	  2014.	  
 
	  
In	   addition	   to	   these	   upstream	   regulators,	   there	   are	   several	   other	   proteins	   that	  
modulate	   the	  activity	  of	  YAP/TAZ.	  Among	   them,	  Homeodomain-­‐interacting	  protein	  
kinase	  2	   (HIPK2),	  which	  promotes	  YAP	  abundance;	  14-­‐3-­‐3	  proteins,	  which	  mediate	  
cytoplasmic	  YAP/TAZ	  retention	  after	  Hippo	  pathway	  activation;	  casein	  kinase	  1	  and	  
β-­‐	   TRCP,	  which	  mediate	   YAP/TAZ	   protein	   degradation;	   and	   finally	   protein	   tyrosine	  






































(KIWTG^The Hippo pathway network. An outline of a cell is depicted, showing the nucleus and the Hippo pathway 
network. Mammalian Hippo pathway comp nents th t promote the activity of Yes-associated protein (YAP) and 
transcriptional co-activator with PDZ-binding motif (TAZ) are shown in green, whereas those that inhibit YAP and TAZ 
activity are shown in red. Pointed and blunt arrowheads indicate activating and inhibitory interactions, respectively. 
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phosphatase	   non-­‐receptor	   type	   14	   (PTPN14),	   which	   promotes	   the	   nucleus-­‐to-­‐
cytoplasm	  translocation	  of	  YAP	  during	  contact	  inhibition	  (Johnson	  and	  Halder,	  2014).	  
YAP	  and	  TAZ	  regulate	  also	  tumour	  cell	  niches	  by	  modulating	  cell–cell	  and	  cell–matrix	  
interactions	   through	   the	   production	   of	   secretory	   proteins,	   such	   as	   cysteine-­‐rich	  
angiogenic	   inducer	   61	   (CYR61),	   amphiregulin	   (AREG;	   an	   epidermal	   growth	   factor	  
family	  member)	  and	  connective	  tissue	  growth	  factor	  (CTGF).	  	  
2.1	  YAP	  AND	  TAZ	  PROTEIN	  STRUCTURE	  	  	  
The	   Yes-­‐associated	   protein	   (YAP)	   transcription	   co-­‐activator	   is	   a	   key	   regulator	   of	  
organ	   size	   and	   development	   (Dong	   et	   al.,	   2007).	   The	   human	   YAP	   gene,	   located	   at	  
11q22,	   can	  be	   transcribed	   into	   at	   least	   two	  major	   isoforms	  of	   that	   are	   derived	  by	  
differential	  splicing	  (Sudol	  et	  al.,	  2012).	  These	  are	  YAP1,	  containing	  one	  WW	  domain	  
and	  YAP2,	  containing	  two	  WW	  domains.	  Molecular	  structure	  of	  YAP	  is	  composed	  by	  
an	   N-­‐terminal	   proline-­‐rich	   domain,	   a	   TEAD-­‐binding	   region,	  WW	   domains,	   an	   SH3-­‐
binding	   motif,	   a	   coiled-­‐coil	   domain,	   a	   transcription	   activation	   domain	   and	   a	   C-­‐
terminal	  PDZ-­‐binding	  motif	  (figure	  5).	  
YAP	   mRNA	   is	   expressed	   in	   a	   wide	   range	   of	   tissues,	   except	   peripheral	   blood	  
leukocytes	  (Zhao	  et	  al.,	  2010).	  Since	  it	   lacks	  of	  a	  DNA-­‐binding	  domain,	  YAP	  controls	  
gene	   expression	   modulating	   the	   activity	   of	   some	   transcription	   factors.	   The	   WW	  
domains	   reflect	   the	   sequence	   motif	   containing	   two	   conserved	   tryptophan	   (W)	  
residues	  and	  they	  have	  been	  shown	  to	  bind	  PPXY	  motif.	  	  
Two	  proteins	  binding	  to	  the	  WW	  domain	  of	  YAP	  have	  been	  identified	  as	  interacting	  
partners:	   WBP-­‐1	   and	   WBP-­‐2	   (WW	   domain	   Binding	   Protein).	   Moreover,	   several	  
transcription	  factors	  such	  RUNX,	  ErbB4	  cytoplasmic	  domain,	  and	  Smad1	  contain	  the	  
PPXY	  motif	  and	  could	  be	  potential	  targets	  for	  YAP,	  although	  none	  of	  them	  has	  been	  
shown	  to	  mediate	  the	  growth-­‐promoting	  function	  of	  YAP.	  
Phosphorylation	   of	   YAP	   by	   the	   Hippo	   pathway	   leads	   to	   its	   sequestration	   in	   the	  
cytoplasm	   and/or	   to	   its	   proteasomal	   degradation.	   Therefore,	   the	   Hippo	   pathway	  
regulates	   YAP	   by	   both	   spatial	   (nuclear-­‐cytoplasmic	   translocation)	   and	   temporal	  
(degradation)	   mechanisms.	   Mechanistically,	   tumour	   suppressor	   kinases	   LATS1/2	  
directly	   phosphorylate	   YAP	   at	   five	   serine/threonine	   residues	   (defined	   by	   the	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consensus	   HxRxxS).	   Mutation	   in	   these	   serine	   residues	   makes	   YAP	   insensitive	   to	  
inhibition	  by	  the	  Hippo	  pathway;	  in	  fact	  the	  most	  common	  used	  mutant-­‐YAP	  protein	  
expresses	  serine	  to	  alanine	  mutations	  in	  all	  these	  LATS	  phosphorylation	  sites	  (Piccolo	  
et	  al.,	  2014).	  
TAZ,	   also	   known	   as	   WWTR1	   (WW-­‐domain	   containing	   transcriptional	   regulator	   1,	  
WWTR1),	  was	  first	  identified	  as	  a	  14-­‐3-­‐3	  binding	  protein.	  Sequence	  analysis	  revealed	  
that	  TAZ	  shares	  homology	  with	  Yes	  associated	  protein	  (YAP),	  previously	  identified	  as	  
a	  binding	  partner	  of	  the	  SH3	  domain	  of	  the	  Src-­‐family	  kinase	  Yes.	  Both	  TAZ	  and	  YAP	  
contain	   WW	   domain,	   a	   14-­‐3-­‐3	   binding	   motif,	   a	   coiled-­‐coiled	   motif	   in	   the	  
transactivation	  domain	  and	  a	  PDZ-­‐binding	  motif	   in	   the	  C-­‐terminal	   (Liu	  et	  al.,	  2011)	  
(Figure	  	  4).	  Those	  motifs	  and	  domains	  are	  critical	  for	  regulating	  TAZ	  function.	  	  
TAZ	   has	   been	   shown	   to	   interact	   with	   and	   regulate	   multiple	   transcription	   factors,	  
such	   as	   Runx2	   (runt-­‐related	   transcription	   factor	   2)	   (Cui	   et	   al.,	   2003),	   PPAR	  
perioxisome	  proliferator-­‐activated	   receptor	  PPAR)	   (Hong	  et	   al.,	   2005),	   TBX5	   (T-­‐box	  
transcription	   factor	   5,	   TBX5)	   (Murakami	   et	   al.,	   2005),	   TEADs	   (TEA	   domain	   family	  
members,	   TEAD)	   (Chan	   et	   al.,	   2009),	   TTF-­‐1	   (thyroid	   TF1,	   TTF1),	   PAX3	   (paired	   box	  
homeotic	  gene	  3,	  PAX3).	  	  
TAZ	  phosphorylation	  at	  Ser89	  mediated	  by	  LATS	  generates	  a	  14-­‐3-­‐3	  binding	  site	  and	  
promotes	  TAZ	  its	  sequestration	  in	  the	  cytoplasm	  (Lei	  et	  al.,	  2008).	  
TAZ	   contains	   four	   consensus	   HxRxxS	   motifs.	   Besides	   Ser89,	   LATS	   kinase	   also	  
phosphorylates	  TAZ	  at	  Ser	  66,	  Ser117	  and	  Ser311.	  TAZ	  is	  a	  very	  unstable	  protein	  with	  
a	  half-­‐life	  of	  2	  hours,	   indicating	  that	  protein	  degradation	   is	   the	  main	  route	   for	  TAZ	  
inhibition	  (Piccolo	  et	  al.,	  2014).	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Figure	  5.	  Schematic	  representation	  depicting	  the	  multiple	  domains	  of	  YAP	  and	  TAZ,	  the	  mapped	  interactions	  
with	  other	  proteins,	  and	  the	  residues	  targeted	  by	  post-­‐translational	  modifications.	  The	  five	  serines	  of	  YAP	  and	  
the	  corresponding	  four	  serines	  of	  TAZ	  that	  are	  targeted	  by	  LATS1/2	  phosphorylation	  are	  shown	  in	  yellow,	  the	  CK1	  
phosphorylation	  sites	  on	  both	  proteins	  are	  shown	  in	  gray,	  and	  the	  c-­‐Abl	  phosphorylation	  site	  on	  YAP	  is	  shown	  in	  
cyan.	   The	   lysine	   residue	  of	   YAP	   targeted	   for	  methylation	  by	   Set7	   is	   also	   shown.	   TEAD	  BD	   is	   the	   TEAD	  binding	  
domain.	   14–3-­‐3	   BD	   is	   the	   domain	   that	   binds	   14–3-­‐3	   proteins	   upon	   phosphorylation	   by	   LATS1/2.	   TAD	   is	   the	  
transcriptional	   activation	   domain.	   PDZ	   BD	   is	   the	   small	   COOH-­‐terminal	   domain	   able	   to	   interact	   with	   proteins	  
bearing	  PDZ	  domains.	  From	  Piccolo	  et	  al.,	  2014.	  
2.2	  YAP	  FUNCTION	  IN	  ORGANS	  AND	  TISSUES	  	  
YAP	  and	  TAZ	  have	  very	  important	  biological	  functions	  in	  several	  tissues.	  One	  of	  the	  
most	   important	   role	   of	   YAP	   and	   TAZ	   is	   the	   control	   of	   the	   organ	   size	   during	  
development.	  In	  particular	  YAP	  overexpression	  in	  mice	  liver	  is	  sufficient	  to	  induce	  a	  
four-­‐fold	  increase	  in	  liver	  mass	  due	  to	  proliferation	  of	  mature	  hepatocytes;	  this	  also	  
leads	  to	  the	  acquisition	  of	  biliary	  duct/liver	  progenitor	  cell	  traits	  by	  the	  hepatocytes	  
(Piccolo	   et	   al.,	   2014).	   This	   phenotype	   is	   dependent	   on	   TEAD-­‐mediated	   gene	  
responses,	   in	   fact	   crossing	   TRE-­‐TEAD2-­‐DN	   (TEAD2-­‐	   dominant-­‐negative	   under	   the	  
control	  of	   a	   tetracycline-­‐responsive	  element)	   transgenic	  mouse	  model	  with	  mouse	  
model	  in	  which	  human	  YAP	  protein	  is	  overexpressed	  in	  a	  liver-­‐specific	  manner	  lead	  
to	   hepatomegaly	   and	   tumorigenesis	   suppression	   driven	   by	   YAP	   overexpression	   as	  
shown	   in	   figure	   6	   (Liu-­‐Chittenden	   et	   al.,	   2012).	   Moreover	   Liu-­‐Chittenden	   and	  
YAP/TAZ nuclear accumulation is a key determinant of
their function. Phosphorylation by LATS also represents a
main input for YAP/TAZ subcellular localization, leading
to sequestration of YAP/TAZ in the cytoplasm. Phosphor-
ylation of YAP S127 creates a binding consensus for 14-3-3
proteins (14, 49, 266), which would then contribute to
keep YAP/TAZ in the cytoplasm. This model is, however,
not entirely coherent with some experimental observa-
tions. 1) S127-phosphorylated YAP can be found in the
nucleus (217). 2) Treatment of cells bearing cytoplasmic
and phosphorylated YAP with the CRM1 inhibitor lep-
tomycinB induces its nuclear accumulation, indicating
that YAP actually keeps on entering the nucleus even
when it is phosphorylated (50, 178). 3) Expression of
YAP S127A in tissues of transgenic mice is not restricted
to the nucleus (12). It is thus possible that YAP phosphor-
ylation on sites other than S127 may cause YAP seques-
tration into additional protein complexes. Moreover, it is
also possible that LATS-mediated phosphorylation af-
fects YAP/TAZ activity by additional modalities. For ex-
ample, phosphorylation might hinder part of the tran-
scriptional functions of YAP/TAZ, as some of the puta-
tive phosphorylation sites overlap with the TEAD and
COOH-terminal transactivation domain, and this may
contribute to nuclear exclusion.
It is worth anticipating here that independent pieces of ev-
idence suggest that some classic “LATS” phosphorylation
sites, including S127, may be actually targeted by kinases
other than LATS1/2: 1) S127 was originally identified as
AKT target; 2) fractionation of liver extracts revealed that
fractions void of LATS1/2 were still able to phosphorylate
YAP S127; 3) in keratinocytes, !-catenin works in concert
with an unknown kinase to sustain YAP phosphorylation in
S127; and 4) in line, attenuation of the metabolic meval-
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FIGURE 1. Schematic representation depicting the multiple domains of YAP and TAZ, the mapped interac-
tions with other proteins, and the residues targeted by posttranslational modifications. The five serines of YAP
and the corresponding four serines of TAZ that are targeted by LATS1/2 phosphorylation are shown in yellow,
the CK1 phosphorylation sites on both proteins are shown in gray, and the c-Abl phosphorylation site on YAP
is shown in cyan. The lysine residue of YAP targeted for methylation by Set7 is also shown. TEAD BD is the
TEAD binding domain. 14–3-3 BD is the domain that binds 14–3-3 proteins upon phosphorylation by
LATS1/2. TAD is the transcriptional activation domain. PDZ BD is the small COOH-terminal domain able to
inte act with proteins be ring PDZ d mains. See text for details.
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collegues	  identified	  a	  small-­‐molecule	  inhibitor,	  verteporfin,	  that	  was	  able	  to	  disrupt	  
YAP/TEAD	  interaction	  open	  the	  possibility	  that	   inhibiting	  TEAD–YAP	   interaction	   is	  a	  
pharmacologically	  viable	  strategy	  against	  the	  YAP	  oncoprotein	  function.	  
	  
Figure	  6.	  TEAD2-­‐DN	  suppressed	  hepatomegaly	  and	  tumorigenesis	  driven	  by	  YAP	  overexpression.	  (A,B)	  Whole	  
amount	   (A)	  and	  hema-­‐	   toxylin/eosin	   (H&E)	   staining	   (B)	  of	   livers	   from	  wild-­‐type	   (WT),	  YAP,	  and	  YAP/TEAD2-­‐DN	  
mice	  treated	  with	  0.2	  g/L	  Dox	  for	  2	  wk	  starting	  at	  3	  wk	  of	  age.	  Bar,	  1	  cm.	  (C,D)	  similar	  to	  A	  and	  B	  except	  that	  mice	  
were	  treated	  with	  1	  g/L	  Dox	  for	  8	  wk	  starting	  at	  birth.	  (E)	  Quantification	  of	  liver-­‐to-­‐body	  weight	  ratio	  for	  animals	  
analyzed	  in	  A	  and	  C.	  Values	  are	  mean	  6	  SEM;	  n	  $	  3	  for	  each	  data	  point.	  (F)	  Survival	  curves	  of	  wild-­‐type,	  YAP,	  and	  
YAP/TEAD2-­‐DN	  mice	   subjected	   to	   0.2	   g/L	   Dox	   treatment	   starting	   at	   3	   wk	   of	   age.	   From	   Liu-­‐Chittenden	   et	   al.,	  
2012).	  
	  
On	   the	   contrary	   YAP	   liver	   specific	   inactivation	   leads	   to	   reduction	   in	   hepatocyte	  
proliferation,	   defective	   bile	   duct	   morphogenesis	   and	   increase	   in	   apoptosis.	   As	   a	  
consequence,	   mice	   display	   a	   mild	   liver	   enlargement,	   steatosis,	   and	   progressive	  
fibrosis	   (Zhang	  et	  al.,	  2010).	  YAP	   liver	  conditional	  knockout	  mice	  display	  decreased	  
duct	  cell	  proliferation	  and	  enhanced	  parenchymal	  damage,	  suggesting	  a	  positive	  role	  
ability to promote anchorage-independent growth of
HPNE (human pancreatic Nestin-expressing) cells in
soft agar (Supplemental Fig. S1C,D; Dong et al. 2007).
Notably, TEAD2-DN’s suppressive activity is specific
to YAP, as overexpression of TEAD2-DN in HPNE cells
did not suppress cell proliferation or anchorage-independent
growth induced by activated KRAS (Supplemental Fig.
S2).
To test the activity of TEAD2-DN in vivo, we gener-
ated transgenic mice expressing TEAD2-DN under the
control of a tetracycline-responsive element (TRE). We
previously reported a transgenic mouse model, ApoE-
rtTA/TRE-YAP, in which human YAP protein can be
overexpressed in a liver-specific (via ApoE-rtTA) and doxy-
cycline (Dox)-dependent (via TRE-YAP) manner (Dong
et al. 2007). Crossing TRE-TEAD2-DN with ApoE-rtTA/
TRE-YAP generated transgenic mice in which YAP and
TEAD2-DN were co-overexpressed in a liver-specific and
Dox-dependent manner. For simplicity, these mice will be
referred to as YAP/TEAD2-DN.
We showed previously that induction of YAP over-
expression starting at 3 wk of age leads to a robust and
uniform expansion of liver size, whereas induction of
YAP overexpression starting at birth leads to widespread
development of hepatocellular carcinoma (HCC) (Dong
et al. 2007). We used these experimental regimes to test
the efficacy of TEAD2-DN in blocking YAP-induced over-
growth and tumorigenesis. In mice subjected to Dox
treatment starting at 3 wk of age, expression of TEAD2-
DN potently suppressed YAP-induced liver overgrowth
(Fig. 1A,B,E), whereas in mice subjected to Dox treatment
starting at birth, expression of TEAD2-DN completely
abolished YAP-induced HCC formation (Fig. 1C–E). Ex-
pression of TEAD2-DN also greatly improved animal
survival; in contrast to YAP transgenic mice, which had
a mean survival of 7 wk after Dox treatment starting at
3 wk of age, YAP/TEAD2-DN mice showed 100% sur-
vival during a 15-wk treatment (Fig. 1F). Unlike YAP-
overexpressing livers, in which hepatocytes are smaller
and more densely packed than wild type, YAP/TEAD2-
DN livers contained hepatocytes of normal size (Fig. 1B),
suggesting that TEAD2-DN may suppress YAP’s ability
to promote cell proliferation and/or survival. Indeed, YAP/
TEAD2-DN livers showed greatly reduced BrdU incorpo-
ration compared with YAP livers (Supplemental Fig.
S3A,D). Furthermore, unlike YAP-overexpressing livers,
which were resistant to Jo-2 (a Fas agonist)-induced hepa-
tocellular apoptosis (Dong et al. 2007), Jo-2 treatment
induced similar levels of apoptosis in YAP/TEAD2-DN
and wild-type livers, as revealed by the widespread hem-
orrhage and apoptotic nuclei in liver histology and caspase
3 cleavage (Supplemental Fig. S3B,C). Thus, TEAD2-DN
suppressed YAP’s proproliferative and anti-apoptotic ac-
tivities. At mRNA levels, TEAD2-DN reversed the up-
regulation of genes that have previously been reported to
be transcriptionally induced in YAP transgenic livers, in-
cludingAfp,Birc5/survivin, c-Myc, Sox4,Ctgf,Opn, Epcam,
and Gpc3 (Supplemental Fig. S3E; Dong et al. 2007). Thus,
TEAD2-DN can restore YAP-induced gene transcription to
wild-type levels.
A trivial explanation for the observed suppression of
YAP-induced phenotypes by TEAD2-DN is that TEAD2-
DN may somehow reduce the expression of the YAP
transgene in the double-transgenic livers. We attempted
to exclude this possibility by comparing YAP protein
levels in YAP versus YAP/TEAD2-DN livers. On the
contrary, however, we found that YAP/TEAD2-DN livers
always sh wed significantly increased levels f YAP pro-
teins compared with YAP transgenic livers, irrespective
f the length of Dox treatment (Supplemental Fig. S4A).
Quantitative real-time PCR analysis revealed similar
level of human YAP mRNA (from th YAP transgene)
and endogenous mouse Yap mRNA in both genotypes
(Suppl mental Fig. S4B), suggesting that TEAD2-DN may
increase YAP protein levels through a post-transcriptional
mechanism; for example, by binding and stabilizing YAP.
We tested this hypothesis in HEK293 cells. Indeed, when
a GFP-tagged YAP was coexpressed with an increasing
amount of HA-tagged TEAD2 or TEAD2-DN, both the
exogenous GFP-YAP and the endogenous YAP protein
levels were increased (Supplemental Fig. S4C). We also
compared the half-life of wild-type YAP and YAPS94A,
Figure 1. TEA 2-DN suppr ssed hepatomegaly and tumorigenesis
driven by YAP overexpression. (A,B) Whole amount (A) and hema-
toxylin/eosin (H&E) staining (B) of livers from wild-type (WT), YAP,
and YAP/TEAD2-DN mice treated with 0.2 g/L Dox for 2 wk
starting at 3 wk of age. Bar, 1 cm. (C,D) similar to A and B except
that mice were treated with 1 g/L Dox for 8 wk starting at birth. (E)
Quantification of liver-to-body weight ratio for animals analyzed in
A and C. Values are mean 6 SEM; n $ 3 for each data point. (F)
Survival curves of wild-type, YAP, and YAP/TEAD2-DN mice
subjected to 0.2 g/L Dox treatment starting at 3 wk of age.
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for	  YAP	  in	  liver	  regeneration	  (Bai	  et	  al.,	  2012).	  
These	  studies	  reveal	  an	  important	  role	  for	  Hippo/YAP	  signaling	  in	  liver	  biology.	  	  
Recently	   it	  was	   demonstrated	   that	   YAP	  plays	   an	   important	   role	   in	   cardiomyocytes	  
proliferation;	  in	  fact	  its	  deletion	  in	  embryonic	  cardiomyocytes	  leads	  to	  a	  reduction	  in	  
cell	  proliferation	  and	   in	  heart	  hypoplasia	  while	  YAP	  overexpression	   increases	  heart	  
size	   (Xin	  et	   al.,	   2013).	  Deletion	  of	  YAP	  postnatally	  was	  associated	  with	  progressive	  
dilated	  cardiomyopathy:	  in	  this	  case	  it	  has	  been	  demonstrated	  a	  specific	  role	  of	  YAP	  
and	  TAZ	  in	  heart	  disorders	  because	  the	  inactivation	  of	  both	  TAZ	  and	  YAP	  accelerated	  
the	  beginning	  of	  the	  cardiac	  disease,	  and	  the	  complete	  YAP/TAZ-­‐null	  hearts	  became	  
unable	   to	   sustain	   postnatal	   life.	   Moreover,	   it	   was	   shown	   that	   in	   adult	   heart	  
overexpression	   of	   activated	   YAP	   induced	   the	   regenerative	   response	   to	  myocardial	  
infarction	  (Del	  Re	  et	  al.,	  2013).	  
These	   evidences	   open	   a	   new	   window	   for	   the	   development	   of	   new	   therapeutic	  
approaches	   that,	   by	   inhibiting	  Hippo	   kinases,	   could	   facilitate	  heart	   regeneration	   in	  
patients	  suffering	  cardiac	  damage.	  
Recently	   a	   key	   role	   of	   YAP	   in	   tissue	   regeneration	   of	   intestinal	   epithelial	   regrowth	  
following	  injury	  has	  emerged.	  Elevated	  YAP	  expression	  is	  seen	  in	  mice	  treated	  with	  
dextran	  sodium	  sulphate	  (DSS),	  a	  chemical	  that	  results	  in	  injury	  and	  inflammation	  of	  
the	  large	  intestine	  and	  initiation	  of	  regenerative	  response.	  Mice	  depleted	  for	  YAP	  in	  
the	  colonic	  epithelium	  do	  not	  show	  defects	  in	  intestinal	  homeostasis	  but	  are	  unable	  
to	  efficiently	  undergo	  a	  regenerative	  response	  following	  DSS	  treatment,	  indicating	  a	  
role	  for	  Hippo	  signalling	  in	  repressing	  regenerative	  responses	  that	  involve	  stem	  cell	  
activation	  (Cai	  et	  al.,	  2010).	  
Barry	  and	  colleagues	  demonstrated	  that	  upon	  whole-­‐body	  irradiation,	  YAP-­‐deficient	  
mice	  showed	  crypt	  hyperplasia	  and	  overgrowth	  in	  both	  small	  intestine	  and	  colon.	  	  
The	  authors	  confirmed	  the	  growth-­‐suppressive	  function	  of	  YAP	  by	  stimulation	  with	  
the	  Wnt	   agonist	   R-­‐spondin1	   (Rspo1),	   a	   potent	   growth	   factor	   for	   intestinal	   crypts.	  
Loss	  of	  YAP	  increased	  Wnt/Rspo1	  hypersensitivity	  and	  induced	  massive	  hyperplasia,	  
which	   was	   accompanied	   by	   upregulation	   of	   Wnt	   targets	   and	   intestinal	   stem	   cell	  
markers.	  Together,	  these	  data	  suggest	  an	  opposite	  roles	  of	  YAP	  in	  the	  intestine:	  on	  
one	   hand	   YAP	   serves	   as	   an	   oncoprotein,	   promoting	   growth	   upon	   DSS-­‐induced	  
intestinal	  damage,	  on	  the	  other	  YAP	  acts	  as	  a	  growth-­‐repressive	  protein	  that	  restricts	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Wnt/Rspo1-­‐induced	   intestinal	   stem-­‐cell	   expansion	   and	   regeneration	   after	  
irradiation-­‐induced	  injury.	  	  
Overexpression	   of	   activated	   YAP	   can	   specifically	   expand	   the	   epidermal	   stem	   cell	  
compartment	  in	  the	  basal	   layer	  of	  the	  epidermis	  while	  YAP	  deletion	  from	  the	  basal	  
layer	  of	  the	  embryonic	  epidermis,	  shows	  reduced	  stratification	  caused	  by	  reduction	  
in	   keratinocyte	   proliferation	   and	   reduced	   stem	   cells	   self-­‐renewal	   in	   mice	  
(Schlegelmilch	  et	  al.,	  2011).	  Cottini	  et	  al.	  in	  2014	  demonstrated	  a	  role	  for	  YAP1	  as	  a	  
tumor-­‐suppressor	   gene	   in	   hematological	   cancers.	   In	   fact,	   they	   observed	   that	  
although	   nuclear	   ABL1	   triggers	   cell	   death	   through	   its	   interaction	   with	   the	   Hippo	  
pathway	   coactivator	   YAP1	   in	   normal	   cells,	   this	   type	   of	   tumours	   escape	   apoptosis	  
preventing	   nuclear	   ABL1-­‐induced	   apoptosis	   as	   a	   result	   of	   genetic	   inactivation	   or	  
reduced	   expression	   of	   the	   Hippo	   transcriptional	   cofactor	   YAP1;	   in	   this	   study	   they	  
proposed	   a	   new	   synthetic-­‐lethal	   approach	   in	   which	   inhibition	   of	   the	   kinase	   STK4,	  
that	   normally	   reduce	   YAP	   levels,	   reactivates	   YAP1	   and	   triggers	   ABL1-­‐dependent	  
apoptosis,	   providing	   the	   rationale	   for	   developing	   STK4	   inhibitors	   for	   clinical	  
evaluation	  in	  haematological	  	  malignancies	  (Cottini	  et	  al.,	  2014).	  
2.3	  THE	  HIPPO	  PATHWAY	  IN	  HUMAN	  CANCERS	  	  	  
Consistent	  with	  the	  critical	  role	  of	  the	  Hippo	  signalling	  in	  growth	  control,	  widespread	  
dysregulation	   or	   mutations	   in	   the	   Hippo	   pathway	   are	   associated	   in	   a	   variety	   of	  
human	   carcinomas.	   However,	   the	   mechanisms	   that	   lead	   to	   Hippo	   pathway	  
deregulation	  and	  YAP/TAZ	  activation	  in	  human	  cancer	  are	  still	  not	  well	  understood.	  
In	  general,	  components	  of	  the	  Hippo	  pathway	  can	  be	  divided	  in	  tumour	  suppressors	  
and	  tumour	  promoters:	  while	  the	  core	  module	  members	  Mst1/2,	  Sav1,	  Lats1/2	  and	  
Mob1	  and	  upstream	  regulators	  are	  mostly	  involved	  in	  tumour	  suppressive	  functions,	  
YAP	   and	   TAZ	   and	   their	   activators	   have	   mainly	   been	   described	   to	   have	   oncogenic	  
roles.	  Abnormally	   elevated	   levels	   and	  nuclear	   localization	  of	   YAP	   and	  TAZ,	   indeed,	  
have	  been	  reported	  in	  many	  human	  cancers,	  including	  breast,	  liver,	  lung,	  skin,	  colon	  
and	  ovarian	  cancers	   (Harvey	  et	  al.,	  2013).	   In	   line	  with	   this,	  preclinical	   studies	  have	  
already	  described	  similar	  phenomena	  in	  murine	  tissue:	  transgenic	  expression	  of	  YAP	  
in	  mouse	   liver	   results	   in	   a	   dramatic	   increase	   of	   liver	  mass	   in	   a	   reversible	  manner,	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hyperplasia,	  and	  eventually	   leads	  to	  tumour	  formation	  (Camargo	  et	  al.,	  2007;	  Dong	  
et	   al.,	   2007),	   confirming	   the	   important	   role	   of	   YAP	   in	   organ	   size	   regulation	   and	  
tumorigenesis	  (figure	  7).	  Moreover,	  in	  mouse	  models,	  YAP	  activation	  is	  able	  to	  drive	  
expansion	   of	   multipotent	   undifferentiated	   progenitor	   cells	   and	   to	   induce	   severe	  
dysplasia	  along	  the	  entire	  intestinal	  epithelium	  (Camargo	  et	  al.,	  2007).	  
	  
Figure	  7.	  YAP	   induces	  organ	  growth	  and	   tumour	   formation	   in	   vivo.	  A	  normal	  mouse	   liver	   (control	  =	  CTL)	  and	  
transgenic	  YAP	  over-­‐expressing	  mouse	  livers	  after	  4	  weeks	  (A)	  or	  for	  3	  months	  (B)	  from	  birth.	  Note	  the	  increased	  
in	  liver	  size	  (after	  4	  weeks	  -­‐	  A)	  and	  the	  widespread	  development	  of	  hepatocellular	  carcinoma	  throughout	  the	  liver	  
(after	  3	  months	  -­‐	  B).	  Modified	  from	  Pan,	  D.	  The	  hippo	  signaling	  pathway	  in	  development	  and	  cancer.	  Dev.	  Cell	  19,	  
491–505	  (2010)	  and	  from	  Dong,	  J.	  et	  al.	  2007).	  
	  
Despite	  the	  fact	  that	  Hippo	  activity	  seems	  to	  be	  frequently	  deregulated	  in	  different	  
human	   cancers,	   most	   of	   the	   Hippo	   pathway	   genes	   are	   not	   commonly	   mutated	  
(Harvey	   et	   al.,	   2013),	   with	   the	   exception	   of	   NF2/Merlin	   gene.	   NF2	   is	   a	   tumour-­‐
suppressor	   protein	   that	   controls	   cell	   growth	   and	   contact-­‐	   dependent	   inhibition	   of	  
proliferation	   and	   that	   has	   been	   characterized	   as	   a	   Hippo	   regulator	   (Zhang	   et	   al.,	  
2010).	   NF2	   gene	   is	   mutated	   with	   high	   frequency	   in	   neurofibromatosis	   type	   2,	   a	  
familiar	  cancer	  syndrome	  characterized	  by	  the	  development	  of	  malignant	  peripheral	  
nerve	  sheath	  tumours	  (Asthagiri	  et	  al.,	  2009).	  Moreover,	  inactivation	  of	  NF2	  gene	  is	  
also	   frequently	   observed	   in	  malignant	   pleural	  mesothelioma	   (Bianchi	   et	   al.,	   1995).	  
Although	  mutations	  of	  other	  Hippo	  pathway	  components	   in	  human	  cancer	  are	   less	  
common,	  evidence	  supports	  a	  role	  of	  this	  pathway	  in	  human	  tumorigenesis:	  down-­‐
regulation	  of	  Mst1/2,	   Sav1,	   Lats1/2	  and	  Mob1	   (tumour	   suppressor	   components	  of	  
the	   pathway)	   has	   been	   reported	   in	   various	   human	   cancers	   by	  many	   authors	   (Pan,	  
2010;	  Zhao	  et	  al.,	  2010).	  	  






Figure 3. YAP induces organ growth and tumour formation in vivo. A normal mouse liver (control = CTL) and 
transgenic YAP over-expressing mouse livers after 4 weeks (A) or for 3 months (B) from birth. Note the increased 
in liver size (after 4 eeks - ) and the idespread development of hepatocellular carcinoma throughout the liver 
(after 3 onths - B). odified from Pan, D. The hippo signaling pathway in development and cancer. Dev. Cell 19, 
491–505 (2010) and from Dong, J. et al. Elucidation of a universal size-control mechanism in Drosophila and 
mammals. Cell 130, 1120–33 (2007). 
 
 
Despite the fact that Hippo activity seems to be frequently deregulated in different human 
cancers, most of the Hippo pathway genes are not commonly mutated48, with the exception of 
NF2/Merlin gene. NF2 is a tumour-suppressor prot in that controls cell growth and contact-
dependent inhibition of proliferation and that has been characterized as a Hippo regulator39. 
NF2 gene is mutated with high frequency in neurofibromatosis type 2, a familiar cancer 
syndrome characterized by the development of malignant peripheral nerve sheath tumours71. 
Moreover, inactivation of NF2 gene is also frequently observed in malignant pleural 
mesothelioma72,73. Although mutations of other Hippo pathway components in human cancer 
are less common, evidence supports a role of this pathway in human tumorigenesis: down-
regulation of Mst1/2, Sav1, Lats1/2 and Mob1 (tumour suppressor components of the pathway) 
has been reported in various human cancers by many authors31,54. However, the fact that the 
core components of the Hippo pathway are essentially unaffected by mutations, suggests that 
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unaffected	   by	   mutations,	   suggests	   that	   mechanisms	   other	   than	   direct	   mutations	  
lead	   to	   the	   aberrant	   activation	   of	   YAP	   and	   TAZ	   in	   cancer,	   such	   as	   a	   metabolism-­‐
related	  mechanism,	  as	  recently	  reported	  (Sorrentino	  et	  al.,	  2014)	  (Wang	  et	  al.,	  2015;	  
Mo	   et	   al.,	   2015),	   or	   hormonal	   mechanisms.	   Since	   YAP	   is	   the	   major	   downstream	  
effector	   of	   the	   Hippo	   pathway,	   it	   is	   not	   surprising	   that	   it	   functions	   as	   a	   tumour	  
promoter:	   over-­‐expression	   of	   YAP	   in	   human	   non-­‐transformed	  mammary	   epithelial	  
cells	   results	   in	   phenotypic	   alterations	   that	   are	  hallmarks	  of	   cancer	   transformation,	  
including	   growth	   factor-­‐independent	   proliferation,	   suppression	   of	   apoptosis	   and	  
EMT	  (Overholtzer	  et	  al.,	  2006;	  Zhao	  et	  al.,	  2008).	  Amplification	  of	  YAP	  gene	  locus	  has	  
been	   observed	   in	   several	   human	   cancers,	   such	   as	   intracranial	   ependymomas,	  
medulloblastomas,	  oral	   and	  oesophageal	   squamous	   cell	   carcinomas,	  non-­‐small	   cell	  
lung	   cancer	   and	   ovarian	   cancer	   (Hong	   and	  Guan,	   2012).	   Consistently,	   elevation	   of	  
YAP	  protein	  levels	  has	  been	  identified	  in	  many	  human	  cancer	  cell	  lines	  and	  primary	  
tumours	   (Harvey	   et	   al.,	   2013).	   Moreover,	   it	   has	   also	   been	   reported	   that	   high	  
expression	  of	  YAP	  as	  well	  as	  deregulation	  of	  the	  Hippo	  pathway	  often	  correlate	  with	  
poor	   patient	   prognosis	   (Harvey	   et	   al.,	   2013);	   for	   instance,	   YAP	   is	   an	   independent	  
prognostic	   marker	   for	   overall	   survival	   and	   disease-­‐free	   survival	   for	   patients	   with	  
hepatocellular	  carcinoma	  	  (Xu	  M.	  Z.	  et	  al.	  2009).	  
Importantly,	  emerging	  evidence	  suggests	   that	   the	  Hippo	  pathway	  can	  modulate	   its	  
effects	   on	   tissue	   size	   by	   the	   direct	   regulation	   of	   stem	   cell	   proliferation	   and	  
maintenance	   (Mo	   et	   al.,	   2014;	   Ramos	   and	   Camargo,	   2012).	   In	   particular,	   recent	  
studies	  have	  reported	  that	  YAP	  and	  TAZ	  are	   implicated	   in	  stem	  cell	  and	  progenitor	  
cell	   self-­‐renewal	  and	  expansion,	  as	  well	  as	   in	  embryonic	  development	   (Camargo	  et	  
al.,	  2007;	  Cao	  et	  al.,	  2008;	  Lian	  et	  al.,	  2010).	  	  
2.4	  THE	  HIPPO	  SIGNALLING	  AND	  STEM	  CELL	  PROPERTIES	  	  
The	  association	  of	   the	  Hippo	  signalling	  with	  stem	  cell	  properties	  has	  been	  recently	  
extended	  to	  include	  cancer	  stem	  cells	  (CSCs).	  According	  to	  the	  model	  that	  described	  
CSC	  characteristics,	  tumour	  has	  a	  phenotypic	  heterogeneity	  in	  its	  cell	  population:	  it	  is	  
composed	   by	   a	   small	   pool	   of	   cancer	   cells,	   the	   cancer	   stem	   cells,	   that	   exhibit	   the	  
ability	   of	   self-­‐renewal	   and	  unlimited	   growth,	   and	   from	  which	   all	   the	  other	  mature	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neoplastic	  cells,	  with	  only	  limited	  capacity	  to	  divide	  and	  survive,	  originate	  (Clarke	  et	  
al.,	  2006;	  Nguyen	  et	  al.,	  2012;	  Schulenburg	  et	  al.,	  2010).	  Indeed,	  a	  cancer	  stem	  cell	  is	  
able	  to	  divide	  both	  in	  a	  symmetric	  and	  asymmetric	  way:	  through	  the	  former	  division	  
it	  can	  expand	  the	  cancer	  stem	  cell	  pool	  that	  remains	  undifferentiated,	  while	  through	  
the	   latter	  division	   it	   creates	  a	  daughter	   cell	   (multipotent	  progenitor)	   that	  exits	   the	  
stem	  cell	  state	  and	  differentiates	  into	  a	  specialized	  end	  cell	  that	  makes	  up	  the	  bulk	  of	  
the	   tumour	   and	   that	   has	   limited	   proliferative	   capacity	   and	   thus	   limited	   survival.	  
Although	  CSCs	  are	  only	  a	  minority	  of	  the	  whole	  tumour,	  they	  are	  thought	  to	  be	  the	  
real	   driving	   force	   of	   the	   disease.	   Indeed,	   conventional	   chemotherapy	   and	  
radiotherapy	  are	  effective	  against	  bulk	  population	  of	  tumour	  cells,	  while	  they	  have	  a	  
relatively	   poor	   effect	   on	   CSCs	   (Dean	   et	   al.,	   2005;	   Diehn	   et	   al.,	   2009).	   As	   a	  
consequence,	  even	  if	  the	  bulk	  of	  the	  tumour	  is	  eliminated,	  few	  CSCs	  that	  survive	  can	  
regenerate	  the	  tumour	  and	  lead	  to	  tumour	  recurrence.	  
In	  this	  regard,	  TAZ	  has	  recently	  been	  shown	  to	  be	  a	  stimulator	  of	  CSC	  traits	  and	  to	  be	  
a	  central	  mediator	  of	  metastatic	  ability	  and	  chemo-­‐resistance	  of	  breast	  cancer	  stem	  
cells	  (Cordenonsi	  et	  al.,	  2011)	  (Bartucci	  et	  al.,	  2015).	  Indeed,	  over-­‐expression	  of	  TAZ	  
can	   lead	   to	   the	   acquisition	  of	   the	  mesenchymal	   phenotype	   in	  mammary	  epithelial	  
cells,	  a	   feature	  called	  epithelial	   to	  mesenchymal	  transition	  (EMT)	  that	   is	  commonly	  
observed	   in	   high-­‐grade	   tumours	   and	   that	   correlates	   with	   metastatic	   spreading	  
(Hanahan	  and	  Weinberg,	  2011).	  
Moreover,	   hyper-­‐activation	   of	   TAZ	   contributes	   to	   chemotherapy	   resistance	   (Lai	   et	  
al.,	   2011)	   which,	   as	   said,	   is	   a	   peculiarity	   of	   CSCs.	   Finally	   TAZ	   resulted	   to	   be	   over-­‐
expressed	   in	  about	  85%	  of	  poor-­‐	  differentiated	  breast	  cancer	  (G3)	  and	  to	  correlate	  
with	   poor	   prognosis	   in	   patients	   (Cordenonsi	   et	   al.,	   2011).	   Other	   studies	   have	   also	  
shown	  that	  nuclear	  TAZ	  is	  highly	  expressed	  in	  high-­‐grade	  glioblastomas	  (Bhat	  et	  al.,	  
2011).	   Ectopic	   expression	   of	   TAZ	   leads	   to	   increased	   invasion,	   self-­‐renewal,	   and	  
tumour	   initiating	  capacity	   to	  generate	  properties	  similar	   to	  mesenchymal-­‐like	  stem	  
cells.	   Collectively,	   it	   is	   clear	   that	   TAZ	   enhances	   the	   self-­‐renewal	   capacity	   and	  
tumorigenic	   potential	   contributing	   to	   both	   the	   initiation	   and	   the	   progression	   of	  
breast	  cancer	  and	  glioma.	  
Instead,	   poor	   data	   about	   YAP	   contribution	   in	   promoting	   CSC	   characteristics	   have	  
been	  reported	  until	  now.	  YAP	  has	  been	  reported	  implicated	  in	  stem	  cell	  features	  of	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neuroprogenitor	   cells	   and	   embryonic	   stem	   cells	   and	   activation	   of	   YAP	   expands	  
multipotent	  progenitor	  cells	  leading	  to	  loss	  of	  differentiation	  in	  the	  pancreas	  and	  in	  
the	  stem	  cell	  compartment	  of	  the	  intestine.	  Recent	  studies	  have	  provided	  additional	  
evidence	  for	  the	  role	  of	  YAP	  in	  stem	  cell	  traits.	  According	  to	  these	  data,	  YAP	  acts	  as	  
an	  essential	  downstream	  effector	  of	  the	  oncogenic	  KRAS	  signalling	  and	  it	  promotes	  
resistance	   development	   and	   tumour	   recurrence	   in	   pancreatic	   adenocarcinoma	  
(Kapoor	  et	  al.,	  2014) and	   lung	  adenocarcinoma	   (Shao	  et	  al.,	  2014).	   In	   these	  KRAS-­‐
dependent	   cancer	  models,	   indeed,	   YAP	   has	   emerged	   to	   be	   able	   to	   bypass	   loss	   of	  
oncogenic	   KRAS	   signalling	   through	   regulation	   of	   the	   EMT-­‐like	   transcriptional	  
program.	  Moreover,	   a	   study	   has	   shown	   that	   YAP	   confers	   stem	   cell	   phenotypes	   to	  
airway	  epithelial	  cells,	  thus	  regulating	  airway	  epithelial	  size	  and	  architecture	  (Zhao	  et	  
al.,	  2014).	   Indeed,	  up-­‐regulation	  of	  YAP	   increases	  stem	  cell	  self-­‐renewal	  and	  blocks	  
terminal	   differentiation	   and,	   consistently,	   YAP	   overexpression	   in	   differentiated	  
secretory	   cells	   causes	   them	   to	   partially	   reprogram	   and	   adopt	   a	   stem	   cell-­‐like	  
identity.	   Furthermore,	   another	   study	  has	  highlighted	   that	   YAP	  activation	   is	   able	   to	  
de-­‐differentiate	   hepatocytes	   into	   ductal	   cells	   bearing	   characteristics	   of	   hepatic	  
progenitors,	   such	   as	   self-­‐renewal	   capability	   (Yimlamai	   et	   al.,	   2014),	   confirming	   a	  
positive	  role	  of	  YAP	  in	  stemness.	  Only	  recently,	  however,	  YAP	  has	  been	  described	  as	  
a	  major	  determinant	  of	  CSC	  properties	  onto	  a	  wide	  variety	  of	  non-­‐transformed	  cell	  
types	  of	  gastrointestinal	  origin,	  including	  oesophageal	  epithelium	  cells,	  immortalized	  
embryonic	   liver	   cells,	   as	  well	   as	   in	  oesophageal	   cancer	   cells	   (Song	  et	  al.,	   2014).	  All	  
together,	   these	   observations	   suggest	   that	   the	   ability	   of	   YAP	   to	  maintain	   stem	   cell	  
property	   and	   to	   confer	   CSC	   traits	   might	   be	   a	   relevant	   part	   of	   the	   mechanism	  
responsible	  for	  its	  oncogenic	  behaviour.	  
In	   summary,	   the	   Hippo	   pathway	   is	   strongly	   linked	   to	   tumorigenesis	   and	   provides	  	  
several	   novel	   potentials	   targets	   for	   emerging	   therapeutic	   strategies.	   Deregulation	  
and/or	   hyper-­‐activation	  of	   YAP	   and	   TAZ	   functions	   have	  been	  described	   in	   a	   broad	  
range	  of	  different	  human	  carcinomas	  and	  their	  activity	  promotes	  multiple	  cancer	  cell	  
phenotypes.	   Thus,	   it	   is	   reasonable	   to	   consider	   YAP	   and	   TAZ	   as	   direct	   or	   indirect	  
potential	   targets	   for	  new	  anticancer	  therapies.	  Several	  preclinical	  data	  support	  this	  
idea:	   experiments	   performed	   with	   human	   cancer	   cell	   lines	   have	   proved	   that	  
reduction	  of	  YAP	  and	  TAZ	  levels	   leads	  to	  decreased	  cell	  proliferation	   in	  vitro	  and	   in	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vivo	   in	   xenograft	   assay	   (Diep	   et	   al.,	   2012).	   Consistently,	   it	   seems	   possible	   that	  
targeting	  the	  main	  down-­‐stream	  effectors	  of	  the	  Hippo	  pathway,	  YAP	  and	  TAZ,	  might	  
inhibit	  characteristics	  of	  cancer	  cells	  at	  many	  levels.	  
3.1	  GLUCOCORTICOIDS	  SIGNALLING	  	  	  
Glucocorticoids	  (GCs)	  are	  a	  class	  of	  Corticosteroid	  hormones	  that	  are	  either	  secreted	  
from	  the	  zona	  fasciculata	  of	  the	  adrenal	  gland	  during	  exposure	  to	  acute	  and	  chronic	  
stress	  or	  administered	  pharmacologically	  mainly	   in	  clinical	   setting	  of	   inflammation.	  
Natural	  Glucocorticoids	  (Cortisol	  in	  human)	  are	  cholesterol-­‐derived	  hormones	  whose	  
synthesis	   and	   relapse	   are	   under	   circadian	   and	   stress-­‐associated	   regulation	   by	   the	  
hypothalamic-­‐pituitary-­‐adrenal	   (HPA)	   axis	   (Biddie	   et	   al.,	   2012).	   Furthermore,	   the	  
availability	  of	  natural	  GCs	  in	  tissues	  is	  regulated	  by	  corticosteroid-­‐binding	  globulin	  in	  
serum	   and	   by	   locally	   expressed	   11β-­‐hydroxysteroid	   dehydrogenase	   (11β	   -­‐HSD)	  
enzymes.	  Two	  iso-­‐enzymes	  are	  responsible	  for	  regulating	  local	  cortisol	   levels	  highly	  
expressed	   in	   key	  metabolic	   tissues	   including	   liver,	   adipose	   tissue,	   and	   the	   central	  
nervous	  system:	  11β-­‐HSD	  type	  I,	  which	  converts	  inactive	  Cortisone	  to	  active	  Cortisol,	  
and	  11β-­‐HSD	   type	   II,	  which	   is	   responsible	   for	   the	   reverse	   reaction	   that	   inactivates	  
cortisol	  (Draper	  and	  Stewart,	  2005).	  
GCs	  play	  a	  central	  role	  in	  critical	  biological	  processes	  that	  are	  necessary	  for	  life,	  such	  
as	   control	   of	   intermediary	  metabolism,	   cell	   growth,	   apoptosis	   and	   differentiation,	  
immune	   and	   inflammatory	   reactions,	   as	   well	   as	   central	   nervous	   system	   and	  
cardiovascular	  functions	  (figure	  8).	  Imbalance	  in	  glucocorticoid	  levels	  such	  as	  chronic	  
elevation	   or	   deficiency	   can	   result	   in	   pathological	   conditions,	   such	   as	   Cushing’s	  
disease	   and	   Addison’s	   disease,	   respectively	   (Kadmiel	   and	   Cidlowski,	   2013)	  
(Vegiopoulos	   and	   Herzig,	   2007).	   Synthetic	   Glucocorticoids	   resemble	   natural	  
Glucocorticoids	  but	  differ	  from	  the	   latter	  by	  their	  potency	  and	  metabolic	  clearance	  
and	  also	  because	  synthetic	  GCs	  do	  not	  bind	  corticosteroid-­‐binding	  globulin	  and	  are	  
thereby	  not	  susceptible	  to	  their	  regulation.	  	  
Prednisone/Prednisolone,	   Betamethasone,	   Dexamethasone,	   Fluticasone	   and	  
Budesonide	  are	  among	  the	  most	  commonly	  prescribed	  GCs	  and	  due	  to	  their	  potent	  
anti-­‐inflammatory	  effects,	  recommended	  for	  a	  variety	  of	  medical	  conditions	  such	  as:	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chronic	   inflammatory	   disorders	   including	   asthma,	   rheumatic	   disease	   and	   skin	  
infections	   as	   well	   as	   for	   immunosuppression	   in	   patients	   undergoing	   organ	  
transplantation.	   In	   addition	   to	   their	   anti-­‐inflammatory	   properties,	   Corticosteroids	  
have	   been	   exploited	   for	   their	   anti-­‐proliferative,	   pro-­‐apoptotic	   and	   anti-­‐angiogenic	  
actions	   for	   the	   treatment	   of	   haematological	   cancers	   (Frankfurt	   and	   Rosen,	   2004;	  
Vilasco	  et	  al.,	  2011).	  
Both	   natural	   and	   synthetic	  GCs	  mediate	   their	   effects	   on	   target	   cells	   by	   binding	   to	  
their	  intracellular	  receptor,	  the	  human	  Glucocorticoid	  Receptor.	  	  
	  
Figure	  8.	  	  Scheme	  of	  glucocorticoids	  function	  in	  the	  body.	  
3.2	  GLUCOCORTICOID	  RECEPTOR	  ACTIVITY	  	  
Glucocorticoid	  Receptor,	  hereafter	  called	  GR,	   is	  expressed	   in	  nearly	  all	   tissue	  types	  
and	   belongs	   to	   the	   nuclear	   receptor	   superfamily	   of	   transcription	   factor	   proteins	  
acting	   as	   a	   ligand-­‐dependent	   transcription	   factor	   that	   positively	   or	   negatively	  
regulates	  the	  expression	  of	  glucocorticoid-­‐responsive	  genes	  (Nicolaides	  et	  al.,	  2010;	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Zhou	  and	  Cidlowski,	  2005).	  	  
In	   the	   absence	   of	   Glucocorticoids,	   the	   GR	   resides	   in	   an	   inactive	   state	   in	   the	  
cytoplasm	   forming	   a	   complex	   with	   heat	   shock	   proteins	   (HSPs)	   90,	   70,	   50,	   20	   and	  
other	   chaperone	   proteins.	   When	   cells	   are	   exposed	   to	   GCs,	   the	   GR	   undergoes	   a	  
conformational	   change	   that	   triggers	   its	   translocation	   to	   the	   nucleus,	   where	   it	   can	  
exert	   its	   actions	   mainly	   as	   a	   transcription	   factors	   (Nixon	   et	   al.,	   2012)	   exerting	   its	  
action	  as	  trans-­‐activator	  or	  trans-­‐repressor,	  but	  also	   independently	  from	  the	  ligand	  
as	  described	  in	  figure	  9	  (Nixon	  et	  al.,	  2012).	  
	  
Figure	  9.	  Glucocorticoid	  (GC)	  action.	  GCs	  act	  through	  several	  mechanisms	  to	  exert	  anti-­‐inflammatory	  effects:	  1)	  
non-­‐genomic	  pathways	  involve	  GC	  receptor	  (GR)-­‐	  mediated	  direct	  interactions	  with	  second	  messenger	  proteins,	  
including	   the	   MAPK	   protein	   JNK,	   inhibiting	   the	   activation	   of	   this	   signalling	   pathway.	   2)	   GR-­‐mediated	  
transactivation	   of	   key	   anti-­‐	   inflammatory	   genes	   involves	   direct	   DNA	   binding	   of	   both	   GR	   dimers	   and	  
monomers/multimers	  to	  GC-­‐response	  elements	  (GRE)	  in	  the	  promoter	  region	  of	  target	  gene.	  3)	  Transrepression	  
of	  pro-­‐	  inflammatory	  genes	  does	  not	  require	  direct	  DNA	  binding	  of	  GR,	  but	  rather	  ‘tethering’	  of	  GR	  monomers	  to	  
DNA-­‐bound	  pro-­‐inflammatory	  transcription	  factors.	  From	  Nixon	  et	  al.,	  2012.	  
	  
GR	   is	   the	   product	   of	   a	   single	   gene,	   NR3C1,	   located	   on	   chromosome	   5q31–32	   in	  
humans;	  alternative	  splicing	  of	  GR	  generates	  two	  main	  isoforms:	  hGR-­‐α	  and	  hGR-­‐β.	  
Furthermore,	   alternative	   translation	   initiation	   sites	   and	   post-­‐translational	  
modifications	   of	   the	  GR	   result	   in	  many	   other	  GR	   isoforms	   and	   a	   complex	   array	   of	  
receptor	   molecules	   (Duma	   et	   al.,	   2006;	   Kadmiel	   and	   Cidlowski,	   2013).	   The	   hGR-­‐α	  
isoform	   contains	   three	   distinct	   functional	   domains	   –	   the	   C-­‐terminal	   ligand	   binding	  
domain	   (LBD),	   the	   DNA-­‐binding	   domain	   (DBD)	   and	   the	   N-­‐terminal	   transactivation	  
Therapeutic actions of GCs to relieve inflammation
GCs mediate many of their effects by binding with the GR
(NR3C1; Hollenberg et al. 1985), a ligand-activated
transcription factor belonging to the nuclear hormone
receptor superfamily. The conventional model (Beato et al.
1995) of GR action is of GR homodimers modulating gene
transcription through direct interactions with DNA. In the
unbound state, monomeric GR is located in the cytosol in
association with a complex of chaperone proteins. Ligand
binding induces conformational changes resulting in dis-
sociation of the chaperone complex, in turn enabling
exposure of the DNA binding and dimerisation domains
and permitting nuclear translocation. A GR homodimer
interacts with GC response elements (GREs) within the
promoter region of target genes in the nucleus, leading to
up-regulation of gene transcription (transactivation). Multiple
genes encoding critical proteins in metabolic pathways, such
as tyrosine aminotransferase (TAT; Grange et al. 2001) or
phosphoenolpyruvate carboxykinase (PEPCK; Petersen et al.
1988, Ruppert et al. 1990), are up-regulated in this manner.
This mechanism of transactivation underpins many of the
metabolic side effects of these drugs. In contrast, GR can also
down-regulate gene transcription by binding with negative
GRE sites. Examples of genes regulated in this way are
POMC (Drouin et al. 1993) and osteocalcin (Meyer et al.
1997b), where GR multimers bind to negative GREs within
promoter regions, repressing gene transcription and influen-
cing negative feedback on the hypothalamic–pituitary–
adrenal (HPA) axis and bone remodelling respectively.
However, not all responses to GCs are mediated in a
manner solely dependent on GR dimers binding with DNA,
and indeed, the ability of GCs to suppress inflammation
involves many other modalities of receptor signalling. Those
pro-inflammatory signalling pathways believed to be most
important in GC action have been reviewed extensively
(De Bosscher & Haegeman 2009) and are summarised in
Fig. 1. GR monomers play a crucial role in the repression of
pro-inflammatory genes. These actions are attributed to GR
monomers tethering with DNA-bound pro-inflammatory
transcription factors NF-kB and AP-1, thus preventing their
actions activating transcription of pro-inflammatory cyto-
kines such as TNFa and IL6 (Barnes 1998). This mechanism
is distinct from those described above as it requires neither
GR dimerisation nor direct DNA binding of the GR
monomer. The relative importance of such dimerisation-
independent mechanisms to suppress inflammation was
elegantly demonstrated in GRdim/dim mice, which express a
mutant GR incapable of dimerisation (Reichardt et al. 2001).
These mice were still able to respond to dexamethasone,
suppressing expression of pro-inflammatory cytokines.
Whilst the predominant anti-inflammatory actions of GCs
are mediated through GR monomer-based repression of pro-
inflammatory transcription factor activity, some of the actions
of GR to reduce inflammation are mediated through
transactivation mechanisms. Here, GR DNA binding is
essential, but dimerisation is not always required. For
example, transcription of the anti-inflammatory protein
IkBa results from GR dimers interacting with hor o e
response elements located within its promoter region
(Heck et al. 1997, Deroo & Archer 2001). However,
transactivation of other anti-inflammatory genes including
activation of interleukin 10 (IL10) have been shown to occur
independently of dimerisation (Unterberger et al. 2008). This
has also been demonstrated for MKP1 (also known as
DUSP1) gene expression, which is induced by GC treatment
even in the presence of the dimerisation-deficient GRmutant
(Abraham et al. 2006). Since prevention of dimerisation does
not abrogate all of the anti-inflammatory actions of GR, this
gives hope that the independent mechanisms underlying these
pathways may be tractable to pharmaceutical manipulation
and aid rational design of new drugs. Simply dissociating
transrepression from transactivation may not represent the
best approach (Belvisi et al. 2001) and indeed to achieve
tissue-specific selectivity, targeting specific interactions
between GR and co-activator/co-repressor proteins may be
more successful (Coghlan et al. 2011).
There have been numerous attempts to develop ‘dis-
sociated’ steroids or ‘selective GR modulators’ with improved
therapeutic indices (McMaster & Ray 2008). This strategy has
been successful previously in the development of selective
oestrogen receptor modulators, where careful manipulation
of intracellular interactions of nuclear hormone receptors
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Figure 1 Glucocorticoid (GC) effects on inflammatory signalling.
GCs act through se eral mechanisms to xe t anti-inflammatory
effects: 1) non-genomic pat ways involve GC receptor (GR)-
mediated direct interactions with second messenger proteins,
including the MAPK protein JNK, inhibiting the activation of this
signalling pathway. 2) GR-mediated transactivation of key anti-
inflammatory genes involves direct DNA binding of both GR dimers
and monomers/multimers to GC-response elements (GRE) in the
promoter region of target gene. 3) Transrepression of pro-
inflammat ry genes does not require direct DNA bindi g of GR, but
rather ‘tethering’ of GR monomers to DNA-bound pro-inflam-
matory transcription factors.
M NIXON and others . Actions of 5a-reduced glucocorticoids112
Journal of Endocrinology (2012) 212, 111–127 www.endocrinology-journals.org
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domain	  (NTD).	  The	  NTD	  has	  a	  strong	  transcriptional	  activation	  function	  (AF-­‐1),	  which	  
allows	  for	  the	  recruitment	  of	  co-­‐regulators	  and	  transcription	  machinery;	  the	  LBD	  also	  
contains	   a	   transactivation	   domain	   (AF-­‐2)	   involved	   in	   transcriptional	   activation	   of	  
target	   genes;	   the	   two	   zinc-­‐finger	   motifs	   present	   in	   the	   DBD	   recognize	   and	   bind	  
specific	  DNA	  sequences,	  that	  is,	  the	  glucocorticoid	  response	  elements	  (GREs)	  on	  the	  
promoter	  of	  target	  genes	  (Gruver-­‐Yates	  and	  Cidlowski,	  2013;	  Nicolaides	  et	  al.,	  2010)	  
(figure	  10).	  Thus,	  the	  hGR-­‐α	  isoform	  is	  able	  to	  bind	  to	  GCs,	  undergo	  conformational	  
changes,	  dissociate	  from	  the	  HSPs,	  homodimerize	  and	  translocate	  into	  the	  nucleus,	  
where	   it	   can	   recruit	   co-­‐regulators	   and	   interact	   directly	   with	   GREs	   to	   exert	  
transcriptional	  effects.	  The	  GR-­‐α/GRE	  complex	  results	  in	  stimulation	  or	  inhibition	  of	  
the	  GRE-­‐	  mediated	  gene	  transcription	  (trans-­‐activation	  effect).	  
	  
	  
Figure	  10.	  Glucocorticoid	  Receptor	  Alpha	  (α-­‐GR)	  structure.	  Modified	  from	  Gruver-­‐Yates,	  A.	  L.	  &	  Cidlowski,	  J.	  a.	  
Tissue-­‐specific	  actions	  of	  glucocorticoids	  on	  apoptosis:	  a	  double-­‐edged	  sword.	  Cells	  2,	  202–23	  (2013).	  
	  
Alternatively,	   the	   ligand-­‐activated	   hGR-­‐α	   can	   modulate	   gene	   expression	  
independently	   of	   binding	   to	   GREs,	   by	   interacting	   with	   other	   transcription	   factors,	  
such	  as	  activator	  protein	  1	   (AP-­‐1),	  nuclear	   factor-­‐ĸB	   (NF-­‐ĸB)	  and	  signal	   transducers	  
and	  activators	  of	  transcription	  5	  (STAT5),	  which	  are	  involved	  in	  cellular	  proliferation,	  
survival	   and	   inactivation	   of	   apoptosis,	   invasion,	   angiogenesis	   and	   carcinogenesis	  
(Moutsatsou	  and	  Papavassiliou,	  2008)	  (Figure	  9).	  
Conversely,	   the	   hGR-­‐β	   isoform	   resides	   constitutively	   in	   the	   nucleus	   and	   acts	   as	   a	  
natural	  dominant-­‐negative	  inhibitor	  of	  the	  hGR-­‐α	  isoform	  (Charmandari	  et	  al.,	  2004).	  
GCs	   regulate	   the	   expression	   of	   a	  wide	   array	   of	   target	   genes	   by	   both	   positive	   and	  
negative	  regulatory	  mechanisms.	  The	  genes	  encoding	  glucocorticoid-­‐induced	  leucine	  
zipper	  (GILZ),	  serum/glucocorticoid-­‐	  regulated	  kinase	  1	  (SGK1),	  tristetraproline	  (TTP),	  
and	  mitogen-­‐activated	  protein	  kinase	  phosphatase-­‐1	  (MKP-­‐1)	  are	  examples	  of	  genes	  





GCs regulate the expression of a wide array of target genes by both positive and negative 
regulatory mechanisms. The genes encoding glucocorticoid-induced leucine zipper (GILZ), 
serum/glucocorticoid- regulated kinase 1 (SGK1), tristetraproline (TTP), and mitogen-activated 
protein kinase phosphatase-1 (MKP-1) are examples of genes up-regulated by activated GR. 
Examples of genes negatively regulated by GR are β-arrestin 2, osteocalcin, and the GR gene 
NR3C1 itself103. 
 
Figure 5. Glucocorticoid Receptor Alpha (α-GR) structure. Modified from Gruver-Yates, A. L. & Cidlowski, J. a. 
Tissue-specific actions of glucocorticoids on apoptosis: a double-edged sword. Cells 2, 202–23 (2013).  
 
6.2.1 Glucocorticoids signalling and cancer therapy 
As previously said, glucocorticoid signalling is almost ubiquitously diffuse various organ 
systems. From a clinical point of view, steroid therapy has been remarkably effective in treating 
various diseases, due to its anti-inflammatory, anti-proliferative, pro-apoptotic, and anti-
angiogenic roles103. Among these, pro-apoptotic action is the most-well-characterized feature 
that has been xploited for cancer treatment. Indeed, GCs are potent ind cers of popto is in 
many cell types and tissues, such as skeletal and muscular system, circulatory system, 
nervous system, endocrine system, reproductive system, and the immune system110. But it is 
owing to their ability to induce apoptosis in lymphocytes that synthetic GCs have been widely 
used in the treatment of haematological malignancies105,112. The apoptotic effects of GCs in 
cells of the immune system have been well-studi d over he years113,114, and GCs ar  now 
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arrestin	  2,	  osteocalcin,	  and	  the	  GR	  gene,	  NR3C1,	  itself	  (Kadmiel	  and	  Cidlowski,	  2013).	  
3.3	  GLUCOCORTICOIDS	  SIGNALLING	  IN	  ORGANS	  	  
Glucocorticoids	  produce	  marked	  effects	  on	  energy	  metabolism	  by	  inhibiting	  glucose	  
utilization	  by	  peripheral	  tissues	  such	  as	  muscles	  and	  stimulating	  glucose	  breakdown	  
to	  maintain	  the	  necessary	  circulating	  levels	  to	  mount	  a	  stress	  response	  (Negi	  et	  al.,	  
2009).	  
Glucocorticoids	   are	   the	  main	   hormones	   involved	   in	   the	   adaptation	   of	   the	   body	   to	  
chronic	  stress.	  In	  fact,	  a	  genome-­‐wide	  analysis	  of	  GC-­‐regulated	  target	  gene	  networks	  
in	   liver	   revealed	   that	   the	  GR	   controls	  many	   aspects	   of	   hepatic	   energy	  metabolism	  
(Vegiopoulos	   and	   Herzig,	   2007).	   The	   best-­‐known	   GC	   function	   is	   the	   ability	   to	  
stimulate	   gluconeogenesis.	   In	   fact	   GC	   lead	   to	   a	   marked	   increase	   in	   the	   levels	   of	  
enzymes	   involved	   in	   the	   conversion	   of	   amino	   acids	   in	   glucose	   and	   cause	   the	  
mobilization	  of	  amino	  acids	  from	  extra	  hepatic	  tissue.	  As	  consequence	  more	  amino	  
acids	   are	   released	   in	   the	   plasma	   and	   become	   available	   to	   enter	   in	   the	  
gluconeogenesis	  process	   that	   leads	   to	   the	   increase	   in	  glycogen	  storage	   in	   the	   liver	  
cells.	  On	  the	  other	  hand	  glucocorticoids	  are	  also	  involved	  in	  a	  moderate	  decrease	  in	  
the	  rate	  of	  glucose	  utilization	  from	  different	  tissues	  in	  the	  body	  leading	  to	  increased	  
glucose	  concentration	  in	  the	  blood	  that	  stimulates	  insulin	  secretion.	  	  
Glucocorticoids	  play	  also	  an	   important	   role	   in	   the	   function	  and	  homeostasis	  of	   the	  
central	   nervous	   system	   (CNS).	   Chronic	   exposure	   to	   supra-­‐physiologic	   levels	   of	  
glucocorticoids	   (GCs)	   in	   Cushing’s	   syndrome	   (CS)	   is	   associated	   with	   an	   increased	  
prevalence	   of	   sleep	   disturbances,	  mood	   alterations,	   psychiatric	   diseases,	   cognitive	  
impairment,	  and	  anatomical	  brain	  changes	  (Bourdeau	  et	  al.,	  2005).	  Different	  studies	  
demonstrated	   the	   presence	   of	   brain	   atrophy	   and	   psychiatric	   disturbances	   such	   as	  
depression	  in	  patients	  affected	  by	  Cushing’s	  syndrome.	  
Glucocorticoids	  regulate	  bone	  physiology	  decreasing	  the	  number	  and	  the	  function	  of	  
osteoblasts.	  These	  effects	  lead	  to	  a	  suppression	  of	  bone	  formation,	  a	  central	  feature	  
in	   the	   pathogenesis	   of	   Glucocorticoid-­‐induced	   osteoporosis.	   Glucocorticoids	  
decrease	  the	  replication	  of	  cells	  of	  the	  osteoblastic	  lineage,	  reducing	  the	  pool	  of	  cells	  
that	  may	  differentiate	   into	  mature	  osteoblasts	   (Canalis	  et	  al.,	  2007).	   In	  addition	   to	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inhibiting	   the	   differentiation	   of	   osteoblasts,	   glucocorticoids	   inhibit	   the	   function	   of	  
the	  differentiated	  mature	  cells.	  Glucocorticoids	  inhibit	  osteoblast-­‐driven	  synthesis	  of	  
type	   I	   collagen,	   the	   major	   component	   of	   the	   bone	   extracellular	   matrix,	   with	   a	  
consequent	   decrease	   in	   bone	   matrix	   available	   for	   mineralization.	   Moreover	  
glucocorticoids	   induce	   the	   apoptosis	   of	   osteocytes.	   As	   a	   result,	   the	   normal	  
maintenance	   of	   bone	   through	   this	   mechanism	   is	   impaired	   and	   the	   biomechanical	  
properties	  of	  bone	  are	  compromised.	  
In	  addition	  to	  profound	  changes	   in	  the	  physiology	  and	  function	  of	  multiple	  tissues,	  
stress	   and	   elevated	   glucocorticoids	   can	   also	   inhibit	   reproduction	   (Whirledge	   and	  
Cidlowski,	   2010).	   The	   stress-­‐induced	   rise	   in	   glucocorticoids	   represses	   GnRH	  
(gonadotropin-­‐releasing	   hormone)	   secretion,	   which	   can	   result	   in	   hypogonadism.	  
Stress	  induces	  an	  elevation	  in	  glucocorticoid	  concentration,	  which	  precedes	  a	  decline	  
in	   testosterone	   concentration	   in	   the	   male	   as	   reported	   in	   patients	   with	   Cushing	  
Syndrome	  not	  only	  at	   the	  hypothalamic	  and	  pituitary	   level,	  but	  also	  directly	   in	   the	  
testes	  inducing	  Leydig	  cell	  apoptosis,	  reducing	  the	  number	  of	  Leydig	  cells	  per	  testis	  
(Whirledge	   and	   Cidlowski,	   2010).	   Glucocorticoids	   display	   also	   an	   important	   role	   in	  
adipose	   tissue	   and	   excess	   of	   GC	   levels	   have	   been	   associated	   to	   the	   Metabolic	  
syndrome,	   a	   clustering	   of	   conditions	   which	   include	   abdominal	   obesity,	   elevated	  
triglycerides,	  low	  high-­‐density	  lipoprotein,	  high	  fasting	  blood	  glucose,	  and	  high	  blood	  
pressure	   (Wang	   et	   al.,	   2005).	   In	   Cushing’s	   syndrome	   infact	   increased	   secretion	   of	  
GCs	  leads	  to	  obesity,	  hypertension,	  hyperlipidemia	  and	  glucose	  intolerance	   (Arnaldi	  
et	  al.,	  2003).	  
Consistently,	   treatment	   of	   obese	   rats	   with	   the	   GR	   antagonist	   RU486	   or	  
adrenalectomy,	   oppose	   the	   obese	   phenotype	   in	   these	   animals	   (Langley	   and	   York,	  
1990;	  Livingstone	  et	  al.,	  2000).	  
During	  mammalian	  fetal	  growth,	  the	  late	  gestation	  rise	  in	  fetal	  glucocorticoid	  levels	  
is	  essential	   for	  the	  maturation	  of	  tissues	  and	  organs	   in	  preparation	  for	  birth.	   	  Mice	  
lacking	  GR	  (GR-­‐/-­‐	  mice)	  die	  neonatally	  because	  they	  are	  unable	  to	  inflate	  their	  lungs	  
due	  to	  severe	  pulmonary	  immaturity	  (Rog-­‐Zielinska	  et	  al.,	  2013).	  	  
A	  direct	   effect	  of	   glucocorticoids	  on	   the	   cardiomyocyte	   structure	  and	   function	  has	  
been	  demonstrated	  revealing	  a	  direct	  and	  dynamic	  role	   for	  glucocorticoids	  and	  GR	  
signaling	  in	  the	  modulation	  of	  cardiomyocyte	  function	  (Ren	  et	  al.,	  2012).	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3.4	  GLUCOCORTICOIDS	  SIGNALLING	  IN	  CANCER	  	  
As	  previously	  said,	  glucocorticoid	  signalling	   is	  almost	  ubiquitously	  diffuse	   in	  various	  
organs.	  From	  a	  clinical	  point	  of	  view,	  steroid	  therapy	  has	  been	  remarkably	  effective	  
in	   treating	   various	   diseases,	   due	   to	   its	   anti-­‐inflammatory,	   anti-­‐proliferative,	   pro-­‐
apoptotic,	  and	  anti-­‐angiogenic	  roles.	  Among	  these,	  pro-­‐apoptotic	  action	  is	  the	  most-­‐
well-­‐characterized	  feature	  that	  has	  been	  exploited	  for	  cancer	  treatment.	  Indeed,	  GCs	  
are	  potent	  inducers	  of	  apoptosis	  in	  many	  cell	  types	  and	  tissues,	  such	  as	  skeletal	  and	  
muscular	   system,	   circulatory	   system,	   nervous	   system,	   endocrine	   system,	  
reproductive	   system,	   and	   the	   immune	   system.	   But	   it	   is	   owing	   to	   their	   ability	   to	  
induce	   apoptosis	   in	   lymphocytes	   that	   synthetic	  GCs	   have	   been	  widely	   used	   in	   the	  
treatment	   of	   haematological	   malignancies	   (Frankfurt	   and	   Rosen,	   2004;	   Smith	   and	  
Cidlowski,	  2010).	  Physiological	  GC-­‐induced	  apoptosis	  plays	  an	   important	  role	   in	  the	  
development	  and	   in	   the	   functions	  of	   the	   immune	  system:	  GCs	  are	   important	   for	  T	  
cell	  selection,	  immune	  system	  homeostasis,	  and	  resolution	  of	  the	  immune	  response	  
following	  clearance	  of	  infection.	  High	  doses	  of	  Glucocorticoids	  are	  known	  to	  induce	  
apoptosis	   in	   thymocytes,	   T	   cells,	   B	   cells,	   macrophages,	   mature	   but	   not	   immature	  
dendritic	  cells,	  eosinophils,	  and	  natural	  killer	  cells.	  Indeed,	  according	  to	  their	  ability	  
to	  efficiently	  kill	  lymphoid	  cells,	  Glucocorticoids	  have	  been	  included	  in	  essentially	  all	  
chemotherapy	   protocols	   for	   hematopoietic	   malignancies:	   they	   are	   prescribed	   to	  
treat	   acute	   lymphoblastic	   leukemia	   (ALL),	   chronic	   lymphoblastic	   leukemia	   (CLL),	  
multiple	   myeloma	   (MM),	   Hodgkin	   Lymphoma	   (HL)	   and	   Non-­‐Hodgkin’s	   Lymphoma	  
(NHL)	  (Smith	  and	  Cidlowski,	  2010).	  Glucocorticoid	  chemotherapy	  is	  limited,	  however,	  
by	  the	  emergence	  of	  GC-­‐induced	  apoptosis	  resistance	  in	  lymphoid	  malignancies	  that	  
is	  increasingly	  reported	  and	  studied	  (Kofler	  et	  al.,	  2003;	  Schlossmacher	  et	  al.,	  2011).	  
Besides	   their	   use	   as	   powerful	   cytotoxic	   agents	   in	   an	   oncological	   setting	   for	   the	  
treatment	   of	   lymphoid	   malignancies,	   Glucocorticoids	   are	   also	   used	   as	   a	   co-­‐
medication	  in	  the	  therapy	  of	  solid	  tumors	  to	  support	  chemotherapy,	  either	  because	  
of	   their	   effectiveness	   in	   treating	   the	  malignancy,	   or	   for	   decreasing	   oedema,	   pain,	  
electrolyte	  imbalance,	  nausea	  and	  emesis	  or	  to	  reduce	  cytotoxic	  reactions	  caused	  by	  
other	  treatment	  regimens	  (Grote	  et	  al.,	  2006;	  Rutz	  and	  Herr,	  2004).	  Indeed,	  GCs	  are	  
often	   associated	   with	   a	   substantial,	   but	   temporary,	   improvement	   in	   symptoms	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caused	   by	   advanced	   disease.	   However,	   the	   divergent	   GR	   activity	   in	   different	   cell	  
types	   is	   striking	   when	   comparing	   GCs	   effects	   on	   lymphocytic	   malignancies	   versus	  
epithelial	   cell-­‐derived	   cancers.	   In	   fact,	   while	   synthetic	   GCs	   are	   routinely	   used	   to	  
induce	   apoptotic	   cell	   death	   in	   malignant	   lymphoid	   cells,	   in	   epithelial	   (i.e.	   “solid”)	  
tumours	   GCs	   have	   been	   reported	   to	   play	   opposite	   effects:	   GCs	   stimulate	   anti-­‐
apoptotic	  gene	  expression	  and	  antagonize	  the	  ability	  of	  chemotherapy	  treatment	  to	  
effectively	  induce	  cell	  death	  (Herr	  et	  al.,	  2009;	  Zhang	  et	  al.,	  2006).	  Moreover	  several	  
retrospective	  analysis	  have	  suggested	  that	  GC	  administration	  induces	  chemotherapy	  
resistance	  in	  cancers	  of	  the	  breast	  and	  lung,	  and	  enhances	  the	  risk	  of	  skin	  cancer	  and	  
perhaps	  lymphoma	  (Herr	  and	  Pfitzenmaier,	  2006).	  Pre-­‐clinical	  data	  suggest	  that	  GCs	  
show	   diverse	   end	   even	   contradictory	   effects	   on	   chemo-­‐sensitivity	   in	   many	   non-­‐
haematological	   tumour	   cells.	  Dexamethasone	   showed	  an	  anti-­‐apoptotic	  effect	   in	   a	  
variety	  of	   cell	   lines	  derived	   from	  malignant	   solid	   tumours,	   including	  breast	   cancer,	  
brain	  cancer,	  cervical	  cancer,	  bone	  cell	  cancer,	  melanoma,	  and	  neuroblastoma.	  Data	  
also	   suggest	   that	  Glucocorticoids	   diminish	   chemotherapy	   effectiveness	   and	   induce	  
treatment	  resistance	  in	  solid	  tumors,	  such	  as	  prostate	  cancer,	  pancreatic	  cancer	  and	  
ovarian	   carcinomas	   (Zhang	   et	   al.,	   2006).	   Thus,	   the	   therapeutic	   outcome	   of	   many	  
solid	   tumours	  may	  be	  negatively	   impacted	  by	  glucocorticoids	  treatment	  depending	  
on	  the	  type	  of	  cancer.	  In	  this	  context	  it	  is	  important	  to	  point	  out	  how	  glucocorticoids	  
treatment	  may	  be	  particularly	  detrimental	  in	  breast	  cancer.	  	  
In	   epithelial	   breast	   cells	  GCs	   are	   generally	   cytoprotective	   also	   in	   normal	   cell	   types	  
(Moran	  et	  al.,	  2000)	  and	  there	   is	  an	  anti-­‐apoptotic	  effect	  of	  GCs	   in	  cancers	  derived	  
from	   this	   tissue.	   In	   fact,	   in	   vitro	   data	   suggest	   that	   Dexamethasone	   could	   protect	  
breast	   cancer	   cells	   from	   chemotherapy-­‐induced	   apoptosis	   (Moran	   et	   al.,	   2000).	  
Moreover,	  two	  breast	  cancer	  and	  ovarian	  xenograft	  studies	  have	  reported	  that	  pre-­‐
treatment	   with	   Dexamethasone	   could	   selectively	   inhibit	   response	   to	   Taxol	  
(Paclitaxel)-­‐induced	   apoptosis	   (Pang	   et	   al.,	   2006;	   Sui	   et	   al.,	   2006).	   Interestingly,	   a	  
recent	   study	   has	   shown	   that	   pre-­‐treatment	   with	   Mifepristone	   (RU486),	   a	   GR	  
antagonist,	   could	   potentiate	   the	   efficacy	   of	   chemotherapy	   in	   GR	   positive	   TNBCs	  
inhibiting	  the	  anti-­‐apoptotic	  signalling	  pathways	  of	  GR	  and	   increasing	  the	  cytotoxic	  
efficiency	  of	  Paclitaxel	  (Skor	  et	  al.,	  2013).	  Finally,	  in	  a	  recent	  meta-­‐analysis	  of	  primary	  
	   30	  
breast	   tumour	   gene	   expression	   from	  1378	   early	   stage	   breast	   cancer	   patients	  with	  
long-­‐term	  clinical	   follow-­‐up,	  high	  expression	  of	   the	  gene	  encoding	   the	  GR	   (NR3C1)	  
has	   been	   found	   to	   significantly	   correlate	   with	   shorter	   relapse-­‐free	   survival	   in	  
patients	   with	   oestrogen	   receptor	   negative	   (ER-­‐)	   breast	   cancer	   either	   treated	   or	  
untreated	   with	   adjuvant	   chemotherapy	   (Pan	   et	   al.,	   2011).	   Conversely,	   in	   patients	  
with	   ER+	   breast	   cancer,	   a	   high	   level	   of	   primary	   tumour	   GR	   expression	   has	   been	  
associated	  with	  a	  better	  outcome	  relative	  to	  low	  GR	  expression.	  From	  a	  clinical	  point	  
of	   view,	   high	  GR	  expression	   correlates	  with	   a	   relatively	   poor	   prognosis	   in	   patients	  
with	   ER-­‐	   breast	   cancer	   and	   with	   a	   significantly	   increased	   risk	   of	   early	   relapse	  
compared	   to	   patients	   with	   ER-­‐	   but	   low	   GR	   expression	   tumours,	   regardless	   of	  
adjuvant	  chemotherapy	  treatment.	  
All	   together,	   these	   data	   provide	   evidence	   suggesting	   that	   exogenous	   GCs,	   and	  
subsequent	   GR	   activation	   in	   tumour	   cell,	   inhibit	   cancer	   cell	   death	   pathways	  
promoting	  cell	  survival	  in	  breast	  cancer.	  	  
4.1	  BREAST	  CANCER	  	  	  
Breast	   cancer	   is	   the	   most	   common	   malignancy	   diagnosed	   in	   women	   around	   the	  
world,	  both	  in	  developed	  and	  in	  developing	  countries	  (Benson	  and	  Jatoi,	  2012;	  Boyle	  
and	  Howell,	   2010).	   Breast	   tumours	   are	   annually	   responsible	   for	   almost	   1.6	  million	  
new	  cases	  of	  cancer	  worldwide	  and	  approximately	  520,000	  deaths	  were	  recorded	  in	  
2012	   (data	   from	   IARC,	  GLOBOCAN	  project	  2012).	  Although	   the	   incidence	  of	  breast	  
cancer	   is	   increasing	  almost	  everywhere	  throughout	   the	  world,	   the	  mortality	   rate	   is	  
declining	   in	   many	   high-­‐income	   countries	   (Autier	   et	   al.,	   2010)	   but	   a	   significant	  
percentage	  of	  these	  patients	  still	  dies,	  mainly	  due	  to	  the	  treatment	  failures	  and	  the	  
inability	  to	  prevent	  metastatic	  spreading	  of	  the	  disease.	  
Management	   of	   breast	   cancer	   relies	   on	   the	   availability	   of	   clinical	   and	   pathological	  
prognostic	   and	   predictive	   factors	   to	   stratify	   individual	   patients	   for	   appropriate	  
therapy.	   	   The	   Nottingham	   Histological	   Score	   (modification	   of	   the	   Scarff-­‐Bloom-­‐
Richardson	  grading	  system)	  (Elston	  and	  Ellis,	  1991)	  is	  the	  most	  used	  grading	  system	  
and	   is	  recommended	  by	  the	  World	  Health	  Organization	  (WHO),	  the	  American	  Joint	  
Committee	  on	  Cancer	   (AJCC)	  and	   the	  Royal	  College	  of	  Pathologists	   (UK	  RCPath).	   In	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this	   score	   the	   nuclear	   grade,	   the	   tubular	   formation	   and	   the	   mitotic	   index	   are	  
considered	   to	   distinguish	   invasive	   carcinomas	   into	   three	   different	   groups	   with	  
prognostic	   relevance:	   grade	  1	   (G1),	   grade	  2	   (G2)	  and	  grade	  3	   (G3)	   tumours.	   These	  
grades	   are	   representative	   of	   the	   degree	   of	   loss	   of	   differentiation	   and	   of	   the	   of	  
acquisition	  of	  various	  mutations	  and	  provide	  a	  predictor	  of	  outcome	  in	  patients	  with	  
invasive	  breast	  cancer;	  in	  fact	  G3	  tumors	  (46%)	  are	  associated	  with	  malignancy	  and	  
high	   risk	   of	   metastasis	   occurrence	   and	   the	   majority	   of	   deaths	   in	   these	   patients	  
occurs	  within	  10	  years.	  However,	  since	  the	  biology	  of	  breast	  cancer	  varies	  a	  lot	  from	  
one	  tumour	  to	  another,	  histological	  grade	  is	  not	  a	  sufficient	  guide	  to	  characterize	  all	  
these	  biological	  differences.	  In	  fact,	  breast	  cancer	  presents	  an	  intrinsic	  inter-­‐tumoral	  
and	  intra-­‐tumoral	  heterogeneity	  and	  this	   is	  one	  of	  the	  main	  factors	  that	  determine	  
risk	  of	  disease	  progression	  and	  therapeutic	  resistance	  (Polyak,	  2011).	  	  
In	  the	  last	  years	  the	  biology	  of	  this	  tumour	  became	  more	  clear:	  there	  are	  ways	  now	  
to	  identify	  sub-­‐types	  of	  breast	  cancer:	  at	  least	  five	  main	  molecular	  classes	  have	  been	  
distinguished	  by	  gene-­‐expression	  profiling	  and	  histological	  staging:	  	  
-­‐	  luminal-­‐A	  characterized	  by	  the	  expression	  of	  oestrogen	  receptor	  (ER)	  and	  its	  target	  
genes,	  low	  rate	  of	  proliferation	  and	  good	  prognosis;	  
	  -­‐	   luminal-­‐B	   characterized	   by	   high	   proliferation	   rate	   and	   incomplete	   sensitivity	   to	  
endocrine	  therapy	  (Prat	  et	  al.,	  2012).	  
-­‐	   HER2-­‐positive	   breast	   cancers	   showing	   amplification	   or	   high	   expression	   of	   the	  
ERBB2	  oncogene.	   These	   tumours	   are	   poorly	   differentiated	   and	  have	   an	   aggressive	  
natural	   history:	   they	   display	   high	   proliferation	   rate,	   high	   frequency	   of	   cerebral	  
metastases	  and	  worse	  prognosis.	  	  
-­‐	  Normal-­‐like	  breast	   cancer	   that	   is	  a	   small	   group	  of	  usually	  well	  differentiated,	  ER-­‐
positive	   and	   HER2-­‐	   negative	   cancers.	   They	   are	   characterized	   by	   the	   expression	   of	  
normal	  tissue	  genes.	  
-­‐	   Basal-­‐like	   breast	   cancer	   subtype	   represents	   approximately	   15%	   of	   all	   breast	  
cancers,	  it	   is	  defined	  by	  the	  expression	  of	  markers	  usually	  present	  in	  normal	  breast	  
myoepithelial	  cells	  (CK5/6	  e	  CK17).	  Among	  them	  a	  large	  percentage	  are	  TNBC	  (Triple-­‐
Negative	  breast	  cancer)	  characterized	  by	   large	  tumour	  size,	  high	  histological	  grade,	  
high	  frequency	  of	  lymph	  node	  affection	  and	  metastases.	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In	   the	   last	   years	   our	   knowledge	   of	   the	   clinical	   behaviour	   of	   breast	   cancer	   has	  
increased	  substantially.	  Identification	  of	  several	  prognostic	  subgroups	  and	  prediction	  
of	  hormone-­‐	  responsive	  and	  hormone-­‐resistant	  disease	  has	  led	  to	  more	  rational	  use	  
of	   endocrine	   and	   cytotoxic	   treatments.	   Breast	   cancer	   is	   sensitive	   to	   multiple	  
cytotoxic	   compounds	   like	   anthracyclines,	   taxanes,	   topoisomerase	   inhibitors,	  
nucleoside	  analogues,	  commonly	  used	  as	  chemotherapeutics,	  both	  in	  breast	  cancer	  
and	   in	   other	   cancers	   (Dobbelstein	   and	   Moll,	   2014).	   However,	   the	   side	   effects	   of	  
these	  treatments	  are	  severe	  and	  sometimes	  can	  be	  as	  lethal	  as	  the	  cancer	  itself.	   In	  
fact,	  due	  to	  their	  lack	  of	  specificity,	  these	  compounds	  affect	  all	  rapidly	  dividing	  cells	  
indiscriminately	  and	  thus	  also	  interest	  tissue	  with	  a	  high	  rate	  of	  turnover,	   i.e.	  bone	  
marrow,	   skin	   and	   epithelium	   of	   gastro-­‐intestinal	   tract.	   Importantly,	   these	  
chemotherapeutics	   can	   also	   give	   rise	   to	   secondary	  malignancies	   (Dobbelstein	   and	  
Moll,	  2014).	  	  
As	  in	  other	  solid	  tumours,	  development	  of	  breast	  cancer	  is	  a	  multi-­‐factorial	  process	  
represented	  by	  a	  chain	  of	  cellular	  and	  molecular	  events	  that	  reflect	  accumulation	  of	  
genetic	   and	   epigenetic	   alterations.	   The	   acquisition	   of	   new	   mutations	   in	   a	  
subpopulation	   of	   tumour	   cells	   is	   often	   responsible	   for	   drug-­‐resistance.	   Thus,	   the	  
pathways	   required	   for	   cancer	   growth	   and	   drug-­‐resistance	   need	   to	   be	   further	  
investigated	   for	   the	   clinical	   advancement	   of	   targeted	   therapies;	   so	   the	   molecular	  
characterization	  of	  signalling	  pathways	  that	  drive	  tumour	  formation	  and	  progression	  
represents	  a	  key	  step	  in	  the	  development	  of	  new	  treatment	  modalities	  and	  targeted	  
cancer	  therapy.	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AIM	  OF	  THE	  THESIS	  
	  
The	  Hippo	  signalling	  pathway	  has	  emerged	  to	  play	  a	  central	  role	  in	  the	  regulation	  of	  
cellular	  biological	  properties,	  which	  are	  fundamental	  in	  both	  organ	  size	  control	  and	  
tumorigenesis.	  The	  YAP	  oncogene	  is	  the	  main	  nuclear	  effector	  of	  the	  Hippo	  tumour-­‐
suppressor	   cascade.	   It	   is	   regulated	   by	   a	   wide	   number	   of	   upstream	   signals	   and	  
proteins	  that	  influence	  its	  activity	  in	  mediating	  cellular	  biological	  processes,	  such	  as	  
cell	  proliferation,	  apoptosis	  and	  stemness.	  Deregulation	  of	  these	  signals	  can	  lead	  to	  
cancer	  formation,	  maintenance	  and	  expansion.	  Indeed,	  the	  Hippo	  pathway	  is	  largely	  
deregulated	  and	  YAP	   is	   often	  over-­‐expressed	  and	   it	   has	   aberrant	   activity	   in	  breast	  
cancer	  as	  well	  as	  in	  several	  other	  human	  carcinomas.	  	  
The	  aim	  of	  this	  thesis	  was	  to	   identify	  new	  pathways	  able	  to	   influence	  and	  regulate	  
YAP	   functions	   in	   breast	   cancer	   and	   to	   study	   mechanisms	   through	   which	   this	  
regulation	  occurs.	   To	   this	   aim	  we	   tested	   a	   library	  of	   FDA-­‐approved	  drugs	   for	   their	  
ability	   to	   regulate	  YAP	  nuclear	   localization	   in	   a	  model	  of	  metastatic	  breast	   cancer.	  
Since	   the	   identified	   compounds	   are	   well-­‐characterized	   in	   their	   targets	   and	  
intracellular	   signaling,	   it	  was	   then	  possible	   to	  elucidate	   the	  molecular	  mechanisms	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RESULTS	  
	  
Identification	  of	  drugs	  regulating	  YAP	  protein	  levels	  in	  cancer	  cells	  
	  
Aiming	  at	  identifying	  novel	  small-­‐molecules	  able	  to	  regulate	  YAP	  functions	  in	  cancer	  
cells	   we	   tested,	   by	   a	   high-­‐content	   screening,	   the	   effect	   of	   a	   collection	   of	   640	  
clinically-­‐used	   compounds	   on	   YAP	   protein	   levels	   and	   in	   the	   breast	   cancer	   cell	   line	  
MDA-­‐MB-­‐231.	  All	   the	  drugs	   used	   in	   this	   screening	  have	   already	   received	   the	   FDA-­‐
approval	   and	   therefore	   have	   been	   characterized	   for	   their	   pharmacokinetic	   and	  
pharmacodynamic	   properties	   as	   well	   as	   for	   their	  molecular	  mechanisms	   of	   action	  
and	   molecular	   targets.	   Cells	   were	   seeded	   in	   384-­‐well	   plates	   and	   cultured	   at	   low	  
density.	   After	   24	   hours	   each	   compound	   of	   the	   library	   was	   transferred	   robotically	  
from	  library	  stock	  plates	  to	  the	  plates	  containing	  the	  cells.	  Drugs	  were	  added	  to	  the	  
culture	   medium	   at	   two	   different	   concentrations	   (1	   and	   10	   μM).	   24	   hours	   after	  
treatment,	   cells	   were	   fixed	   and	   processed	   immediately	   for	   YAP-­‐specific	  
immunofluorescence	   analysis	   (Figure	   1a).	   The	   effect	   of	   each	   compound	   in	  
modulating	  the	  total	  YAP	  protein	   levels	  was	  assessed	  by	  detecting	  the	  YAP-­‐specific	  
staining	   and	   by	   quantifying	   the	   YAP-­‐relative	   fluorescence	   intensity	   at	   single-­‐cell	  
level.	   The	   image	   acquisition	   was	   performed	   using	   an	   automated	   high-­‐content	  
screening	  fluorescence	  microscope	  (Molecular	  Devices)	  at	  a	  10x	  magnification.	  The	  
screening	   was	   performed	   in	   duplicate	   and	   4,500	   cells	   were	   analyzed	   per	  
experimental	  condition	  and	  replicate.	  
Several	  compounds	  were	  able	  to	  significantly	  modify,	  although	  at	  different	  degrees,	  
YAP	  protein	  levels.	  Among	  them	  Statins	  that	  based	  on	  our	  recent	  studies	  emerged	  as	  	  
a	   class	   of	   compounds	   with	   strong	   YAP	   inhibitory	   effect	   (Sorrentino	   et	   al.,	   2014).	  
These	   drugs	   belong	   to	   the	   mevalonate	   pathway	   inhibitors	   class	   and	   are	   used	   to	  
reduce	   the	   cholesterol	   levels	   in	   patients	   with	   cardiovascular	   diseases	   (Opie	   et	   al.,	  
2015).	   Interestingly	   as	   shown	   in	   Figure	   1b,	   statins	   emerged	   as	   the	  most	   effective	  
drugs	   in	   reducing	   the	   YAP	   protein	   levels	   thus	   confirming	   the	   reliability	   of	   our	  
screening.	   However,	   analysing	   the	   results	   of	   the	   screening	   we	   become	   interested	  
also	   on	   a	   group	   of	   molecules	   that	   strongly	   increased	   YAP	   fluorescence	   intensity	  
(Figure	  1b).	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Of	  note,	  most	  of	  the	  identified	  hits,	  Betamethasone,	  Prednisolone,	  Dexamethasone,	  
Fluocinolone,	   belong	   to	   the	   same	   pharmacological	   class	   of	   Glucocorticoids	   (Figure	  
1b,	  c	  and	  d	  and	  Table	  1).	  Therefore	  among	  the	  640	  FDA-­‐approved	  drugs	  tested	  in	  our	  
assay,	   we	   identified	   Glucocorticoids	   as	   the	   main	   class	   of	   compounds	   that	  
significantly	  increased	  the	  YAP	  protein	  levels	  thus	  suggesting	  that	  the	  Glucocorticoid	  
Receptor	  signalling	  pathway	  could	  regulate	  the	  biological	  activity	  of	  YAP.	  	  
	  
Breast	  Cancer	  cells	  are	  fully	  responsive	  to	  glucocorticoids	  stimulation	  	  
The	  expression	  of	  GR	  has	  been	  reported	   in	  various	  breast	  cancer	  cell	   lines	   (Skor	  et	  
al.,	  2013).	  Therefore	  we	  first	  tested	  whether	  the	  MDA-­‐MB-­‐231	  cells	  were	  responsive	  
to	  pharmacological	  activation	  of	  GR.	  The	  activation	  of	  endogenous	  GR	  was	  assessed	  
monitoring	   the	   transcriptional	   activation	   of	   GR	   in	   cells	   using	   the	   pGL4.36	  
luc2P/MMTV/Hygro	   luciferase	   reporter	   assay.	   The	   vector	   contains	   MMTV	   LTR	  
(Murine	  Mammary	  Tumor	  Virus	  Long	  Terminal	  Repeat)	  that	  drives	  the	  transcription	  
of	  the	  luciferase	  reporter	  gene	  luc2P	  in	  response	  to	  transcriptional	  activation	  of	  the	  
Glucocorticoid	   Receptor.	   As	   shown	   in	   Figure	   2a,	   after	   administration	   of	  
Betamethasone	  (BM,	  a	  synthetic	  glucocorticoid	  agonist)	  for	  24	  hours,	  MDA-­‐MB-­‐231	  
cells	   showed	   a	   strong	   enhancement	   of	   the	   GR-­‐induced	   luminescent	   signal.	  
Moreover,	  when	  cells	  were	  co-­‐treated	  with	  Mifepristone	   (RU486,	  a	  GR	  antagonist)	  
the	   signal	   decreased	   to	   basal	   levels,	   meaning	   that	   the	   increase	   in	   luminescence	  
signal	   was	   specifically	   due	   to	   GR	   activation	   and	   that	   MDA-­‐MB-­‐231	   cells	   show	   an	  
intact	  GR	  signalling	  pathways.	  This	   finding	   indicates	   that	   the	  MDA-­‐MB-­‐231	  cell	   line	  
expresses	  endogenous	  GR,	  which	  is	  fully	  responsive	  to	  glucocorticoid	  stimulation.	  
Inactive	   GR	   proteins	   are	   localized	   in	   the	   cytoplasm	   bound	   to	   chaperone	   proteins	  
(e.g.	  HSP90)	  and	  following	  agonist	  stimulation	  they	  translocate	  to	  the	  nucleus	  where	  
exert	   their	   transcriptional	   activity	   (Nicolaides	  et	   al.,	   2010).	   Thus,	  we	  examined	   the	  
nuclear	   translocation	   of	   Glucocorticoid	   Receptor	   in	   MDA-­‐MB-­‐231	   cells	   after	  
treatment	   with	   Betamethasone.	   For	   this	   purpose	   we	   overexpressed	   a	   construct	  
composed	   by	   the	   cDNA	   of	   the	   GR	   fused	   to	   that	   of	   the	   green	   fluorescent	   protein	  
(GFP-­‐GR)	   and	   analysed	   its	   subcellular	   localization	   by	   fluorescence	   microscopy.	   As	  
expected,	   in	   absence	   of	   stimulation,	   the	   GR	   localized	   in	   the	   cytoplasm,	   while	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addition	   of	   Betamethasone	   clearly	   promoted	   its	   accumulation	   into	   the	   nucleus	  
(Figure	   2b).	   Similar	   results	   were	   obtained	   by	   monitoring	   the	   translocation	   of	  
endogenous	  GR	  by	  immunofluorescence	  (data	  not	  shown).	  
These	  data	  demonstrate	  that	  the	  triple	  negative	  breast	  cancer	  MDA-­‐MB-­‐231	  cell	  line	  
is	   fully	   responsive	   to	  endocrine	  stimulation	  by	  glucocorticoid	  and	   therefore	  can	  be	  
used	   as	   a	   cellular	   model	   to	   test	   the	   role	   of	   Glucocorticoid	   Receptor	   signalling	   in	  
regulating	  YAP	  protein	  levels	  and	  activity.	  
Glucocorticoids	  receptor	  directly	  increase	  YAP	  levels	  and	  activity	  	  	  
According	   to	   the	   results	   of	   the	   screening	   previously	   described,	   Glucocorticoids	  
represent	   the	   main	   class	   of	   drugs	   able	   to	   significantly	   increase	   YAP	   fluorescence	  
intensity.	   In	   order	   to	   validate	   the	   screening	   and	   to	   assess	   if	   the	   increase	   in	  
fluorescence	  intensity	  corresponded	  to	  an	  increase	  in	  total	  YAP	  protein	  levels,	  MDA-­‐
MB-­‐231	   cells	   were	   treated	   with	   Betamethasone	   1	   μM	   for	   24	   hours	   and	   then	  
analysed	  for	  YAP	  protein	  amount	  by	  western	  blot.	  As	  shown	  in	  Figure	  2c,	  treatment	  
with	  Betamethasone	  led	  to	  a	  significant	  increase	  in	  YAP	  protein	  levels	  both	  in	  MDA-­‐
MB-­‐231	  and	   in	   another	  breast	   tissue	  derived	   cell	   line,	  MCF10A-­‐M2	   (Cordenonsi	   et	  
al.,	   2011).	   Importantly,	   blocking	   the	   GR	   activation	   by	   co-­‐administrating	   RU486,	  
almost	   totally	   abolished	   the	   increase	   of	   YAP	   levels	   in	   the	   cells,	  meaning	   that	   YAP	  
protein	  levels	  are	  specifically	  influenced	  by	  GR	  activation.	  Interestingly,	  the	  levels	  of	  
TAZ	   were	   unchanged	   upon	   Betamethasone	   administration,	   indicating	   that	  
glucocorticoids	   regulate	   specifically	   the	   intracellular	   levels	   of	   YAP	   protein	   leaving	  
unaltered	  its	  homolog	  protein	  TAZ	  (Figure	  2c). 
Being	  YAP	  a	  transcriptional	  co-­‐activator,	  we	  sought	  to	  test	  whether	  the	   increase	   in	  
its	   protein	   levels	   corresponded	   to	   an	   increase	   in	   its	   biological	   functions	   by	  
monitoring	  the	  mRNA	   levels	  of	  a	  canonical	  YAP	  target	  gene.	  One	  of	   the	  most-­‐well-­‐
characterized	  YAP	  target	  genes	  that	  mediate	  several	  YAP	  biological	   functions	   is	  the	  
ankyrin	  repeat	  domain	  1	  (Ankrd1)	  gene	  (Dupont	  et	  al.,	  2011;	  Sorrentino	  et	  al.,	  2014;	  
Yu	  et	  al.,	  2012).	  This	  gene	  is	  mainly	  known	  to	  encode	  for	  the	  cardiac	  ankyrin	  repeat	  
protein	  (CARP)	  and	  to	  be	  involved	  in	  pathogenesis	  of	  hypertrophic	  cardiomyopathy	  
(Arimura	  et	  al.,	  2009).	  However,	  it	  has	  also	  been	  characterized	  as	  a	  YAP	  target	  gene	  
(Dupont	   et	   al.,	   2011;	   Yu	   et	   al.,	   2012)	   in	   breast	   cancer	   cells	   and	   in	   ovarian	   cancer,	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where	   its	   expression	   correlates	   with	   chemotherapy	   sensitivity	   and	   with	   clinical	  
outcome	  (Scurr	  et	  al.,	  2008).	  Interestingly,	  treatment	  with	  Betamethasone	  1	  μM	  for	  
24	   hours	   led	   to	   a	   dramatic	   up-­‐regulation	   of	   ANKRD1	   protein	   (Figure	   2d).	   As	   co-­‐
treatment	   with	   RU486	   blunted	   this	   effect,	   we	   concluded	   that	   up-­‐regulation	   of	  
ANKRD1	  was	  specifically	  triggered	  by	  the	  GR	  activation.	  Moreover,	  to	  formally	  prove	  
that	   GC	   induced	   ANKRD1	   expression	   through	   YAP	   transcriptional	   activation,	   we	  
knocked	   down	   YAP	   by	   siRNA	   transfection	   for	   48	   hours	   before	   Betamethasone	  
treatment.	   Strikingly,	   knocking-­‐down	   YAP	   completely	   prevented	   the	   ANKRD1	  
increase	   prompted	   by	   Betamethasone,	   strongly	   suggesting	   that	   glucocorticoid	  
signalling	   enhances	   YAP	   transcriptional	   activity	   (Figure	   2d).	   Altogether,	   these	  
findings	   suggest	   that	  Glucocorticoid	  Receptor	   activate	   a	   signalling	   able	   to	   increase	  
YAP	  nuclear	  activity	  in	  breast	  cancer	  cells.	  
Glucocorticoid	  receptor	  directly	  regulates	  YAP	  mRNA	  transcription	  	  
Glucocorticoid	  receptor	  belongs	  to	  the	  nuclear	  receptor	  superfamily	  of	  transcription	  
factor	  proteins	  and	  functions	  as	  a	  ligand-­‐dependent	  transcription	  factor	  that	  is	  able	  
to	   bind	   the	   promoter	   of	   glucocorticoid-­‐responsive	   genes	   regulating	   positively	   or	  
negatively	  their	  expression	  (Frankfurt	  and	  Rosen,	  2004;	  Smith	  and	  Cidlowski,	  2010).	  	  
To	   find	   out	   whether	   the	   increase	   in	   YAP	   protein	   levels	   was	   an	   effect	   of	   direct	  
glucocorticoid	   receptor	   activity	   on	   YAP	  mRNA	  expression,	  MDA-­‐MB-­‐231	   cells	  were	  
treated	  with	  betamethasone	  for	  24	  hours	  and	  then	  analysed	  for	  the	  amount	  of	  YAP	  
mRNA	  transcript.	  As	  reported	  in	  Figure	  2e	  YAP	  mRNA	  expression	  was	  increased	  upon	  
treatment	   with	   betamethasone	   and	   the	   concomitant	   administration	   of	  
RU486 prevented	   this	   transcriptional	   induction	   suggesting	   that	   glucocorticoids	   are	  
able	  to	  increase	  YAP	  expression	  at	  the	  transcriptional	  level.	  	  
We	  then	  hypothesized	  that	  GR	  could	  directly	  recognize	  and	  bind	  the	  YAP	  promoter	  
thus	   triggering	   the	   transcription	  of	   its	  mRNA.	  To	   identify	  predicted	  GR	  binding	  site	  
we	  inspected	  the	  promoter	  sequence	  of	  YAP	  gene	  using	  the	  LASAGNA	  algorithm	  (Lee	  
and	  Huang,	  2013). This	  analysis	  revealed	  a	  DNA	  region	  located	  at	  -­‐1150	  to	  -­‐900	  bp	  
upstream	  of	  the	  first	  YAP	  exon	  with	  statistically	  significant	  prediction	  to	  be	  bound	  by	  
the	  GR	  (Figure	  2f).	  Chromatin	  immunoprecipitation	  (ChIP)	  assay	  was	  then	  performed	  
in	  MDA-­‐MB-­‐231	   cells	   treated	  with	   vehicle	   or	   betamethasone	   100	   nM	   for	   6	   hours	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(Polman	   et	   al.,	   2012)	   to	   confirm	   the	   recruitment	   of	   GR	   to	   the	   YAP	   promoter.	   As	  
shown	   in	   Figure	   2g	   GR	   was	   recruited	   on	   YAP	   promoter	   after	   Betamethasone	  
treatment	   while	   the	   negative	   control	   (heterochromatin	   region)	   doesn’t	   show	   any	  
recruitment,	  thus	  confirming	  that	  YAP	  is	  a	  bona	  fide	  glucocorticoid-­‐responsive	  gene	  
in	  breast	  cancer	  cells.	  
To	   further	   demonstrate	   the	   effect	   of	   GR	   activation	   on	   YAP	   mRNA	   levels	   and	  
biological	   activity	   in	   vivo,	   we	   performed	   experiment	   in	   vivo	   using	   the	   Drosophila	  
model	   and	   analysing	   the	   biological	   activity	   of	   the	   YAP	   Drosophila	   ortholog	   Yorkie	  
(YKI).	  As	  shows	   in	  figure	  2h,	  treatment	  of	  the	  developing	  flies	  with	  Betamethasone	  
led	  to	  a	  significant	  increase	  of	  YKI	  mRNA	  levels	  in	  the	  ovary	  tissue	  (Figure	  2h).	  In	  line,	  
the	  mRNA	  levels	  of	  the	  YKI	  target	  genes,	  Drosophila	  inhibitor	  of	  apopotosis	  protein-­‐1	  
(DIAP1),	  and	  Expanded	  (Ex),	  were	  concomitantly	  increased	  in	  the	  same	  tissue	  (Figure	  
2h).	  
Our	   findings	   suggest	   that	   glucocorticoid	   receptor	   directly	   promotes	   YAP	   mRNA	  
transcription	  in	  vitro	  and	  in	  vivo	  in	  response	  to	  glucocorticoid	  stimulation.	  
	  
Glucocorticoids	   regulate	   YAP	   nuclear	   localization	   by	   promoting	   its	   de-­‐
phosphorylation	  and	  nuclear	  accumulation	  	  
Being	   a	   transcriptional	   co-­‐activator,	   YAP	   is	   strongly	   influenced	   by	   its	   sub-­‐cellular	  
localization,	  which	  correlates	  with	  its	  biological	  activity	  (Zhao	  et	  al.,	  2007).	   	   Indeed,	  
when	  YAP	  is	   localized	  in	  the	  cytoplasm	  it	   is	  phosphorylated	  and	  bound	  to	  14-­‐3-­‐3	  in	  
an	  inactive	  state	  and	  is	  actively	  degraded	  in	  a	  proteasome-­‐dependent	  manner.	  In	  the	  
nucleus	   YAP	   is	   instead	   protected	   from	   phosphorylation	   and	   degradation	   and	   can	  
interact	   with	   several	   transcription	   factors	   modulating	   their	   activity	   (Piccolo	   et	   al.,	  
2014).	   The	   evidence	   that	   GCs	   not	   only	   increased	   YAP	   protein	   levels	   but	   also	   its	  
transcriptional	  activity	  suggests	  that	  GCs	  might	  not	  only	  increase	  the	  amount	  of	  YAP	  
mRNA	  and	  protein,	  but	  could	  also	  trigger	  the	  YAP	  nuclear	  translocation	  essential	  for	  
its	  transcriptional	  activity.	  Thus,	  we	  assessed	  the	  YAP	  subcellular	  localization	  in	  cells	  
treated	   with	   GCs.	   At	   first,	   we	   re-­‐analysed	   the	   data	   obtained	   by	   the	   high	   content	  
screening	  described	  above	  extracting	   information	  about	   the	  effect	  of	   the	  drugs	  on	  
YAP	   nuclear	   localization.	   Interestingly,	   Glucocorticoids	   clustered	   together	   as	   drugs	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able	  to	  significantly	  increase	  the	  YAP	  nuclear	  localization	  (Figure	  2a	  and	  b),	  meaning	  
that	  GC	  are	  able	  not	  only	  to	  increase	  the	  YAP	  protein	  levels,	  but	  also	  to	  promote	  its	  
nuclear	  accumulation.	  	  
To	   demonstrate	   that	   the	   increased	   YAP	   nuclear	   localization	   observed	   in	   the	  
screening	   was	   not	   an	   unspecific	   consequence	   of	   the	   GC-­‐induced	   increase	   of	   YAP	  
protein	   levels,	   we	   first	   transfected	   YAP	   in	   MDA-­‐MB-­‐231	   cells.	   As	   shown	   in	  
Supplementary	  Figure	  1a	  YAP	  overexpression	  led	  to	  a	  strong	  increase	  of	  YAP	  mRNA	  
levels.	  Interestingly	  enough,	  the	  increase	  of	  YAP	  protein	  levels	  did	  not	  correlate	  with	  
any	   increase	   of	   YAP	   nuclear	   localization	   (Supplementary	   figure	   1b).	   Indeed,	   the	  
majority	  of	   transfected	  cells	   showed	  cytoplasmic-­‐localized	  YAP	  meaning	   that	  other	  
signals,	   in	   addition	   to	   the	   general	   increase	   of	   YAP	   protein	   levels,	   are	   required	   to	  
foster	  YAP	  nuclear	  localization.	  
Among	   post-­‐translational	   signals	   controlling	   the	   cytoplasmic	   retention	   and	  
degradation	  of	  YAP,	  phosphorylation	  (in	  particular	  on	  Ser127),	  is	  a	  critical	  one.	  In	  fact	  
dephosphorylated	   YAP	  entirely	   accumulates	   in	   the	  nucleus.	  Of	   note,	   conversely	   to	  
the	  overexpressed	  WT	  form	  of	  YAP,	  which	  showed	  mainly	  cytoplasmic	   localization,	  
the	  overexpressed	  unphosphorylable	  YAP	  mutant	   (YAP-­‐5SA)(Pan,	  2010)	  was	  mainly	  
nuclear	  (Supplementary	  figure	  1b).	  
We	  thus	   tested	  whether	  Glucocorticoids	  could	  promote	  YAP	  de-­‐phosphorylation	   in	  
addition	  to	  increasing	  its	  protein	  levels.	  Western	  blot	  analysis	  of	  protein	  lysates	  from	  
MDA-­‐MB-­‐231	  and	  MCF10A-­‐M2	  cells	  treated	  with	  betamethasone	  showed	  a	  dramatic	  
reduction	  of	  the	  levels	  of	  Serine	  127	  phosphorylated	  YAP	  and	  this	  effect	  was	  totally	  
prevented	  by	  RU-­‐486	  (Figure	  3c).	  As	  expected,	  Betamethasone	  was	  able	  to	  promote	  
YAP	   nuclear	   localization	   in	   three	   different	   breast	   cancer	   cell	   lines	   and	   RU-­‐486	  
efficiently	  prevented	  this	  effect	  (Figure	  3d	  and	  e).	  	  
Of	  note,	  GR-­‐induced	  YAP	  nuclear	  accumulation	  was	  seen	  also	  in	  HeLa	  cells	  meaning	  
that	  the	  hormonal	  control	  of	  YAP	  nuclear	  localization	  might	  not	  be	  restricted	  to	  the	  
breast	  tissue	  (Figure	  3d).	  	  	  
Altogether	  these	  results	  demonstrate	  that	  GCs	  trigger	  YAP	  transcriptional	  activation	  
through	  the	  combined	  effect	  of	  increasing	  its	  mRNA	  levels	  and	  of	  inducing	  its	  nuclear	  
accumulation	  by	  specifically	  reducing	  its	  inhibitory	  phosphorylation.	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Glucocorticoids	   promote	   YAP	   nuclear	   accumulation	   by	   controlling	   actin	  
cytoskeleton	  dynamics	  	  
One	   of	   the	   most	   established	   inputs	   controlling	   YAP	   nuclear	   localization	   is	   the	  
activation	  of	  the	  Hippo	  pathway.	  In	  particular	  LATS1	  kinase	  activation	  is	  responsible	  
for	   YAP	   phosphorylation	   and	   cytoplasmic	   retention	   downstream	   of	   the	   Hippo	  
pathway	  (Johnson	  and	  Halder,	  2014).	  To	  test	  if	  LATS1	  was	  involved	  in	  the	  GC-­‐induced	  
YAP	   de-­‐phosphorylation	   we	   checked	   the	   levels	   of	   LAST1	   and	   its	   active	  
phosphorylated	   form	   (pLATS1)	   after	   BM	   and	   RU486	   treatment.	   As	   shown	   in	  
supplementary	   figure	   1c	   we	   could	   not	   observe	   any	   change	   in	   LATS1	   and	   pLATS1	  
levels	  after	  treatments	  suggesting	  that	  this	  kinase	  is	  not	  involved	  in	  the	  regulation	  of	  
YAP	  phosphorylation	  by	  GC	  treatment.	  
Recently,	  several	  studies	  pointed	  out	  that	  mechanical	  forces	  and	  physical	  cues,	  such	  
as	   perturbation	   in	   extracellular	   matrix	   (ECM)	   stiffness	   and	   in	   cell	   geometry	  
contribute	   to	   development,	   differentiation,	   stemness	   and	   tumour	   progression	  
(Jaalouk	   and	   Lammerding,	   2009;	   McBeath	   et	   al.,	   2004).	   In	   the	   last	   years,	   an	  
important	  upstream	  mechanism	  controlling	  YAP	  activity	  has	  emerged:	  YAP	  is	  under	  
the	  control	  of	  mechanical	  signals	  exerted	  by	  ECM	  rigidity	  and	  cell	  shape	  (Dupont	  et	  
al.,	   2011;	   Yu	   et	   al.,	   2012).	   In	   this	   contest,	   the	   activity	   of	   Rho	  GTPases,	   a	   family	   of	  
proteins	  that	  control	  actin	  cytoskeleton	  dynamics	  and	  cell	  geometry	  has	  emerged	  as	  
a	   fundamental	   input	   in	   controlling	   YAP	   phosphorylation	   and	   nuclear	   localization	  
(Dupont	   et	   al.,	   2011;	   Sansores-­‐Garcia	   et	   al.,	   2011;	   Wada	   et	   al.,	   2011).	   Similarly,	  
metabolic	  cues	  have	  been	   linked	  to	  YAP	  activation	  through	  Rho	  GTPases	  activation	  
via	  geranylgeranylation	  (Sorrentino	  et	  al.,	  2014).	   Importantly,	  the	  regulation	  of	  YAP	  
phosphorylation	  and	  activity	  by	   cytoskeleton	   rearrangements	  does	  not	   involve	   the	  
activation	  of	  LATS1/2	  kinases	  (Dupont	  et	  al.,	  2011).	  	  
By	  microscopy	   analysis	   we	   noticed	   that	   cells	   receiving	   Betamethasone	   underwent	  
marked	   morphological	   changes	   with	   a	   clear	   increase	   in	   cell-­‐size	   and	   spreading,	  
suggesting	  that	  GCs	  could	  promote	  a	  strong	  rearrangement	  of	  the	  actin	  cytoskeleton	  
leading	  to	  cell	  shape	  alteration	  (Figure	  4a).	  	  
Thus,	   we	   tested	   if	   Glucocorticoids	   could	   affect	   YAP	   nuclear	   localization	   acting	  
directly	   through	   mechanical	   cues.	   To	   this	   aim,	   cells	   were	   treated	   with	  
Betamethasone	   1	   μM	   for	   24	   hours.	   To	   verify	   whether	   the	   treatment	   caused	   an	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alteration	   of	   actin	   cytoskeleton	   we	   analysed	   the	   actin	   cytoskeleton	   through	  
Phalloidin	  staining	  (which	  is	  commonly	  used	  to	  highlight	  the	  actin	  microfilaments)	  by	  
fluorescent	  microscopy.	  The	  immunofluorescence	  images	  show	  that	  Betamethasone	  
treatment	  dramatically	  increased	  the	  formation	  of	  F-­‐actin	  stress	  fibers	  in	  MDA-­‐MB-­‐
231	  cells	  (Figure	  4b).	  	  
To	   formally	   link	   the	   effect	   of	   GCs	   to	   YAP	   nuclear	   localization	   and	   activity	   through	  
cytoskeletal	  cues,	  we	  decided	  to	  pharmacologically	  prevent	  the	  actin	  polymerization	  
by	   treating	   cells	   with	   Latrunculin-­‐A,	   an	   F-­‐actin	   destabilizing	   toxin	   that	   binds	   actin	  
monomers	   and	   prevents	   them	   from	   undergoing	   polymerization	   (Dupont	   et	   al.,	  
2011).	  As	  shown	  in	  Figure	  4c,	  with	  this	  experimental	  set-­‐up,	  Betamethasone	  totally	  
failed	  to	  increase	  the	  amount	  of	  F-­‐actin	  stress	  fibers.	  More	  importantly,	  Latrunculin-­‐
A	  treatment	  prevented	  the	  induction	  of	  YAP	  nuclear	  localization	  and	  transcriptional	  
activity	  (as	  assessed	  by	  monitoring	  the	  levels	  of	  its	  target	  gene	  ANKRD1)	  triggered	  by	  
Betamethasone	  (Figure	  4f	  and	  g),	  suggesting	  that	  F-­‐actin	  polymerization	  is	  required	  
for	   YAP	   activation	   by	   GCs.	   Of	   note,	   similar	   results	   were	   also	   obtained	   by	   using	  
statins,	   which	   inhibit	   several	   Rho-­‐GTPases	   (Sorrentino	   et	   al.,	   2014),	   essential	  
component	  of	  the	  actin	  polymerization	  machinery	  (Figure	  4g).	  
Hence,	   these	   data	   indicate	   that	   the	   ability	   of	   GCs	   to	   induce	   actin	   polymerization	  
plays	  a	  major	  role	   in	  promoting	  YAP	  nuclear	  accumulation	  and	  activity.	  Conversely,	  
in	   conditions	   in	   which	   actin	   cannot	   be	   polymerized	   (e.g.	   after	   Latrunculin-­‐A	  
treatment),	  Glucocorticoids	  fail	  to	  activate	  YAP.	  	  
Interestingly,	   the	   control	   of	   YAP	   exerted	   by	   glucocorticoid	   at	   transcriptional	   level	  
(Figure	   4e)	   is	   clearly	   uncoupled	   from	   the	   cytoskeleton-­‐mediated	   one.	   Indeed	   cells	  
treated	  with	   betamethasone	   in	   presence	   of	   latrunculin-­‐A	   still	   show	   increased	   YAP	  
mRNA	  and	  protein	  amount	  (Figure	  4e)	  but	  this	  is	  not	  sufficient	  to	  sustain	  its	  nuclear	  
function	  due	  to	  the	  lack	  of	  YAP	  de-­‐phosphorylation	  (Figure	  4e	  and	  f).	  
Therefore	  these	  data	  indicate	  the	  existence	  of	  two	  independent	  mechanisms	  of	  YAP	  
regulation	   by	   glucocorticoids:	   on	   one	   hand	   glucocorticoid	   receptor	   increases	   YAP	  
mRNA	  expression	  leading	  to	  YAP	  protein	  accumulation	  within	  the	  cell,	  on	  the	  other	  
glucocorticoids	   promote	   actin	   polymerization	   leading	   to	   YAP	   de-­‐phosphorylation,	  
nuclear	  accumulation	  and	  activity.	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Glucocorticoids	   are	   serum	   factors	   that	   counteract	   the	   GPCRs-­‐mediated	  
negative	  regulation	  of	  YAP	  	  	  	  
When	  our	  senses	  perceive	  an	  environmental	  stress	  such	  as	  danger	  or	  a	  threat,	  cells	  
in	  the	  nervous	  and	  endocrine	  systems	  work	  closely	  together	  to	  prepare	  the	  body	  for	  
action.	  Often	  referred	  to	  as	  the	  “fight	  or	  flight”	  or	  “stress	  response”,	  this	  remarkable	  
example	   of	   cell	   communication	   elicits	   instantaneous	   and	   simultaneous	   responses	  
throughout	   the	  body.	   In	   this	  context,	  Epinephrine	  and	  Cortisol	  are	  secreted	  by	   the	  
same	  glands	  during	   stress;	   Epinephrine	   is	   involved	   in	   the	   “fight-­‐or-­‐flight”	   response	  
and	  temporary	  increase	  in	  energy	  production	  while	  Cortisol	  is	  an	  important	  mediator	  
in	  long	  term	  stress	  response.	  	  
Recently	   it	   has	   been	  demonstrated	   that	   YAP	   is	   regulated	   by	   a	   large	   number	   of	  G-­‐
protein-­‐coupled	   receptor	   (GPCR)	   that	   can	   either	   activate	   or	   inhibit	   the	   Hippo-­‐YAP	  
pathway	  depending	  on	  the	  coupled	  G	  protein	  (Yu	  et	  al.,	  2012).	  As	  consequence,	  the	  
YAP	   nuclear	   activity	   can	   be	   regulated	   by	   several	   serum	   components,	   such	   as	  
lysophosphatidic	   acid	   (LPA),	   sphingosine	   1-­‐phosphophate	   (S1P),	   glucagon	   or	  
epinephrine	  acting	  through	  GPCRs	  signalling.	  	  
Rho-­‐GTPases	   are	   known	   downstream	   mediators	   of	   GPCRs	   and	   orchestrate	   actin	  
cytoskeleton	  rearrangement	  upon	  their	  activation	  (Yu	  et	  al.,	  2012).	  Interestingly,	  the	  
control	  of	  YAP	  nuclear	  activity	  by	  GPCRs	  agonists/antagonists	  has	  been	  found	  to	  be	  
mediated	  by	  Rho-­‐GTPases	  and	  requires	  actin	  cytoskeleton	  remodelling	  (Fa-­‐Xing	  Yu	  et	  
al.,	   2012).	  GPCRs	   coupled	   to	   alphas	  G-­‐proteins,	   are	   among	   the	  most	   effective	   YAP	  
regulators.	   In	  particular,	   Isoprenaline	  and	   its	  analogous	  Salmeterol	   (Yu	  et	  al.,	  2012)	  	  
show	   potent	   YAP	   inhibitory	   effect	   acting	   through	   the	   beta-­‐adrenergic	   receptors.	  
Thus	  we	  asked	  whether	  GC	  could	  counteract	  the	  inhibitory	  effect	  of	  beta-­‐adrenergic	  
receptor	   agonists,	   which	   are	   present	   in	   the	   serum	   by	   controlling	   the	   actin	  
cytoskeleton.	  To	  this	  aim,	  we	  decided	  to	  treat	  MDA-­‐MB-­‐231	  cells	  with	  the	  known	  b2-­‐
adrenergic	   agonist	   Salmeterol.	   As	   expected,	   Salmeterol	   inhibited	   YAP	   nuclear	  
localization	   by	   increasing	   its	   phosphorylation	   (Figure	   5a	   and	   b).	   Interestingly,	  
treatment	  with	   betamethasone	   efficiently	   rescued	   the	   nuclear	   YAP	   localization	   by	  
preventing	   its	  phosphorylation	   (Figure	  5a,	  b	  and	   c).	  Moreover,	  RU486	  blunted	   this	  
Betamethasone-­‐induced	  effect,	  meaning	  that	  inhibition	  of	  YAP	  phosphorylation	  was	  
specifically	  dependent	  on	  GR	  activation	  (Figure	  5a,	  b	  and	  c).	  Of	  note,	  betamethasone	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could	  not	  only	  rescue	  the	  YAP	  nuclear	  localization	  in	  presence	  of	  Salmeterol,	  but	  also	  
restore	  YAP	  transcriptional	  activity	  (Figure	  5d).	  
Thus,	  we	  can	  conclude	  that	  adrenergic	  and	  glucocorticoid	  stress	  signalling	  can	  exert	  
opposite	  effect	  in	  regulating	  YAP	  biological	  activity	  in	  cancer	  cells.	  
Glucocorticoids	  sustain	  breast	  cancer	  stem	  cells	  by	  activating	  YAP	  	  	  
Cancer	  stem	  cells	  (CSCs)	  are	  a	  sub-­‐population	  of	  cancer	  cells	  known	  to	  play	  a	  major	  
role	   in	   breast	   cancer	   development,	   metastasis,	   drug	   resistance	   and	   tumour	  
recurrence	   (Dittmer	   and	   Rody,	   2013).	   The	  most	  widely	   used	   assay	   to	  monitor	   the	  
number	  of	  breast	  cancer	  stem	  cells	  in	  mixed	  populations	  of	  stem	  and	  differentiated	  
cells	   is	   an	   in	   vitro	   cultivation	   system	  known	  as	  mammosphere	  assay	   (Dontu	  et	   al.,	  
2003).	  This	  in	  vitro	  assay	  is	  suitable	  for	  testing	  peculiar	  characteristics	  of	  stem	  cells,	  
such	   as	   self-­‐	   renewal	   and	   ability	   to	   generate	   differentiated	   progeny.	   In	   order	   to	  
perform	   this	   assay,	   cells	   are	   removed	   from	   culture	   plates	   and	   then	   cultured	   in	   a	  
specific	  stem-­‐cell	  growth	  medium	  in	  “ultra-­‐	  low	  attachment”	  plates	  that	  prevent	  cell	  
adherence.	  These	  experimental	  conditions	  allow	  for	  growth	  only	  of	  mammary	  stem	  
cells	   (and	   progenitor	   cells	   in	   an	   undifferentiated	   state),	   based	   on	   their	   ability	   to	  
proliferate	  in	  suspension	  and	  to	  develop	  non-­‐adherent	  spheres.	  Once	  formed,	  these	  
spheres	   are	   disrupted	   and	   plated	   for	   a	   second	   time	   in	   the	   same	   conditions	  
(secondary	   generation	   mammospheres).	   Importantly,	   transient	   amplifying	   or	  
differentiated	  cells	  have	  a	  limited	  ability	  to	  form	  mammospheres,	  whereas	  stem	  cells	  
are	   able	   to	   generate	   spheres	   that	   can	   be	   passaged	   beyond	   multiple	   generations	  
(from	  primary	  to	  secondary	  generation)	  (Figure	  6a).	  Thus,	  considering	  the	  number	  of	  
secondary	  and	  following	  mammospheres,	   it	   is	  possible	  to	  evaluate	  the	  cancer	  stem	  
cells	  self-­‐renewal	  capability	  and,	  therefore,	  the	  presence	  and	  the	  amount	  of	  cancer	  
stem	  cells.	  
In	   this	  context,	  TAZ	  activity	  has	  been	  shown	   increased	   in	  basal	  breast	  cancers	   that	  
show	   a	   more	   stem-­‐cell-­‐like	   phenotype	   (Cordenonsi	   et	   al.,	   2011).	   Indeed,	   TAZ	  
hyperactivity	  promotes	  tumorigenic	  potential	  by	  the	  acquisition	  of	  additional	  cancer	  
cell	   phenotypes	   and,	   among	   these,	   enhancing	   stem-­‐cell-­‐like	   properties	   plays	   a	  
central	   role.	   More	   recently,	   also	   YAP	   has	   been	   found	   to	   be	   determinant	   in	  
maintaining	   stem	   cell	   phenotypes	   and	   in	   conferring	   CSC	   properties	   to	   several	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different	  cell	  types	  (Cao	  et	  al.,	  2008;	  Lian	  et	  al.,	  2010;	  Song	  et	  al.,	  2014;	  Yimlamai	  et	  
al.,	  2014;	  Zhao	  et	  al.,	  2014).	  This	  evidence	  suggests	  that	  stemness	  could	  be	  pivotal	  in	  
YAP	  oncogenic	  behaviour.	  
Considering	   the	   results	   previously	   obtained,	  we	   aimed	   to	   determine	  whether	   YAP	  
induction,	  promoted	  by	  glucocorticoid	  treatment,	  might	  play	  a	  causal	  role	  in	  defining	  
CSC	  traits.	  To	  this	  aim,	  we	  used	  derivatives	  of	  the	  non-­‐tumorigenic	  human	  mammary	  
MCF10A	   cell	   line:	   RAS-­‐transformed	   MCF10A-­‐T1k	   cells	   (M2	   cells,	   Figure	   6b	   and	   c)	  
(Cordenonsi	   et	   al.,	   2011).	   Cells	  were	   grown	   in	   a	   specific	   stem-­‐cell	   growth	  medium	  
and	  cultured	  for	  two	  mammosphere	  generations	  with	  or	  without	  Hydrocortisone	  0.5	  
μg/ml.	  About	  two	  weeks	  later,	  only	  mammospheres	  that	  resulted	  to	  be	  over	  200	  μm	  
were	  considered	  for	  analysis.	  As	  shown	  in	  Figure	  6b	  glucocorticoid	  treatment	  led	  to	  
dramatic	   induction	   of	   secondary	   mammospheres,	   meaning	   that	   GR-­‐signalling	   is	  
essential	  for	  cancer	  stem	  cell	  self-­‐renewal.	  To	  formally	  demonstrate	  that	  GCs	  led	  to	  
CSCs	   expansion	   by	   inducing	   YAP	   biological	   activity,	   endogenous	   YAP	  was	   knocked	  
down	   through	   siRNA	   transfection	   for	   48	   hours	   before	   performing	   the	   assay.	  
Strikingly,	   knocking	   down	   YAP	   in	   M2	   cells	   almost	   totally	   prevented	   the	   ability	   of	  
Hydrocortisone	   to	   induce	  CSCs	   self-­‐renewal,	   proving	   that	   YAP	   is	   a	   key	   executor	   of	  
the	  GCs-­‐induced	  stem	  cell	  traits	  in	  cancer	  cells	  (Figure	  6b	  and	  c).	  
We	  thus	  reasoned	  that	   if	  YAP	   is	  a	  downstream	  nuclear	  effector	  responsible	  for	  the	  
ability	   of	   GCs	   to	   sustain	   CSCs	   self-­‐renewal,	   we	   can	   expect	   that	   cells	   expressing	   a	  
constitutively	  nuclear-­‐localized	  form	  of	  YAP	  (YAP-­‐5SA),	  should	  be	  totally	  capable	  to	  
form	   mammospheres	   even	   in	   absence	   of	   GR-­‐signalling.	   Strikingly,	   expressing	   this	  
nuclear	   form	   of	   YAP,	   CSCs	   completely	   bypassed	   the	   requirement	   of	   GR-­‐signalling	  
(Figure	   6b	   and	   c).	  We	   could	   thus	   prove	   that	   YAP	  plays	   a	   central	   role	   in	   sustaining	  
mammary	   cancer	   stem	   cell	   expansion	   and	   that	   the	   positive	   role	   of	   GCs	   on	   YAP	  
accounts	  for	  the	  ability	  of	  these	  hormones	  to	  control	  CSCs	  traits.	  	  
As	  previously	   said,	   cancer	   stem	  cells	   (CSCs),	   are	  defined	   as	   the	   fraction	  of	   tumour	  
cells	   specifically	   endowed	   with	   self-­‐renewal	   and	   tumour-­‐seeding	   potential	   and	  
ability	   to	   spawn	   non-­‐CSC	   progeny	   (Visvader	   and	   Lindeman,	   2008);	   CSCs	   are	  
responsible	   of	   metastasis,	   drug	   resistance	   and	   tumour	   recurrence	   (Dittmer	   and	  
Rody,	   2013).	   Due	   to	   the	   results	   obtained	   before	  we	   asked	  whether	   glucocorticoid	  
receptor	  inhibitor	  RU486	  could	  be	  able	  to	  blunt	  the	  expansion	  of	  cancer	  stem	  cells.	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To	   this	   aim,	   M2	   cells	   were	   treated	   for	   24	   hours,	   then	   the	   cells	   were	   grown	   in	   a	  
specific	   stem-­‐cell	   growth	   medium	   (see	   experimental	   procedures	   section)	   and	  
cultured	   for	   two	  mammosphere	   generations	  with	   or	  without	   RU486.	   As	   shown	   in	  
Figure	   6e,	   RU486	   treatment	   dramatically	   reduced	   the	   number	   of	   secondary	  
mammospheres	   generated	   by	   MCF10A-­‐M2	   cells.	   In	   line,	   RU486	   treatment	   led	   to	  
strong	   reduction	   of	   the	   population	   of	   cells	   expressing	   specific	   breast	   cancer	   stem	  
cells	  marker	  CD44+/CD24–	  (Fillmore,	  2007)	  (Figure	  6d	  and	  supplementary	  figure	  1d).	  	  
To	   test	  whether	   this	   effect	  was	   due	   to	   a	   general	   effect	   of	   RU486	   in	   reducing	   cell	  
viability	  and	  proliferation	  we	  performed	  viability	  assay	  after	  treatment	  of	  MCF10A-­‐
M2	   cells	   (pleated	   in	   petri	   dishes)	  with	   two	  RU486	   doses.	   Strikingly,	   after	   5	   day	   of	  
treatment	  RU486	  treatment	  didn’t	  show	  any	  effect	  on	  cell	  viability	   (Figure	  6f)	   thus	  
suggesting	  that	  its	  inhibitory	  effect	  was	  specific	  for	  cancer	  stem	  cells.	  	  These	  results	  
suggest	  that	  RU486	  is	  a	  promising	  FDA-­‐approved	  drug	  that	  can	  be	  used	  for	  targeting	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DISCUSSION	  	  	  
In	   the	   last	   decades,	   research	   on	   the	   complex	   biology	   of	   cancer	   has	   increased	  
substantially	  and	  has	   led	   to	  a	  deeper	  knowledge	  about	   the	  molecular	  mechanisms	  
underlying	   cancer	   formation	   and	   expansion.	   The	   Hippo	   signaling	   cascade	   has	  
emerged	  as	  an	  evolutionally	  conserved	  tumour	  suppressor	  pathway	  involved	  both	  in	  
organ	  size	  control	  and	  cancer	  development.	   It	  plays	  a	  crucial	   role	   in	   regulating	   the	  
transcription	   of	   several	   genes,	   involved	   in	   fundamental	   cellular	   processes,	   such	   as	  
proliferation	  and	  apoptosis,	  organ	  growth,	  embryonic	  development,	  differentiation	  
and	   stem	   cell	   functions.	   Consistently,	   dysregulation	   of	   the	   Hippo	   signalling	   and	  
hyper-­‐activation	  of	  its	  major	  downstream	  effector	  Yes-­‐associated	  protein	  (YAP)	  have	  
been	   associated	   with	   cancer	   onset	   in	   a	   broad	   range	   of	   different	   human	   tumours	  
(Johnson	   and	   Halder,	   2014)	   (Harvey	   et	   al.,	   2013).	   Increasing	   data,	   in	   fact,	   have	  
pinpointed	  YAP	  as	  an	  established	  human	  oncogene	  and,	  in	  particular,	  recent	  studies	  
have	  yielded	  evidence	  that	  YAP	  is	  able	  to	  confer	  cancer	  stem	  cell	  features,	  including	  
epithelial	   to	   mesenchymal	   transition	   (EMT),	   chemoresistance	   and	   tumour	   relapse	  
(Kapoor	  et	  al.,	  2014)	  (Song	  et	  al.,	  2014).	  
In	   the	   present	   work,	   we	   reveal	   for	   the	   first	   time	   that	   YAP	   is	   finely	   regulated	   by	  
hormonal	  signals	  and,	  in	  particular,	  by	  the	  Glucocorticoid	  Receptor	  (GR)	  pathway.	  	  
We	  were	  able	  to	  identify	  a	  class	  of	  well-­‐known	  compounds,	  namely	  Glucocorticoids	  
(GCs),	   which	   significantly	   increased	   YAP	   protein	   levels	   and	   activity.	   After	  
demonstrating	   that	   MDA-­‐MB-­‐231	   cells	   were	   fully	   responsive	   to	   GR-­‐signalling,	   we	  
could	   analyze	   the	   mechanisms	   through	   which	   Glucocorticoids	   regulate	   YAP,	   at	   a	  
molecular	   level.	   We	   demonstrate	   that	   GCs	   are	   able	   to	   boost	   YAP	   signaling	   by	   i)	  
increasing	  YAP	  mRNA	  expression	  leading	  to	  YAP	  protein	  accumulation	  within	  the	  cell	  
and	   ii)	   by	   promoting	   actin	   polymerization	   with	   the	   consequent	   YAP	   de-­‐
phosphorylation,	   nuclear	   accumulation	   and	   activity.	   Interestingly,	   we	   showed	   that	  
this	  regulation	  is	  specific	  for	  YAP	  and	  not	  for	  TAZ	  protein.	  	  
Importantly,	  cytoskeleton	  acts	  through	  a	  complex	  network	  of	  distinct	  mechanisms	  to	  
relay	  mechanical	  signals	  that	  regulate	  YAP	  activity	  (Dupont	  et	  al.,	  2011;	  Halder	  et	  al.,	  
2012).	   Even	   if	   our	   results	   have	   not	   revealed	   how	   Glucocorticoids	   induce	   actin-­‐
polymerization	  yet,	  we	  have	  pioneered	  for	  further	  investigation.	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In	   summary,	   our	   findings	   indicate	   GCs,	   via	   the	   GR-­‐signaling,	   as	   a	   new	   hormonal-­‐
dependent	   pathway	   that	   significantly	   impacts	   in	   YAP	   regulation	   and	   activity.	  
Moreover,	  our	   results	   implicate	  an	   important	   role	  of	  YAP	  as	  a	  key	  executor	  of	   the	  
biological	   program	   exerted	   by	   Glucocorticoids	   in	   breast	   cancer	   and	   likely	   in	   other	  
tissues	   controlled	   by	   GR	   action.	   We	   might	   also	   speculate	   that	   YAP	   behaves	   as	   a	  
“stress-­‐responsive”	   protein	   that	   is	   recruited	   by	   Glucocorticoids	   to	   execute	   their	  
physiological	  processes.	  
From	   a	   clinical	   point	   of	   view,	   these	   results	   may	   have	   important	   implications.	  
Glucocorticoids	   are	   a	   widely	   prescribed	   class	   of	   drugs.	   The	   anti-­‐inflammatory	   and	  
immune-­‐modulatory	  effects	  of	  Glucocorticoids	   and	   the	  GC-­‐induced	  apoptosis	  have	  
led	   to	   their	   use	   in	   many	   clinical	   settings.	   In	   particular,	   GCs	   have	   largely	   been	  
exploited	   for	   their	   pro-­‐apoptotic	   activity	   in	   the	   treatment	   of	   haematological	  
malignancies	   (Frankfurt	   and	   Rosen,	   2004;	   Vilasco	   et	   al.,	   2011).	   Indeed,	  
Glucocorticoids	  are	  extremely	  important	  and	  a	  first	  line	  of	  defense	  in	  the	  therapy	  of	  
hematopoietic	   cancers.	   Although	   the	   apoptotic	   effects	   of	   Glucocorticoids	   in	   the	  
immune	  system	  cells	  have	  been	  well	  studied	  over	  the	  years,	  molecular	  mechanisms	  
of	  action	  of	  GC-­‐induced	  apoptosis	  have	  constantly	  been	  updated	  (Gruver-­‐Yates	  and	  
Cidlowski,	  2013).	  A	  recent	  study	  has	  reported	  YAP	  over-­‐expression	  as	  an	  activator	  of	  
ABL1/p73-­‐mediated	  apoptosis	  in	  the	  context	  of	  haematological	  malignancies	  (Cottini	  
et	  al.,	  2014).	  Previous	  work	  has	  also	  demonstrated	  that,	  in	  response	  to	  DNA	  damage,	  
YAP	   interacts	  with	  p73	  and	  promotes	  a	  p73-­‐dependent	  apoptotic	  program	  (Lapi	  et	  
al.,	   2008).	   Considering	   the	  major	   role	   played	   by	   GC-­‐induced	   apoptosis	   in	   treating	  
haematological	  cancers,	   it	   is	  conceivable	   that	  GCs	  might	  mediate	  part	  of	   their	  pro-­‐
apoptotic	   effect	   by	   up-­‐regulating	   YAP	   and	   thus	   activating	   its	   p73	   dependent	   pro-­‐
apoptotic	  function.	  Experiments	  to	  prove	  this	  hypothesis	  are	  however	  required.	  	  	  
GCs	   are	   given	   at	   varying	   doses	   to	   alleviate	   acute	   toxicity	   and	   to	   protect	   healthy	  
tissue	   (e.g.,	   bone	   marrow)	   against	   the	   long-­‐term	   effects	   caused	   by	  
chemotherapeutic	  drugs.	  As	  a	  result,	  the	  use	  of	  GCs	  has	  widely	  been	  endorsed	  for	  a	  
supportive-­‐care	   role	   in	   cancer	  patients	  with	   solid	   tumours,	   including	  breast	   cancer	  
(Frankfurt	  and	  Rosen,	  2004;	  Vilasco	  et	  al.,	  2011).	  
In	   contrast	   to	   the	   effects	   seen	   in	   hematological	   malignancy	   mounting	   clinical	  
evidence	  has	  suggested	  that	  GR	  activation	  by	  GCs	  could	  induce	  therapy-­‐resistance	  in	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several	   solid	   tumours	   (Zhang	   et	   al.,	   2006),	   however	   the	   underlying	   molecular	  
mechanisms	   of	   this	   cell/tissue	   type-­‐specific	   GC	   signaling	   is	   still	   not	   completely	  
understood.	  	  
The	  data	  presented	  in	  this	  thesis	  suggest	  a	  new	  mechanism	  to	  explain	  the	  effects	  of	  
Glucocorticoids	  on	  cancer	  growth	  and	  how	  they	  can	  lead	  to	  chemoresistance.	  These	  
results	   in	   fact	   demonstrate	   that	   GC-­‐signaling	   directly	   controls	   the	   level	   and	   the	  
biological	  activity	  of	  YAP,	  with	  consequent	  increase	  cell	  proliferation	  and	  survival	  of	  
cancer	   cells.	   YAP	   has	   been	   shown	   to	   contribute	   to	   cancer	   stem	   cell	   growth	   and	  
expansion	  (Cao	  et	  al.,	  2008;	  Lian	  et	  al.,	  2010;	  Song	  et	  al.,	  2014;	  Yimlamai	  et	  al.,	  2014;	  
Zhao	   et	   al.,	   2014).	   Here,	   we	   have	   clearly	   shown	   that	   GCs	   have	   a	   direct	   role	   in	  
triggering	  breast	  CSCs	  expansion,	  by	  promoting	  YAP	  nuclear	  localization	  and	  activity.	  
Since	  CSCs	  are	  directly	  linked	  to	  chemoresistance	  and	  tumour	  regeneration	  (Dean	  et	  
al.,	   2005;	   Visvader	   et	   al.,	   2009)	   it	   is	   conceivable	   that	   GCs	   could	   decrease	  
chemotherapeutical	   response	   of	   breast	   cancers	   (and	   possibly	   in	   other	   tumors)	  
through	  YAP-­‐dependent	  CSCs	  expansion.	  	  
Importantly	  Glucocorticoid	  doses	  used	  during	  our	  experimental	   in	  vitro	  procedures	  
were	   comparable	   to	   the	   GC	   plasma	   concentrations	   detectable	   in	   vivo	   in	   cancer	  
patients	  receiving	  GCs	  as	  supportive	  therapy	  (Brady	  et	  al.,	  1987;	  Nakade	  et	  al.,	  2008).	  
Consistently,	   we	   can	   speculate	   that	   Glucocorticoids	   might	   preserve	   the	   ability	   to	  
stimulate	   YAP	   activity	   also	   in	  murine	  models	   and	   in	   clinical	   setting.	   Thus,	   harmful	  
effects	   induced	   by	   Glucocorticoids	   on	   patients’	   response	   to	   anti-­‐cancer	   treatment	  
could	  be	  justified	  by	  this	  new	  hormonal	  regulation	  of	  YAP.	  	  
Further	  in	  vivo	  experiments	  and	  clinical	  experimentations	  are	  however	  necessary	  to	  
support	  this	  hypothesis.	  
In	   conclusion,	   our	   results	   suggest	   that	   Glucocorticoids	   co-­‐administration	   as	   a	  
supportive	   care	   during	   chemotherapy	   or	   radiation	   treatment	   in	   breast	   cancer	  
patients	   might,	   in	   part,	   have	   a	   detrimental	   role	   for	   the	   therapeutic	   success.	  
Moreover,	  since	  Glucocorticoids	  are	  extensively	  used	  in	  cancer	  clinical	  settings,	  our	  
findings	  could	  have	  clinical	  relevance:	  we	  suggest	  the	  Hippo/YAP	  pathway	  could	  be	  a	  
potential	  target	  to	  be	  taken	  into	  account	  to	  prevent,	  or	  at	  least	  limit,	  negative	  effects	  
shown	  by	  Glucocorticoids	  on	  chemo-­‐sensitivity	  in	  breast	  cancer	  patients.	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EXPERIMENTAL	  PROCEDURES	  
	  
CELL	  LINES	  AND	  CULTURE	  CONDITIONS	  
	  
Cell	  lines	  used	  in	  this	  thesis	  were:	  
	  
-­‐	  MDA-­‐MB-­‐231	   cell	   line:	   human	  epithelial	   cells	   derived	   from	   triple	   negative	  breast	  
cancer	  subtype;	  MDA-­‐MB-­‐231	  cells	  were	  cultured	  in	  DMEM	  (LONZA)	  supplemented	  
with	  10%	  FBS	  (Fetal	  Bovine	  Serum)	  and	  with	  1%	  antibiotics	  (penicillin	  100U/mL	  and	  
streptomycin	  10μg/mL).	  	  
-­‐	  SUM-­‐149	  cell	  line:	  human	  epithelial	  cells	  derived	  from	  triple	  negative	  breast	  cancer	  
subtype;	   SUM-­‐149	   cells	   were	   cultured	   in	   DMEM/F12	   (LONZA)	   (1:1)	   supplemented	  
with	  5%	  HS	  (Horse	  Serum)	  and	  with	  1%	  antibiotics.	  	  
-­‐	   HeLa	   cell	   line:	   human	  epithelial	   cells	   derived	   from	   cervical	   carcinoma;	  HeLa	   cells	  
were	  cultured	  in	  DMEM	  supplemented	  with	  10%	  FBS	  and	  with	  1%	  antibiotics.	  	  
-­‐	   MII	   cell	   line	   (RAS-­‐transformed	   MCF10A-­‐T1k	   cell	   line):	   non-­‐tumorigenic	   human	  
mammary	  MCF10A	   cell	   line,	   transformed	   with	   RAS-­‐transfection	   and	   derived	   from	  
xenograft-­‐passaged	  MCF10-­‐AneoT	   cells138;	   MII	   cells	   were	   cultured	   in	   DMEM/F12	  
(1:1)	  supplemented	  with	  5%	  HS	  and	  1%	  antibiotics.	  	  
	  
HIGH	  CONTENT	  SCREENING	  
For	   the	   screening	  experiments,	  MDA-­‐MB-­‐231	  cells	   (3.0×103	  per	  well)	  were	   seeded	  
on	   black	   clear-­‐bottom	   384-­‐well	   plates	   (PerkinElmer).	   Twenty-­‐four	   hours	   later,	   the	  
FDA-­‐	  approved	  drugs	  were	  transferred	  robotically	  from	  library	  stock	  plates	  (0.1mM	  
and	   1mM	   in	   DMSO)	   to	   the	   plates	   containing	   the	   cells;	   controls	   were	   added	   to	  
columns	  1,	  2,	  23	  and	  24	  of	  each	  plate.	  Cells	  were	  fixed	  at	  48	  h	  after	  plating,	  i.e.	  24h	  
after	  addition	  of	  drugs,	  and	  processed	  immediately	  for	  immunofluorescence.	  Briefly,	  
cells	   were	   fixed	   with	   4%	   paraformaldehyde	   for	   15	   min,	   permeabilized	   with	   0.5%	  
Triton	  X-­‐100	  in	  phosphate	  buffered	  saline	  (PBS)	  solution	  for	  10	  min,	  followed	  by	  30	  
min	  blocking	   in	  3%	  FBS.	  Cells	  were	   then	   incubated	  with	   a	  mouse	  antibody	  against	  
YAP/TAZ	  (Santa	  Cruz	  Biotechnology)	  diluted	   in	  blocking	  solution	  for	  1	  h.	  Cells	  were	  
further	  washed	  with	  PBS	  and	  incubated	  for	  1h	  with	  a	  secondary	  antibody	  conjugated	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to	   Alexa	   Fluor-­‐568	   (Life	   Technologies),	   and	   stained	   with	   Hoechst	   33342	   (Life	  
Technologies).	  
Image	   acquisition	   was	   performed	   using	   an	   ImageXpress	   Micro	   automated	   high-­‐
content	   screening	   fluorescence	   microscope	   (Molecular	   Devices)	   at	   a	   10x	  
magnification;	   a	   total	   of	   16	   images	   were	   acquired	   per	   wavelength,	   well	   and	  
replicate,	  corresponding	  to	  ca.	  4,500	  cells	  analyzed	  per	  experimental	  condition	  and	  
replicate.	  Image	  analysis	  to	  identify	  cells	  presenting	  predominantly	  nuclear	  YAP/TAZ	  
localization	  was	   performed	   using	   the	   ‘Multi-­‐Wavelength	   Translocation’	   application	  
module	  implemented	  in	  MetaXpress	  software	  (Molecular	  Devices).	  
Screening	  was	  performed	  in	  duplicate,	  at	  two	  drug	  concentrations	  (1μM	  and	  10μM);	  
final	  concentration	  of	  DMSO	  in	  the	  culture	  medium	  was	  1%	  (v/v)	  for	  all	  experimental	  




Plated	   cells	  were	   lysed	  with	   Lysis	  Buffer	   (NP40	  1%,	  Tris-­‐HCL	  pH=7.5%	  50mM,	  NaCl	  
300mM,	  EDTA	  1mM)	  solution,	  supplemented	  with	  protease	  inhibitors	  (CLAP	  0.1mM	  
and	   PMSF	   1mM)	   and	  with	   phosphatase	   inhibitors	   (NaF	   5mM	   and	   Na3VO4	   1mM),	  
and	  were	  harvested.	   Cells	  were	   then	   centrifuged	   at	   10,000	   rpm	   for	   10	  minutes	   at	  
4°C.	   Concentration	   of	   proteins	   in	   the	   lysate	   was	   then	   quantified	   with	   the	  
spectroscopic	   analytical	   procedure	   Bradford	   Protein	   Assay	   (Bio-­‐	   Rad).	   Samples	  
obtained	   were	   denatured	   in	   Laemmli	   Sample	   Buffer	   2X	   or	   6X	   and	   boiled	   for	  
Electrophoresis.	  
WESTERN	  BLOT	  
Western	   blotting	   allows	   the	   antibody	   detection	   of	   specific	   proteins	   from	   extracts	  
made	  from	  cells.	  In	  order	  to	  make	  the	  proteins	  accessible	  to	  antibody	  detection	  they	  
were	  moved	  from	  within	  the	  gel	  onto	  a	  membrane	  made	  of	  nitrocellulose	  with	  the	  
blotter	   Trans-­‐Blot	   Transfer	   Cell.	   The	  membrane	  was	   incubated	   in	   Blotto-­‐Tween	  20	  
solution	  (milk	  powder	  5%	  w/v	  in	  PBS	  solution,	  added	  with	  Tween20	  0.2%	  w/v)	  for	  30	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minutes	   and	   then	   incubated	   with	   primary	   antibody	   over-­‐night.	   The	   next	   day,	  
membrane	   was	   incubated	   with	   secondary	   antibody	   for	   at	   least	   30	   minutes	   and	  
finally	   developed	   in	   photographic	   plates	   with	   the	   solution	   kits	   ECL	   or	   ECL-­‐Plus	  
(Amersharm).	  
The	  antibodies	  used	  for	  western	  blot	  were:	  Anti-­‐YAP/TAZ	  (1:1000)	  is	  sc101199	  (Santa	  
Cruz	   Biothecnology);	   Anti-­‐pYAP	   (1:1000)	   (Ser127)	   is	   4911S	   (Cell	   Signaling);	   anti-­‐
ANKRD1	   (1:1000)	   is	   11427-­‐1-­‐AP	   (Proteintech	   DBA);	   Anti-­‐actin	   (1:2000)	   is	   C11	  
(Sigma);	   Anti-­‐vinculin	   (1:5000)	   is	   V4505	   (Sigma);	   Phalloidin-­‐Rhodamine	   is	   R415	  
(Molecular	  Probes)	  (used	  in	  immunofluorescence).	  
	  
TRANSFECTIONS	  
siRNA	   transfections	   were	   performed	   to	   knock-­‐down	   endogenous	   levels	   of	   YAP	   in	  
MDA-­‐MB-­‐	   231	   and	   in	  MII	   cells.	   Transfections	   were	   performed	  with	   Lipofectamine	  
RNAi-­‐MAX	   (Life	   technologies)	   in	   antibiotic-­‐free	   medium	   according	   to	   the	  
manufactured	   instructions.	   In	   detail	   RNAi-­‐MAX	   Lipofectamine	   was	   diluited	   in	  
Optimem	  medium	  (Invitrogen)	  and,	  separately,	  siRNA-­‐YAP	  and	  siRNA-­‐control	  (siRNA	  
Qiagen	   1027281)	   were	   also	   diluited	   in	   Optimem	   medium;	   after	   5	   minutes	   of	  
incubation,	   RNAi-­‐MAX	   Lipofectamine	   solution	   was	   added	   to	   siRNA	   solutions	   and	  
they	   were	   incubated	   for	   20	   minutes;	   mixed	   solutions	   were	   finally	   added	   to	   the	  
medium	   of	   cells,	   plated	   24	   hours	   before.	   After	   48	   hours	   from	   transfections,	   cells	  
were	  analysed.	  GFP-­‐GR	  transfection	  was	  performed	  in	  MDA-­‐MB-­‐231	  cells	  in	  order	  to	  
transiently	   over-­‐express	   the	   construct	   composed	   by	   the	   GR	   fused	   to	   the	   green	  
fluorescence	   protein	   (GFP-­‐GR).	   Transfection	   was	   performed	   with	   Lipofectamine	  
2000	   (Invitrogen)	   in	   antibiotic-­‐free	   medium	   according	   to	   the	   manufactured	  
instructions.	  In	  details,	  Lipofectamine	  was	  diluited	  in	  Optimem	  medium	  (Invitrogen)	  
and	   separately	   another	   solution	  with	  GFP-­‐GR	   and	  Optimem	  was	   prepared;	   after	   5	  
minutes	   of	   incubation,	   Lipofectamine	   solution	   was	   added	   to	   GFP-­‐GR	   solution	   and	  
they	   were	   incubated	   for	   20	   minutes;	   mixed	   solutions	   were	   finally	   added	   to	   the	  
medium	  of	  cells,	  plated	  24	  hours	  before.	  After	  24	  hours	   from	  GFP-­‐GR	  transfection,	  
cells	   were	   treated	   with	   Betamethasone	   for	   24	   hours,	   and	   then	   examined	   by	  
fluorescence	  microscopy	  to	  detect	  sub-­‐	  cellular	  localization	  of	  GR-­‐GFP.	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LUCIFERASE	  REPORTER	  ASSAY	  
Luciferase	  assay	  was	  used	   to	  monitor	   the	   transcriptional	   activation	  of	  endogenous	  
Glucocorticoid	  Receptor	  (GR)	  in	  MDA-­‐MB-­‐231	  cells.	  Luciferase	  assay	  was	  performed	  
in	  MDA-­‐	  MB-­‐231	  cells	  with	  the	  GR-­‐responsive	  reporter	   luc2.	  Cells	  were	  transfected	  
with	  the	  MMTV	  reporter	  plasmid	  pGL4.36[luc2P/MMTV/Hygro],	  (Promega)	  and	  with	  
CMV-­‐Renilla	   to	   normalize	   for	   transfection	   efficiency.	   The	  MMTV	   reporter	   plasmid	  
pGL4.36	  contains	  the	  MMTV	  LTR	  which	  encompasses	  the	  natural	  GRE	  sequences	  and	  
drives	   the	   transcription	   of	   the	   luciferase	   Cells	   were	   then	   valued	   at	   fluorescence	  
microscopy.	  
QUANTITATIVE	  REAL-­‐TIME	  PCR	  
For	   total	  RNA	  extraction,	  cells	  were	  harvested	   in	  Qiazol	   lysis	   reagent	   (a	  solution	  of	  
phenol	  and	  guanidinium	  thiocyanate)	  (Qiagen)	  and	  contaminant	  DNA	  was	  removed	  
by	   specific	   DNase	   treatment.	   Retro-­‐transcription	   of	   the	   extracted	   RNA	   was	  
performed	   using	   the	   Quantitec	   Reverse	   Transcription	   kit	   (Qiagen).	   The	   obtained	  
cDNA	  was	  properly	  diluited	  and	  used	  in	  qRT-­‐	  PCR	  reactions.	  Quantitative	  Real-­‐Time	  
PCR	   is	   a	   technique	   used	   to	   quantify	   mRNA	   of	   the	   genes	   of	   interest.	   qRT-­‐PCR	  
reactions	   were	   performed	   with	   the	   reagent	   SsoAdvanced	   SYBR	   Green	   Supermix	  
(Biorad)	   using	   CFX96	   Touch	   Real-­‐Time	   PCR	   Detection	   System	   and	   analysed	   with	  
Biorad	  CFX	  Manager	  Software.	  Expression	  levels	  are	  always	  given	  relative	  to	  histone	  
H3.	  Primer	  sequences	  used	  in	  qRT-­‐PCR	  are	  described	  below:	  
GENE	   PRIMER	  NAME	   PRIMER	  SEQUENCE	  
H3	   FW	   GTGAAGAAACCTCATCGTTACAGGCCTGGT	  
	   REV	   CTGCAAAGCACCAATAGCTGCACTCTGGAA	  
ANKRD1	   FW	   CACTTCTAGCCCACCCTGTGA	  
	   REV	   CCACAGGTTCCGTAATGATTT	  
YAP1	   FW	   GCCGGAGCCCAAATCC	  
	   REV	   GCAGAGAAGCTGGAGAGGAATG	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IMMUNOFLUORESCENCE	  ASSAY	  
For	   the	   immunofluorescence	   assay,	   cells	  were	   cultured	   in	   6-­‐multi-­‐well	   plates	  with	  
square	   glass	   coverslips	   so	   that	   cells	   could	   attach	   to	   the	   coverslips.	   24h	   later	   cells	  
were	  treated	  with	  drugs	  and	  control	  treatments	  were	  added.	  48h	  after	  plating,	   i.e.	  
24h	   after	   addition	   of	   drugs,	   cells	   were	   fixed	   and	   processed	   immediately	   for	  
immunofluorescence.	   In	   detail,	   cells	   were	   fixed	   to	   coverslips	   with	   4%	  
paraformaldehyde	  for	  15	  min,	  cell	  membranes	  were	  permeabilized	  with	  0.1%	  Triton	  
X-­‐100	   in	  Phosphate	  Buffered	   Saline	   (PBS)	   solution	   for	   10	  min,	   and	   cells	   then	  were	  
incubate	  in	  Blocking	  Buffer	  (3%	  Fetal	  Bovine	  Serum	  (FBS)	  [Gibco]	  in	  PBS	  solution)	  for	  
30	  minutes.	   Next,	   cells	   were	   incubated	   with	   an	   antibody	   against	   YAP	   (Santa	   Cruz	  
Biotechnology)	   diluted	   (1:100)	   and	   with	   Rhodamine	   phalloidin	   peptide	   diluted	  
(1:700)	  in	  Blocking	  Buffer	  solution	  in	  a	  humidified	  chamber	  at	  37°C	  for	  1	  hour.	  Cells	  
were	   further	  washed	  with	   PBS	   and	   incubated	   again	   in	   the	   humidified	   chamber	   at	  
37°C	   for	   40	   min	   with	   a	   secondary	   antibody,	   diluted	   (1:500)	   for	   YAP	  
immunofluorescence	   in	  Blocking	  Buffer	  solution	  and	  conjugated	  to	  Alexa	  Fluor-­‐568	  
(Life	  Technologies).	  Finally	  cells	  were	  stained	  with	  Hoechst	  33342	  (Life	  Technologies)	  
and	  coverslips	  were	  mounted	  on	  glass	  slides	   for	   the	  analysis	  with	  the	   fluorescence	  
microscopy.	  
RNA	  EXTRACTION	  AND	  QRT-­‐PCR	  FROM	  DROSOPHILA	  OVARIES	  
Wild	   type	   individuals	   from	   the	   Oregon-­‐R	   strain	   were	   maintained	   for	   the	   entire	  
development	  on	  the	  food	  added	  with	  betametasone	  1	  µM.	  The	  ovaries	  from	  females	  
treated	   with	   betametasone	   were	  manually	   dissected	   in	   Ringer’s	   solution	   (182mM	  
KCl,	  46mM	  NaCl,	  3mM	  CaCl2,	  10mM	  Tris-­‐HCl,	  pH7.5).	  Total	  RNA	  was	  extracted	  from	  	  
40	  ovaries	  using	   the	  RNAqueos-­‐4	  PCR	  Kit	   (AMBION).	  To	  remove	  any	  DNA	  from	  the	  
preparation,	   the	   samples	   were	   incubated	   with	   DNase	   I	   RNase	   free	   (AMBION;	   1	  
Umg−1	  RNA)	  at	  37	  °C	  for	  30	  min,	  in	  a	  total	  volume	  of	  100	  μl.	  After	  this	  treatment,	  the	  
enzyme	   was	   inactivated	   with	   the	   DNase	   inactivation	   reagent	   (AMBION).	   DNase-­‐
treated	   RNA	   was	   precipitated	   at	   −80	   °C	   overnight	   and	   after	   centrifugation	   it	   was	  
dissolved	  in	  50	  μl	  of	  nuclease-­‐free	  water.	  In	  the	  first-­‐strand	  cDNA	  synthesis,	  5	  µg	  of	  
total	   RNA	   were	   used	   as	   a	   template	   for	   oligonucleotide	   dT	   primed	   reverse	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transcription	  using	  SuperScript	   III	  RNaseH-­‐reverse	   transcriptase	   (Life	  Technologies).	  
Real-­‐time	   PCR	   was	   performed	   in	   the	   SmartCycler	   Real-­‐time	   PCR	   (Cepheid)	   using	  
SYBR	  green	  (Euroclone)	  according	  to	  manufacturer’s	  protocol.	  For	  quantification	  of	  
the	  transcripts	  we	  used	  the	  2ΔΔCt	  method.	  	  
The	  primer	  sequences	  are:	  
diap1	  F	  5’GAAAAAGAGAAAAGCCGTCAAGT3’	  
diap1	  R	  5’TGTTTGCCTGACTCTTAATTTCTTC3’	  
yki	  F	  GCGCCTTGCCGCCGGGATG	  
yki	  R	  GCTGGCGATATTGGATTCTC	  
rp49	  F	  ATCGGTTACGGATCGAACAA	  	  
rp49	  R	  GACAATCTCCTTGCGCTTCT	  	  
	  
MAMMOSPHERE	  ASSAY	  
To	   obtain	   mammospheres,	   cells	   from	   monolayer	   cultures	   were	   enzymatically	  
disaggregated	  (0.05%	  Trypsin-­‐EDTA)	  to	  a	  single	  cell	  cultures,	  passed	  through	  a	  40	  μm	  
single	  cell	  strainer,	  plated	  a	  clonogenic	  density	  (2500	  cells/cm2),	  grown	  in	  “ultra-­‐low	  
attachment”	  plates	  that	  prevent	  cell	  adherence,	  and	  cultured	  in	  a	  specific	  stem-­‐cell	  
growth	  medium	   that	   preserves	   cells	   in	   undifferentiated	   state.	   In	   detail,	   cells	  were	  
grown	   for	   7-­‐10	   days	   in	   MEBM	   (Mammary	   Epithelial	   Basal	   Medium-­‐Serum	   free)	  
[Lonza]	   supplemented	   with	   B27	   (Invitrogen),	   20	   ng/ml	   EGF	   (PROSPEC),	   20	   ng/ml	  
bFGF	   (BD	   Biosciences),	   4	   μg/ml	   heparin	   (StemCell	   Technologies	   Inc.),	   0.5	   μg/ml	  
Hydrocortisone	  (Sigma)	  and	  5	  μg/ml	  Insulin	  (Sigma)	  in	  low	  attachment	  24	  well	  plates	  
(Coroning)	  in	  a	  humidified	  incubator	  at	  37°C,	  5%	  CO2.	  Primary	  mammospheres	  (≥200	  
μm)	  were	  obtain,	  collected,	  counted	  and	  again	  enzymatically	  disaggregated	  as	  above	  
to	   re-­‐	   plate	   cells	   at	   clonogenic	   densities	   to	   obtain	   secondary	   mammospheres.	  
Percentages	   of	   mammosphere	   forming	   efficienties	   (%MFE)	   were	   calculated	   as	  
number	   of	  mammospheres	   divided	   by	   the	   plated	   cell	   number	   and	  multiplied	   by	   a	  
hundred.	  Mammospheres	  were	  counted	  with	  a	  20x	  objective	  on	  an	  Olympus	  CK30	  
microscope.	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REAGENTS	  AND	  PLASMIDS	  
The	   library	   of	   FDA-­‐approved	   drugs	   (Screen-­‐Well	   FDA-­‐Approved	   Drug	   Library,	   640	  
chemical	   compounds	   dissolved	   at	   10mM	   in	   DMSO)	   was	   obtained	   from	   Enzo	   Life	  
Sciences	   (Enzo	   Life	   Sciences	   Inc.,Plymouth	   Meeting,	   PA,	   USA).	   The	   following	  
compounds	  were	  purchased	  from	  Sigma	  Aldrich:	  	  
L5163	  100UG	   Latrunculin	  A	  	  
H0888-­‐1G	   Hydrocortisone	  BioReagent,	  suitable	  for	  cell	  culture	  	  
F8880-­‐100MG	   Fluocinolone	  acetonide	  
SML0005-­‐5MG	   Cerivastatin	  
S5068-­‐10MG	   Salmeterol	  
B7005-­‐100MG	   Betamethasone	  
M8046-­‐100MG	   Mifepristone	  
	  
CHROMATIN	  IMMUNOPRECIPITATION	  PROCEDURE	  
	  
Proteins	   were	   cross-­‐linked	   to	   DNA	   by	   adding	   formaldehyde	   directly	   to	   culture	  
medium	  to	  a	  final	  concentration	  of	  1%	  and	  incubate	  for	  10	  minutes	  at	  22-­‐25°C.	  The	  
reaction	  was	  blocked	  by	  adding	  glycine	  (in	  PBS1X)	  to	  a	  final	  concentration	  of	  0,125M.	  
Cells	   are	   washed	   using	   ice	   cold	   PBS	   containing	   protease	   inhibitors	   (1mM	  
phenylmethylsulfonyl	  fluoride	  (PMSF),	  1microgram/ml	  aprotinin	  and	  1microgram/ml	  
pepstatin	  A),	  scraped,	  and	  pellet	  was	  obtained	  by	  centrifuge	  for	  4	  minutes	  at	  2000	  
rpm	  at	  4°.	  
Nuclei	   were	   resuspended	   in	   5	   volumes	   of	   lysis	   buffer	   [Pipes	   (piperazine	   N,N	   bis	  
zethone	  sulfonic	  acid)	  pH	  8	  5mM,	  KCl	  85mM,	  NP40	  0,5%]	  plus	  protease	  inhibitors	  for	  
20	  minute	   on	   ice.	   Then	   nuclei	   are	   Centrifuged	   for	   10min	   at	   2000rpm	   at	   +4°C	   and	  
resuspended	  in	  SDS-­‐Lysis	  Buffer	  (1%SDS;	  10mMEDTA;	  50mM	  Tris-­‐HCl,	  pH8.1)	  for	  10	  
minutes	  on	  ice.	  
Then	  Nuclei	  are	  sonicated	  to	  shear	  DNA	  to	  lengths	  between	  500	  and	  800	  basepairs	  
Sonicated	   DNA	   was	   seen	   by	   gel	   electrophoresis.	   DNA	   was	   incubated	   and	  
immunoprecipitated	   with	   rabbit	   anti-­‐GR	   (Santa	   Cruz	   Biotech.)	   and	   rabbit	   anti-­‐IgG	  
using	   Pierce	   ChIP-­‐grade	   Protein	   A/G	   magnetic	   beads	   (Thermo	   Fisher	   Scientific,	  
Rockford,	  IL,	  USA).	  
Primers	  used	  for	  the	  amplification	  of	  the	  different	  regulatory	  regions	  are:	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YAP	  promoter	  -­‐1150	  to	  -­‐900	  fw:	  	  GCTCCTTGTACATCAGGTGCC	  
YAP	  promoter	  -­‐1150	  to	  -­‐900	  rev	  :	  GGACTCCGTTAATGTGGACTGA	  
Negative	  CTR	  	  fw:	  	  CAACCAAAGCCCATGTCCTC	  
Negative	  CTR	  rev:	  	  AGGCACGCTACAGGGCTTC	  
The	   promoter	   occupancy	   was	   measured	   using	   the	   CFX96	   Touch	   Real-­‐Time	   PCR	  
Detection	  System	  and	  analysed	  with	  Biorad	  CFX	  Manager	  software.	  The	  experiment	  
was	  repeated	  two	  times.	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FIGURES	  	  
	  	  
Figure	  1.	   Identification	  of	  drugs	   regulating	  YAP	  protein	   levels	   in	   cancer	   cells.	   (a)	  Schematic	  representation	  of	  
the	  high-­‐content	  screening.	  MDA-­‐MB-­‐231	  cells	  were	  seeded	  in	  384-­‐well	  plates	  and	  24h	  later	  the	  FDA-­‐approved	  
compounds	   were	   added	   to	   cells	   at	   1	   or	   10μM.	   24h	   after	   treatment,	   cells	   were	   fixed	   and	   processed	   for	  
immunofluorescence	  for	  YAP/TAZ	  and	  stained	  with	  Hoechst.	  Automated	  image	  acquisition	  and	  analysis	  was	  then	  
performed	   to	   detect	   the	   YAP-­‐relative	   fluorescence	   intensity	   at	   single-­‐cell	   level	   and	   to	   analyse	   the	   subcellular	  
localization	  of	  YAP.	  The	   screening	  was	  performed	   in	  duplicate;	   ca.	  4,500	  cells	  were	  analysed	  per	  experimental	  
condition	   and	   replicate.	   (b)	   Results	   of	   the	   screening.	   Levels	   of	   YAP	   fluorescence	   intensity	   are	   increased	   by	  
Glucocorticoids	  and	  are	   reduced	  by	  Statins.	  Red	  dashed	   line	   represents	   the	   fluorescence	   levels	   in	  cells	   treated	  
with	   dimethylsulphoxide	   (DMSO).	   AU=arbitrary	   units.	   (c)	   Quantification	   of	   YAP	   fluorescence	   levels	   from	   the	  
screening.	   Representative	   YAP	   fluorescence	   levels	   in	   cells	   treated	   with	   DMSO	   or	   Glucocorticoids	   are	   shown.	  
Values	   are	   normalized	   on	   fluorescence	   levels	   of	   DMSO	   (red	   dashed	   line;	   set	   as	   1.0).	   AU=arbitrary	   units.	   (d)	  
Representative	  images	  of	  immunofluorescence	  from	  the	  screening.	  MDA-­‐MB-­‐231	  cells	  stained	  for	  Hoechst	  (blue	  
colour)	  and	  YAP	  (red	  colour)	  after	  treatment	  with	  DMSO	  or	  with	  three	  Glucocorticoids	  present	  in	  the	  library	  are	  
shown:	  YAP-­‐related	  fluorescence	  increased	  with	  Glucocorticoid treatment.	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Table	   1.	   FDA-­‐approved	   drugs	   from	   screening	   that	   increase	   YAP	   fluorescence	   intensity.	   FDA-­‐approved	   drugs	  
from	  the	  screening	  that	  increase	  YAP	  fluorescence	  intensity.	  List	  of	  the	  main	  FDA-­‐	  approved	  compounds	  from	  the	  
library	  used	   in	  the	  screening	  that	   increase	  YAP	  fluorescence	   intensity	  at	  high	   levels.	  Drugs	  highlighted	   in	  green	  
belong	  to	  the	  Glucocorticoids	  class.	  Values	  indicate	  relative	  YAP	  fluorescence	  intensity	  in	  MDA-­‐MB-­‐231	  cells	  after	  
treatments.	  Values	  are	  normalized	  on	  YAP	  fluorescence	  levels	  after	  treatment	  with	  dimethylsulphoxide	  (DMSO)	  
(highlighted	  in	  red),	  set	  as	  1.0.	  Round	  1	  intensity=YAP	  fluorescence	  intensity	  in	  the	  first	  round	  of	  the	  screening;	  







Drug Round 1 intensity Round 2 intensity Average intensity 
Etoposide 1.74 1.70 1.72 
Cytarabine 1.76 1.49 1.63 
Topotecan 1.65 1.48 1.57 
Clobetasol propionate 1.46 1.63 1.55 
Methylprednisolone 1.51 1.51 1.51 
Albendazole 1.71 1.23 1.47 
Triamcinolone 1.52 1.33 1.42 
Hydrocortisone 21-
acetate 
1.34 1.48 1.41 
Mitomycin c 1.39 1.41 1.40 
Fluocinolone acetonide 1.50 1.26 1.38 
Dexamethasone 1.46 1.30 1.38 
Kasugamycin 1.28 1.41 1.35 
Betamethasone 1.42 1.26 1.34 
Hydrocortisone 1.30 1.38 1.34 
Fluoxetine 1.69 0.93 1.31 
Fenbendazole 1.47 1.10 1.29 
Melengestrol acetate 1.20 1.37 1.29 
Prednisolone 1.31 1.14 1.22 
Vinorelbine 1.38 1.06 1.22 
Rufloxacin 1.54 0.89 1.21 
Corticosterone 1.13 1.29 1.21 
Tolfenamic acid 1.23 1.18 1.20 
Flubendazole 1.27 1.13 1.20 
DMSO 1.00 1.00 1.00 
 
Table 1. FDA-approved drugs from the screening that increase YAP fluorescence intensity. List of the main FDA-
approved compounds from the library used in the screening that increa e YAP fluoresc nce intensity at high levels. 
Drugs highlighted in green belong to the Glucocorticoids class. Values indicate relative YAP fluorescence intensity 
in MDA-MB-231 cells after treatments. Values are normalized on YAP fluorescence levels after treatment with 
dimethylsulphoxide (DMSO) (highlighted in red), set as 1.0. R und 1 intensity=YAP fluorescence intensity in the 
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Figure	   2.	  MDA-­‐MB-­‐231	   cells	   are	   responsive	   to	   glucocorticoid	   treatment.	   (a)	   Effect	  of	  Betamethasone	  on	   the	  
induction	   of	   transcriptional	   activity	   of	   endogenous	   Glucocorticoid	   Receptor	   in	   MDA-­‐MB-­‐231	   cells	   assayed	   by	  
luciferase	  reporter	  assay.	  Quantification	  of	  GR-­‐induced	  luminescent	  signal	  is	  shown.	  Cells	  were	  transfected	  with	  
MMTV-­‐luc	   and	   treated	  with	  DMSO	  or	   1μM	  Betamethasone	   alone	   or	  with	   RU486	   (1μM)	   for	   24	   hours.	  NT=not	  
treated	  (DMSO);	  BM=Betamethasone;	  RU486=Mifepristone;	  RLU=relative	  light	  units.	  Error	  bars	  represent	  mean	  ±	  
s.d.;	   experiment	   repeated	   three	   times.	   Statistical	   significance	   is	   indicated	   by	   p-­‐value:	   **p<0.01	   vs	   DMSO.	   (b)	  
Betamethasone	   promotes	   nuclear	   translocation	   of	   the	   Glucocorticoid	   Receptor	   in	   MDA-­‐MB-­‐231	   cells.	   Cells	  
overexpressing	   GFP-­‐GR	  were	   treated	  with	   DMSO	   or	  with	   Betamethasone	   (1μM)	   for	   24	   hours.	   Representative	  
images	   of	   immunofluorescence	   for	   GFP-­‐GR	   subcellular	   localization	   are	   shown:	   Betamethasone	   promotes	   the	  
cytoplasmic-­‐to-­‐nucleus	   translocation	  of	   the	   fusion	  protein.	  NT=not	   treated	   (DMSO);	  BM=Betamethasone;	  GFP-­‐	  
GR=Green	  Fluorescence	  Protein-­‐Glucocorticoid	  Receptor	  fusion	  protein.	  (c)	  Glucocorticoids	  increase	  YAP	  protein	  
levels	   in	  MDA-­‐MB-­‐231	   and	  MCF-­‐10A-­‐M2.	  Western	   Blot	   analysis	   showing	   total	   YAP	   and	   TAZ	   protein	   levels	   of	  
MDA-­‐MB-­‐231	  and	  MCF-­‐10A-­‐M2	  cells	  treated	  with	  DMSO	  or	  1μM	  Betamethasone	  alone	  or	  with	  1μM	  RU486	  for	  
24	   hours.	   Values	   are	   calibrated	   on	   actin	   levels.	   NT=not	   treated	   (DMSO);	   BM=Betamethasone;	  
RU486=Mifepristone.	  (d)	  Glucocorticoids	  increase	  YAP	  transcriptional	  activity	  and	  protein	  level	  of	  a	  well-­‐known	  
target	   gene	   ANKRD1.	   Western	   Blot	   of	   ANKRD1	   protein	   levels	   in	   MDA-­‐MB-­‐231	   cells	   is	   shown.	   Cells	   were	  
transfected	  with	  indicated	  siRNA	  for	  48	  hours	  and	  then	  treated	  with	  DMSO	  or	  1μM	  Betamethasone	  alone	  or	  with	  
1μM	  RU486	   for	  24	  hours.	  Values	  are	  calibrated	  on	  actin	   levels.	   siCTL=control	   siRNA;	  siYAP=YAP	  siRNA;	  NT=not	  
treated	   (DMSO);	   BM=Betamethasone;	   RU486=Mifepristone.	   (e)	   Glucocorticoid	   receptor	   induces	   YAP	   mRNA	  
transcription	  (e)	  Quantitative	  PCR	  analysis	  of	  YAP	  mRNA	  expression	  in	  MDA-­‐MB-­‐231	  cells.	  Values	  are	  normalized	  
to	  YAP	  mRNA	  levels	  in	  not	  treated	  cells	  (set	  as	  1.0)	  Cells	  were	  treated	  with	  DMSO	  or	  1μM	  Betamethasone	  alone	  
or	  with	  1μM	  RU-­‐486.	   (f)	  Glucocorticoid	   receptor	  directly	  promotes	  YAP	  mRNA	  transcription.	  Schematic	  graph	  
illustrating	   genomic	   location	   of	   YAP	   gene.	   The	   putative	   promoter	   region	   chipped	   by	   chromatin	  
immunoprecipitation	  (ChIP)	  are	  also	  reported.	  (g)	  ChiP	  analysis	  was	  performed	  in	  MDA-­‐MB-­‐231	  cells	  (3*107	  cells)	  
treated	  for	  6	  hours	  and	  then	  fixed.	  Data	  are	  normalized	  to	  negative	  CTR,	  a	  region	  of	  heterochromatin.	  	  Error	  bars	  
represent	  mean	  ±	  s.d.	  from	  n	  =	  2	  replicates.	  
Glucocorticoids	   promotes	   YAP	   mRNA	   transcription	   and	   activity	   in	   vivo.	   (h)	  Quantitative	   PCR	   analysis	   of	   YKI	  
DIAP1	   and	   Expanded	   mRNA	   expression	   extracted	   from	   40	   female	   individuals.	   The	   ovaries	   from	   female	   were	  
maintained	   for	   the	   entire	   development	   on	   the	   food	   added	  with	   betamethasone	   1	  µM.	   	   Error	   bars	   represent	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Figure	   3.	   Glucocorticoids	   regulate	   YAP	   protein	   localization.	   (a)	   Results	   of	   the	   high-­‐content	   screening.	   YAP	  
nuclear	  localization	  is	  increased	  by	  Glucocorticoids.	  (b)	  Validation	  experiments	  of	  the	  screening	  in	  MDA-­‐MB-­‐231	  
cells.	  Quantification	  of	   cells	  with	  nuclear	  YAP.	  Cells	  were	   treated	  with	  DMSO	  or	  Betamethasone	  1μM	   for	  24h;	  
cells	   were	   then	   fixed	   and	   processed	   for	   immunofluorescence	   for	   YAP.	   Representative	   blot	   of	  
immunofluorescence	   analysis	   is	   shown.	   NT=not	   treated	   (DMSO);	   BM=Betamethasone;	   RU486=Mifepristone.	  
Glucocorticoids	  regulate	  YAP	  phosphorylation	  at	  S127.	  (c)	  Western	  Blot	  of	  MDA-­‐MB-­‐231	  and	  MCF10A-­‐M2	  cells	  
after	   treatment	  with	  DMSO	  or	  1μM	  Betamethasone	  alone	  or	  with	  1μM	  RU486	  for	  24	  hours.	  Total	  YAP	  protein	  
levels	  and	  phospho-­‐YAP	  protein	   levels	  are	  shown.	  Values	  are	  calibrated	  on	  actin	   levels	  of	  cells.	  NT=not	  treated	  
(DMSO);	   BM=Betamethasone;	   RU486=Mifepristone;	   pYAP=YAP	   phosphorylation	   on	   residue	   Ser127.	  
Glucocorticoids	  regulate	  YAP	  nuclear	  localization	  in	  different	  cell	   lines.	  (d	  left)	  Quantification	  of	  MDA-­‐MB-­‐231	  
cells	  with	  nuclear	  YAP	  after	  treatment	  with	  DMSO	  or	  1μM	  Betamethasone	  or	  Fluocinolone	  1	  μM	  alone	  or	  with	  
1μM	  RU486	  for	  24	  hours.	  Data	  are	  derived	  from	  n	  =	  2	  independent	  experiments.	  Error	  bars	  represent	  mean	  ±	  s.d.	  
(d	  right)	  Quantification	  of	  HeLa,	  MCF10A-­‐RAS	  and	  SUM-­‐149	  cells	  with	  nuclear	  YAP	  after	  treatment	  with	  DMSO	  or	  
1μM	   Betamethasone	   alone	   or	   with	   1μM	   RU486	   for	   24	   hours.	   Data	   are	   derived	   from	   n	   =	   3	   independent	  
experiments.	   Error	   bars	   represent	   mean	   ±	   s.d;*p<0.01	   vs	   DMSO.	   (e)	   Representative	   images	   of	  
immunofluorescence	  in	  breast	  cancer	  cell	  line	  SUM-­‐149	  are	  shown.	  Cells	  were	  stained	  for	  Hoechst	  (blue	  colour)	  
and	  YAP	   (red	  colour):	  YAP	   localization	   is	  mainly	   cytoplasmic	   in	  not	   treated	   (NT)	   cells,	  whereas	  Betamethasone	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Figure	  4	  (a)	  Representative	  image	  of	  MDA-­‐MB-­‐231	  cell	   lines	  treated	  with	  DMSO	  or	  with	  Betamethasone	  (1μM)	  
alone	  or	  with	  RU-­‐486	   (1μM)	   for	   24	  hours.	  Glucocorticoids	   promote	   YAP	   nuclear	   accumulation	   by	   controlling	  
actin	  cytoskeleton	  dynamics.	  (b)	  Betamethasone	  increases	  the	  formation	  of	  F-­‐actin	  stress	  fibers	  in	  MDA-­‐MB-­‐231	  
cells.	  Cells	  were	   treated	  with	  DMSO	  or	  with	  Betamethasone	   (1μM)	   for	  24	  hours	  and	   then	   fixed,	  processed	   for	  
immunofluorescence	   and	   stained	   for	   Phalloidin.	   Representative	   images	   of	   the	   actin	   microfilaments	   (F-­‐actin)	  
within	   the	   cells	   are	   shown.	   NT=not	   treated	   (DMSO);	   BM=Betamethasone.	   (c)	   Latrunculin-­‐A	   prevents	  
Betamethasone-­‐induced	   formation	  of	  F-­‐actin	   stress	   fibers.	  Cells	  were	   treated	  with	  1μM	  Latrunculin-­‐A	  alone	  or	  
with	  1μM	  Betamethasone	  for	  24	  hours,	  and	  then	  processed	  for	  immunofluorescence	  and	  stained	  for	  Phalloidin	  
as	   in	   a.	   Representative	   images	   of	   the	   actin	   microfilaments	   within	   the	   cells	   are	   shown.	   (d)	   Quantification	   of	  
nuclear	  YAP	   levels	   in	  cells	   treated	  with	  DMSO	  or	  1μM	  Betamethasone	  alone	  or	  with	  1μM	  Latrunculin-­‐A	   for	  24	  
hours.	   Representative	   blots	   are	   shown.	   NT=not	   treated	   (DMSO);	   BM=Betamethasone;	   latA=Latrunculin-­‐A.	   (e)	  
Western	  blot	   of	   Total	   YAP	  protein	   levels	   and	  phospho-­‐YAP	  protein	   levels	   are	   shown.	  Values	   are	   calibrated	  on	  
vinculin	   levels	   in	  MDA-­‐MB-­‐231	  cells	   treated	  with	  1μM	  Latrunculin-­‐A	  alone	  or	  with	  1μM	  Betamethasone	   for	  24	  
hours.	  NT=not	  treated	  (DMSO);	  BM=Betamethasone;	  latA=Latrunculin-­‐A.	  (f)	  Quantitative	  PCR	  analysis	  of	  ANKRD1	  
mRNA	  expression	  in	  MDA-­‐MB-­‐231	  cells.	  Values	  are	  normalized	  to	  ANKRD1	  mRNA	  levels	  in	  not	  treated	  cells	  (set	  
as	   1.0)	   Cells	  were	   treated	  with	  DMSO	  or	   1μM	  Betamethasone	   alone	   or	  with	   1μM	   Latrunculin-­‐A	   for	   24	   hours.	  
Error	  bars	  represent	  mean	  ±	  s.d.	  from	  n	  =	  3	  biological	  replicates;	  *p<0.01	  vs	  DMSO.	  (g)	  Western	  Blot	  of	  ANKRD1	  
protein	   levels	   in	  MDA-­‐MB-­‐231	   cells	   is	   shown.	  Cells	  were	   treated	  with	  DMSO	  or	  1μM	  Betamethasone	  alone	  or	  
with	  1μM	  Latrunculin-­‐A	  or	  with	  1μM	  Cerivastatin	  (CER)	  for	  24	  hours.	  Values	  are	  calibrated	  on	  vinculin	  levels.	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Figure	  5.	  Glucocorticoids	  counteract	  the	  GPCRs-­‐mediated	  negative	  regulation	  of	  YAP.	  (a)	  Representative	  images	  
of	  immunofluorescence	  in	  breast	  cancer	  cell	   line	  MDA-­‐MB-­‐231	  are	  shown.	  Cells	  were	  stained	  for	  Hoechst	  (blue	  
colour)	  and	  YAP	  (red	  colour):	  YAP	  localization	  is	  mainly	  cytoplasmic	  after	  treatment	  with	  Salmeterol	  10	  μM	  (left)	  
and	   become	   nuclear	  when	   cells	   are	   co-­‐treated	  with	   Betamethasone	   1μM	   (middle)	   alone	   or	  with	   RU486	   1μM	  
(right)	   for	   24h.	   (b)	   Quantification	   of	   nuclear	   YAP	   by	   immunofluorescence.	   Cells	   treated	   as	   in	   (a).	   Error	   bars	  
represent	  mean	  ±	  s.d.	  from	  n	  =	  3	  biological	  replicates;	  *p<0.01	  vs	  DMSO.	  (c)	  Western	  Blot	  of	  MDA-­‐MB-­‐231	  cells	  
treated	  as	  in	  (a).	  Cel	  Total	  YAP	  protein	  levels	  and	  phospho-­‐YAP	  protein	  levels	  are	  shown.	  NT=not	  treated	  (DMSO);	  
BM=Betamethasone;	  RU486=Mifepristone.	   (d)	  Quantitative	  PCR	  analysis	  of	  ANKRD1	  mRNA	  expression	   in	  MDA-­‐
MB-­‐231	  cells.	  Cells	  are	  knocked	  down	  for	  YAP	  through	  siRNA	  transfection	  for	  48	  hours	  before	  Salmeterol	  10	  uM	  
treatment	   with	   or	   alone	   betamethasone.	   Error	   bars	   represent	   mean	   ±	   s.d.	   from	   n	   =	   3	   biological	   replicates;	  












Taken all together, these results suggest that Glucocorticoids sustain YAP protein levels and 
biological activity with consequent expansion of cancer stem cell sub-population. Moreover, 
this evidence suggests that, by increasing the number of CSCs, Glucocorticoids can exert a 
detrimental role in response to chemotherapeutic drugs. 
 
Figure 12. Glucocorticoids induce mammary cancer stem cell self-renewal and CSC features. (a) Hydrocortisone 
induces formation of m mmospheres in M2 c lls by activating YAP. The number of secondary mammospheres 
after treatments and siRNA transfections are indicated. Cells were transfected with the indicated siRNA for 48 
hours. Then, M2-transfected cells and 5SA-YAP-overexpressing M2 cells were grown in a specific stem-cell growth 
medium and cultured in non-adherent conditions with or without Hydrocortisone 0.5 µg/ml. 7 days after, primary 
mammospheres were quantified, disaggregated and re-plated in the same conditions. After further 7 days, 
secondary mammospheres obtained were counted. Error bars represent mean ± s.d. from n = 3 biological 
replicates. * indicates statistical significance: p<0.01; NS=not significant. (b) Optical microscope photographs of 
secondary mammospheres obtained after indicated treatments and transfections. HC=Hydrocortisone; 
siCTL=control siRNA; siYAP=YAP siRNA; YAP5SA=M2 cells that stably express the constitutively nuclear-localized 
form of YAP. (c) Betamethasone reduces Taxol-induced apoptosis in MDA-MB-231 cells. Western Blot of the 
apoptosis marker PARP-85 is shown. Cells were treated with or without Taxol 10µM and with Betamethasone 1µM 
alone or with RU468 1µM for 24 hours. NT=not treated (DMSO); BM=Betamethasone; RU468=Mifepristone; PARP-
85= apoptosis marker: p85 fragment of PARP protein.  Values are calibrated on actin levels. 
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  Figure	  6	  Mammosphere	  assay’s	   scheme	   (a)	  Cells	  are	  grown	   in	  non-­‐adherent	  conditions	   in	  a	  specific	  stem-­‐cell	  
growth	  medium.	   Primary	  mammospheres	   (M1)	   obtained	   are	   enzymatically	   disaggregated	   and	   cells	   are	   grown	  
again	  in	  the	  same	  culture	  conditions	  to	  obtain	  secondary	  mammospheres	  (M2).	  This	  process	  of	  disaggregation	  of	  
mammospheres	  and	  of	  specific	  culture	  of	  cells	  can	  be	  repeated	  several	  times	  to	  obtain	  tertiary	  (M3),	  quaternary	  
mammosphere	  (M4)	  etc.	  Glucocorticoids	  induce	  mammary	  cancer	  stem	  cells	  self-­‐renewal	  and	  CSC	  features.	  (b)	  
Hydrocortisone	   induces	   formation	  of	  mammospheres	   in	  M2	   cells	   by	   activating	   YAP.	   The	  number	  of	   secondary	  
mammospheres	   after	   treatments	   and	   siRNA	   transfections	   are	   indicated.	   Cells	   were	   transfected	   with	   the	  
indicated	  siRNA	  for	  48	  hours.	  Then,	  M2-­‐transfected	  cells	  and	  5SA-­‐YAP-­‐overexpressing	  M2	  cells	  were	  grown	  in	  a	  
specific	  stem-­‐cell	  growth	  medium	  and	  cultured	   in	  non-­‐adherent	  conditions	  with	  or	  without	  Hydrocortisone	  0.5	  
μg/ml.	   7	   days	   after,	   primary	   mammospheres	   were	   quantified,	   disaggregated	   and	   re-­‐plated	   in	   the	   same	  
conditions.	  After	  further	  7	  days,	  secondary	  mammospheres	  obtained	  were	  counted.	  Error	  bars	  represent	  mean	  ±	  
s.d.	   from	   n	   =	   3	   biological	   replicates.	   *	   indicates	   statistical	   significance:	   p<0.01;	   NS=not	   significant.	   (c)	  Optical	  
microscope	   photographs	   of	   secondary	  mammospheres	   obtained	   after	   indicated	   treatments	   and	   transfections.	  
HC=Hydrocortisone;	   siCTL=control	   siRNA;	   siYAP=YAP	   siRNA;	   YAP5SA=M2	   cells	   that	   stably	   express	   the	  
constitutively	  nuclear-­‐localized	  form	  of	  YAP.	  (d)	  CD44/CD24	  FACS	  analysis	  (fluorescence	  activated	  cell	  sorting)	  of	  
M2	  cell	  line;	  histograms	  representative	  of	  CD44+/CD24-­‐	  M2	  cells	  treated	  for	  1	  week	  with	  RU-­‐486	  1	  uM	  are	  shown.	  
(e)	  RU-­‐486	  reduces	  the	  formation	  of	  M2	  mammospheres	  formation.	  Cells	  were	  treated	  with	  RU-­‐486	  1	  uM	  and	  10	  
uM	   for	   48	   hours.	   Then	   cells	   were	   grown	   in	   mammospheres	   as	   previously	   described	   in	   Figure	   6b.	   Error	   bars	  
represent	  mean	  ±	  s.d.	   from	  n	  =	  3	  biological	   replicates.	   (f)	  Viability	  assay	  of	  control	  and	  MCF-­‐10A-­‐RAS	  cell	   lines	  
after	   treatment	  with	  RU-­‐486	  1	   and	  10	  μM	   for	  5	  days.	  Data	   are	  normalized	   to	  untreated.	   Error	  bars	   represent	  












Figure 11. Mammosphere assay’s scheme. Cells are grown in non-adherent conditions in a specific stem-cell 
growth medium. Primary mammospheres (M1) obtained are enzymatically disaggregated and cells are grown again 
in the same culture conditions to obtain secondary mammospheres (M2). This process of disaggregation of 
mammospheres and of specific culture of cells can be repeated several times to obtain tertiary (M3), quaternary 
mammosphere (M4) etc.    
 
In this context, TAZ activity has been shown to be increased in basal breast cancers that show 
a more stem-cell-like phenotype83. Indeed, TAZ hyperactivity promotes tumorigenic potential 
by the acquisition of additional cancer cell phenotypes27 and, among these, enhancing stem-
cell-like properties plays a central role. More recently, also YAP has been found to be 
determinant in maintaining stem cell phenotypes and in conferring CSC properties to several 
different cell types76,77,89–91. This evidence suggests that stemness could be pivotal in YAP 
oncogenic behaviour.  
That said, and considering the results previously obtained, we aimed to determine whether 
YAP induction, promoted by glucocorticoid treatment, plays a causal role in defining CSC traits. 
To this aim, we used derivatives of the non-tumorigenic human mammary MCF10A cell line: 
RAS-transformed MCF10A-T1k cells (MII cells)83,138. Cells were grown in a specific stem-cell 
growth medium and cultured for two mammosphere generations with or without 
Hydrocortisone 0.5 µg/ml. About two weeks later, only mammospheres that resulted to be over 
200 µm were considered for analysis. As shown in figure 12.a and b, glucocorticoid treatment 





































Taken all together, these results suggest that Glucocorticoids sustain YAP protein levels and 
biological activity with consequent expansion of cancer stem cell sub-population. Moreover, 
this evidence suggests that, by increasing the number of CSCs, Glucocorticoids can exert a 
detrimental role in response to chemotherapeutic drugs. 
 
Figure 12. Glucocorticoids induce mammary cancer stem cell self-renewal and CSC features. (a) Hydrocortisone 
induces formation of mammospheres in M2 cells by activating YAP. The number of secondary mammospheres 
after treatments and siRNA transfections are indicated. Cells were transfected with the indicated siRNA for 48 
hours. Then, M2-transfected cells and 5SA-YAP-overexpressing M2 cells were grown in a specific stem-cell growth 
medium and cultured in non-adherent conditions with or without Hydrocortisone 0.5 µg/ml. 7 days after, primary 
mammospheres were quantified, disaggregated and re-plated in the same conditions. After further 7 days, 
secondary mammospheres obtained were counted. Error bars represent mean ± s.d. from n = 3 biological 
replicates. * indicates statistical significance: p<0.01; NS=not significa t. (b) Optical microscop  photographs of 
secondary mammospheres obtained aft r in icated treatments and transfections. HC=Hydrocortisone; 
siCTL=control siRNA; siYAP=YAP siRNA; YAP5SA=M2 cells that stably express the constitutively nuclear-localized 
form of YAP. (c) Betamethasone reduces Taxol-induced apoptosis in MDA-MB-231 cells. Western Blot of the 
apoptosis marker PARP-85 is shown. Cells were treated with or without Taxol 10µM and with Betamethasone 1µM 
alone or with RU468 1µM for 24 hours. NT=not treated (DMSO); BM=Betamethasone; RU468=Mifepristone; PARP-
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replicates. * indicates statistical significan e: p<0.01; NS=not significant. (b) Optical microscope photographs of 
secondary mammospheres obtained after indicated treatments and transfections. HC=Hydrocortisone; 
siCTL=control siRNA; siYAP=YAP siRNA; YAP5SA=M2 cells that stably express the constitutively nuclear-localized 
form of YAP. (c) Betamethasone reduces Taxol-induced apoptosis in MDA-MB-231 cells. Western Blot of the 
apoptosis marker PARP-85 is shown. Cells were treated with or without Taxol 10µM and with Betamethasone 1µM 
alone or with RU468 1µM for 24 hours. NT=not treated (DMSO); BM=Betamethasone; RU468=Mifepristone; PARP-
85= apoptosis marker: p85 fragment of PARP protein.  Values are calibrated on actin levels. 
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Supplementary	   Figure	   1.	   (a)	   Quantitative	   PCR	   of	   YAP	   mRNA	   expression	   in	   stable	   clone	   of	   M2	   cell	   line	  
constitutively	   expressing	   YAP.	   (b)	   Representative	   immunofluorescence	   of	  M2	   cell	   line	   expressing	   YAP	  WT	   and	  
YAP	  5SA.	  (c)	  Western	  blot	  of	  MDA-­‐MB-­‐231	  cell	  line	  treated	  with	  betamethasone	  alone	  or	  with	  RU-­‐486.	  (d)	  Facs	  
analysis	  showing	  CD44/CD24	  markers	  after	  treatment	  with	  RU-­‐486.	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During	  my	  PhD	  I	  have	  been	  involved	  in	  the	  following	  publications:	  
Sorrentino,	  G.,	  Mioni,	  M.,	  Giorgi,	  C.,	  Ruggeri,	  N.,	  Pinton,	  P.,	  Moll,	  U.,	  Mantovani,	  F.,	  
and	  Del	  Sal,	  G.	  (2013).	  The	  prolyl-­‐-­‐isomerase	  Pin1	  activates	  the	  mitochondrial	  
death	  program	  of	  p53.	  Cell	  Death	  Differ	  20,	  198-­‐-­‐-­‐208.	  	  	  
ABSTRACT:	  In	  response	  to	  intense	  stress,	  the	  p53	  tumor	  suppressor	  rapidly	  mounts	  a	  
direct	  mitochondrial	  death	  program	  that	  precedes	  transcription-­‐mediated	  apoptosis.	  
By	   eliminating	   severely	   damaged	   cells,	   this	   pathway	   contributes	   to	   tumor	  
suppression	  as	  well	  as	  to	  cancer	  cell	  killing	  induced	  by	  both	  genotoxic	  drugs	  and	  non-­‐
genotoxic	  p53-­‐reactivating	  molecules.	  Here	  we	  have	  explored	  the	  role	  played	  in	  this	  
pathway	  by	  the	  prolyl-­‐isomerase	  Pin1,	  a	  crucial	  transducer	  of	  p53’s	  phosphorylation	  
into	   conformational	   changes	   unleashing	   its	   pro-­‐apoptotic	   activity.	   We	   show	   that	  
Pin1	  promotes	  stress-­‐induced	  localization	  of	  p53	  to	  mitochondria	  both	  in	  vitro	  and	  in	  
vivo.	  In	  particular,	  we	  demonstrate	  that	  upon	  stress-­‐induced	  phosphorylation	  of	  p53	  
on	   Ser46	   by	   HIPK2,	   Pin1	   stimulates	   its	   mitochondrial	   trafficking	   signal,	   i.e.	  
monoubiquitination.	   This	   pathway	   is	   induced	   also	   by	   the	   p53-­‐	   activating	  molecule	  
RITA,	   and	   we	   demonstrate	   the	   strong	   requirement	   of	   Pin1	   for	   the	   induction	   of	  
mitochondrial	   apoptosis	   by	   this	   compound.	   These	   findings	   have	   significant	  
implications	  for	  treatment	  of	  p53-­‐expressing	  tumors	  and	  for	  prospective	  use	  of	  p53-­‐
activating	  compounds	  in	  clinics.	  	  
Sorrentino,	   G.,	   Ruggeri,	   N.,	   Specchia,	   V.,	   Cordenonsi,	   M.,	   Mano,	   M.,	   Dupont,	   S.,	  
Manfrin,	  A.,	  Ingallina,	  E.,	  Sommeggio,	  R.,	  Piazza,	  S.,	  Rosato,	  A.,	  Piccolo,	  S.,	  Del	  
Sal,	  G.	  (2014).	  Metabolic	  control	  of	  YAP	  and	  TAZ	  by	  the	  mevalonate	  pathway.	  
Nature	  Cell	  Biology,	  doi:10.1038/ncb2936	  	  
ABSTRACT:	   The	   YAP	   and	   TAZ	   mediators	   of	   the	   Hippo	   pathway	   (hereafter	   called	  	  
YAP/TAZ)	   promote	   tissue	   proliferation	   and	   organ	   growth.	   However,	   how	   their	  
biological	  properties	   intersect	  with	  cellular	  metabolism	  remains	  unexplained.	  Here,	  
we	   show	   that	   YAP/TAZ	   activity	   is	   controlled	   by	   the	   SREBP/mevalonate	   pathway.	  
Inhibition	   of	   the	   rate-­‐limiting	   enzyme	   of	   this	   pathway	   (HMG-­‐CoA	   reductase)	   by	  
statins	   opposes	   YAP/TAZ	   nuclear	   localization	   and	   transcriptional	   responses.	  
Mechanistically,	   the	   geranylgeranyl	   pyrophosphate	   produced	   by	   the	   mevalonate	  
cascade	  is	  required	  for	  activation	  of	  Rho	  GTPases	  that,	  in	  turn,	  activate	  YAP/TAZ	  by	  
inhibiting	   their	   phosphorylation	   and	   promoting	   their	   nuclear	   accumulation.	   The	  
mevalonate–YAP/TAZ	   axis	   is	   required	   for	   proliferation	   and	   self-­‐renewal	   of	   breast	  
cancer	  cells.	   In	  Drosophila	  melanogaster,	   inhibition	  of	  mevalonate	  biosynthesis	  and	  
geranylgeranylation	   blunts	   the	   eye	   overgrowth	   induced	   by	   Yorkie,	   the	   YAP/TAZ	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orthologue.	   In	   tumour	  cells,	  YAP/TAZ	  activation	   is	  promoted	  by	   increased	   levels	  of	  
mevalonic	   acid	   produced	   by	   SREBP	   transcriptional	   activity,	  which	   is	   induced	   by	   its	  
oncogenic	  cofactor	  mutant	  p53.	  These	  findings	  reveal	  an	  additional	  layer	  of	  YAP/TAZ	  
regulation	  by	  metabolic	  cues.	  
	  
	  
	  
